Melanoma · Web of Medicine

On this page

Quick Reference

RxDrug of choiceNivolumab + ipilimumab (first-line for advanced melanoma regardless of BRAF status); neoadjuvant ipilimumab + nivolumab for resectable stage III

AltAlternativesPembrolizumab monotherapy; nivolumab + relatlimab; dabrafenib + trametinib (BRAF-mutant); encorafenib + binimetinib (BRAF-mutant); TIL therapy (lifileucel) for anti-PD-1-refractory; tebentafusp (uveal melanoma, HLA-A*02:01+)

⊘AvoidCytotoxic chemotherapy as first-line; BRAF inhibitor monotherapy (must combine with MEK inhibitor); whole-brain radiotherapy for asymptomatic brain metastases if systemic therapy available; high-dose corticosteroids (≥10 mg prednisone equivalent/day) without managing irAE, may blunt immunotherapy efficacy

DxTest of choiceExcisional biopsy with 1-3 mm margins (diagnosis and microstaging); BRAF V600 mutation testing (stage III/IV); PET-CT (staging stage IIC+); brain MRI (stage IV); sentinel lymph node biopsy (T1b-T3)

ScKey scoreAJCC 8th edition staging (TNM); Breslow thickness; sentinel lymph node status; serum LDH; diagnosis-specific GPA for brain metastases; ctDNA detection (post-surgery landmark)

→When to referSuspicious lesion → dermatology for biopsy; stage I+ → surgical oncology for wide excision and SLNB; stage III+ → medical oncology for systemic therapy; brain metastases → radiation oncology and/or neurosurgery; genetic counseling for familial cases (≥3 primaries, family history, early onset); pregnancy-associated melanoma → maternal-fetal medicine

Early detection through total-body skin examination in high-risk individuals is critical. For advanced melanoma, combination immunotherapy (nivolumab + ipilimumab) yields the highest long-term survival (10-year OS 43%). For resectable stage III, neoadjuvant ipilimumab + nivolumab is the new standard (12-month EFS 83.7%). BRAF/MEK inhibitors offer rapid disease control but less durable benefit; sequencing immunotherapy first is preferred for BRAF-mutant patients. Adjuvant therapy with anti-PD-1 or targeted therapy significantly improves RFS in high-risk resected disease. Avoid cytotoxic chemotherapy and unnecessary corticosteroids in patients receiving immunotherapy.

Melanoma is the deadliest form of skin cancer, arising from melanocytes, with an estimated 300,000 new cases worldwide in 2022 and a rising incidence of thick (>4 mm) tumors. Prognosis has dramatically improved with immune checkpoint inhibitors and targeted therapies: 10-year overall survival now reaches 43% with nivolumab plus ipilimumab in advanced disease, and neoadjuvant immunotherapy is transforming resectable stage III management. Stage at diagnosis remains the strongest prognostic determinant, and all treatment decisions hinge on accurate staging (AJCC 8th edition) and molecular profiling (BRAF, NRAS, KIT). Early detection through total-body skin examination in high-risk individuals is critical to reducing mortality.

Overview and Recommendations

Background

•Melanoma is a malignant neoplasm of melanocytes, the pigment-producing cells of the skin, mucosa, uveal tract, and leptomeninges, and is the deadliest form of skin cancer, accounting for the vast majority of skin-cancer deaths. Incidence has risen steadily in fair-skinned populations; in the United States, the lifetime risk is now approximately 1 in 68, and the incidence of thickest tumors (T4, >4.0 mm) increased 3.32% per year from 2010 to 2018, signaling a shift toward later detection rather than overdiagnosis.
•Cutaneous melanoma is the most common subtype (~90%), but distinct variants include acral lentiginous melanoma (palms, soles, nailbeds; not UV-related, KIT mutations), mucosal melanoma (sinonasal, anogenital; aggressive, low mutational burden), and uveal melanoma (primary intraocular; GNAQ/GNA11 mutations, 15-GEP/PRAME stratifies metastasis risk). Superficial spreading melanoma (~70%) and nodular melanoma (~15%) are the major histologic patterns within cutaneous disease.
•Approximately 40-50% of cutaneous melanomas harbor an activating BRAF V600 mutation (most commonly V600E), which drives constitutive MAPK pathway signaling and is targetable with BRAF/MEK inhibitor combinations. NRAS mutations occur in 15-20%, KIT mutations in acral/mucosal subtypes, and NF1 loss in ~15%, these are generally mutually exclusive. UV-induced mutagenesis (C→T transitions) is the dominant environmental etiology, but acral and mucosal melanomas arise through UV-independent mechanisms.
•Melanoma has the highest propensity for brain metastasis among solid tumors: in stage III disease, the cumulative incidence of CNS metastasis is 15.8% at 5 years. Untreated metastatic melanoma historically carried a 5-year survival <10%, but modern immunotherapy (nivolumab + ipilimumab) now achieves a median overall survival of 71.9 months and a 10-year survival rate of 43% (CheckMate 067). For resected stage III, adjuvant nivolumab yields a median recurrence-free survival of 61.1 months at 9-year follow-up.
•Host risk factors include fair skin, high nevus count (>50 nevi confers 2- to 4-fold risk), atypical (dysplastic) nevi, family history, and immunosuppression. The attributable risk from seven easily obtained clinical features (including nevus count, freckling, and sunburn history) is 86% for men and 89% for women, underscoring that the vast majority of melanomas arise from identifiable, potentially modifiable factors.

Evaluation

•Suspect melanoma in any patient presenting with a changing pigmented lesion, apply the ABCDE criteria (Asymmetry, Border irregularity, Color variation, Diameter >6 mm, Evolution) and the “ugly duckling” sign (a lesion that looks different from the patient’s other nevi). Nodular melanomas may grow rapidly (weeks) and can be amelanotic (pink, red, flesh-colored), leading to frequent misdiagnosis as basal cell carcinoma or pyogenic granuloma.
•Ask about prior sun exposure history, blistering sunburns (especially in childhood), indoor tanning bed use, personal or family history of melanoma or pancreatic cancer, and immunosuppression (transplant, HIV, CLL). In women, inquire about pregnancy status, postpartum diagnosis is associated with increased mortality (aHR 1.84).
•Examine the total skin surface, including scalp, nails, interdigital web spaces, palms, soles, and mucosal surfaces. Document the lesion’s size, color variegation, ulceration, bleeding, and surrounding satellites. Palpate the regional lymph node basins (axillary, inguinal, cervical) for adenopathy. Dermoscopy by a trained clinician increases diagnostic accuracy by 10-30% over naked-eye examination.
•Perform an excisional biopsy with 1-3 mm peripheral margins, extending to the subcutaneous fat, to obtain a full-thickness specimen for accurate microstaging. Avoid shave biopsy for suspicious lesions, incomplete sampling can underestimate Breslow thickness and preclude sentinel lymph node biopsy (SLNB) eligibility. If shave is unavoidable, a deep saucerization is preferred over superficial shave.
•The pathologist must report Breslow thickness (to nearest 0.1 mm), ulceration (present/absent), dermal mitotic rate (mitoses/mm²), and peripheral/deep margin status. Additional features, tumor-infiltrating lymphocytes (TILs), regression, lymphovascular invasion, microsatellitosis, inform prognosis and SLNB decision-making. For melanoma in situ, Mohs micrographic surgery with immunohistochemistry (Melan-A, SOX10) is recommended.
•Order BRAF V600 mutation testing on all patients with stage III or IV cutaneous melanoma using a validated assay (NGS, PCR, or immunohistochemistry). Also consider KIT mutation testing for acral and mucosal subtypes, and NTRK fusion testing for rare cases. PD-L1 immunohistochemistry provides predictive information but is neither necessary nor sufficient for checkpoint inhibitor benefit.
•Stage all patients according to AJCC 8th edition: T category combines Breslow thickness and ulceration (e.g., T1a: <0.8 mm nonulcerated; T1b: 0.8-1.0 mm or <0.8 mm with ulceration). N category integrates number of positive nodes, microscopic vs. macroscopic involvement, and in-transit/satellite metastases. M category depends on distant site and serum LDH level (normal vs. elevated). Sentinel lymph node biopsy is the most important staging procedure for clinically node-negative patients, recommended for T2-T3 (>1.0-4.0 mm) and considered for T1b (0.8-1.0 mm or <0.8 mm with ulceration); not recommended for T1a.
•Routine imaging is not indicated for stage 0-IIA (asymptomatic). For stage IIC, III (any N), and IV, obtain chest/abdomen/pelvis CT with IV contrast; PET-CT is more sensitive for distant metastases and is preferred when surgical resection of oligometastatic disease is planned. Brain MRI with contrast is mandatory for stage IV and should be considered for stage III, especially with neurological symptoms. Be aware of the ~5.8% false-positive rate of PET-CT.
•Consider circulating tumor DNA (ctDNA) testing at the postoperative landmark (≤12 weeks after resection) for stage III disease, detectable ctDNA confers a 3.42-fold increased risk of relapse and may guide intensified surveillance or adjuvant therapy decisions. Tumor-informed bespoke assays can detect molecular residual disease a median 128 days before radiographic relapse.
•Genetic counseling and germline testing should be offered to patients with ≥3 primary melanomas, families with ≥3 cases of melanoma or pancreatic cancer, or personal history of multiple atypical nevi. High-penetrance genes include CDKN2A (20-40% of familial cases; also confers ~50-fold increased risk of pancreatic cancer) and BAP1 (associated with uveal melanoma and mesothelioma). Cascade testing of at-risk relatives is essential.

Management

•For primary melanoma without nodal involvement (stage 0-II), perform wide local excision with margins based on Breslow thickness: melanoma in situ - 0.5-1.0 cm; ≤1 mm - 1 cm; 1.01-2 mm - 1-2 cm; >2 mm - 2 cm. For T1b-T3 melanomas, offer sentinel lymph node biopsy (SLNB) after discussion of risks and benefits. Completion lymph node dissection after positive SLNB improves regional control but does not improve melanoma-specific survival; nodal observation with serial ultrasound is an acceptable alternative for low-volume micrometastatic disease.
•For resectable macroscopic stage III melanoma (clinically palpable nodes or in-transit metastases), prefer neoadjuvant therapy: administer two cycles of ipilimumab 1 mg/kg plus nivolumab 3 mg/kg every 3 weeks, followed by surgical resection 4-6 weeks after cycle 2. Then, based on pathologic response: if major pathologic response (≤10% viable tumor) - continue adjuvant nivolumab (480 mg q4w) for up to 12 months; if no major response - consider dabrafenib + trametinib (if BRAF-mutant) or alternative. This regimen (NADINA trial) achieved 83.7% 12-month event-free survival vs. 57.2% with adjuvant nivolumab alone (HR 0.32). An alternative is neoadjuvant pembrolizumab 200 mg q3w for 3 doses before surgery, then 15 doses adjuvant (SWOG S1801).
•For patients with resected stage IIB-IV melanoma who did not receive neoadjuvant therapy, offer adjuvant immunotherapy: nivolumab 240 mg q2w (or 480 mg q4w) or pembrolizumab 200 mg q3w (or 400 mg q6w) for up to 12 months (category 1). In KEYNOTE-716, adjuvant pembrolizumab improved 36-month distant metastasis-free survival to 84.4% vs. 74.7% (HR 0.59). For BRAF V600-mutant stage III melanoma, adjuvant dabrafenib 150 mg BID plus trametinib 2 mg daily for 12 months is also category 1 (COMBI-AD: 10-year RFS HR 0.52; OS HR 0.80, not significant). Adjuvant therapy for stage IIIA (AJCC v8) is controversial, retrospective data show no clear benefit over observation; shared decision-making is essential.
•First-line therapy for advanced (unresectable stage III or IV) melanoma is determined by BRAF status, performance status, and patient preference. For most fit patients, regardless of BRAF status, initiate ipilimumab 3 mg/kg plus nivolumab 1 mg/kg every 3 weeks for 4 doses, followed by nivolumab maintenance (240 mg q2w or 480 mg q4w). CheckMate 067 reported median OS 71.9 months for the combination; 10-year OS 43%. Grade 3-4 immune-related adverse events (irAEs) occur in 55-59%, requires proactive toxicity monitoring and management with corticosteroids, TNF inhibitors, or other immunosuppressants per established algorithms.
•For patients with contraindications to high-dose corticosteroids, autoimmune disease, or those who prefer lower toxicity, alternatives include: (1) nivolumab 240 mg q2w or pembrolizumab 200 mg q3w monotherapy (10-year OS ~34-37%, grade 3-4 irAEs 13-16%); (2) nivolumab 480 mg plus relatlimab 160 mg fixed-dose combination q4w (median PFS 10.1 vs. 4.6 months for nivolumab alone; grade 3-4 18.9%). Pembrolizumab is also available as 400 mg q6w for convenience.
•For patients with BRAF V600-mutant advanced melanoma, the preferred first-line strategy is immunotherapy (nivolumab + ipilimumab) based on DREAMseq (2-year OS 71.8% with immunotherapy-first vs. 51.5% with targeted therapy-first). BRAF/MEK inhibitors are a category 1 alternative for rapid disease control: dabrafenib 150 mg BID + trametinib 2 mg daily (median PFS 11.0 months; grade 3-4 32%), encorafenib 450 mg daily + binimetinib 45 mg BID (median PFS 14.9 months; grade 3-4 40%), or vemurafenib 960 mg BID + cobimetinib 60 mg daily (21 days on/7 off; median PFS 12.3 months; grade 3-4 39%). Reserve targeted therapy for patients with high tumor burden, symptomatic disease, or contraindications to immunotherapy.
•For patients whose disease progresses on anti-PD-1 therapy, options include: (1) ipilimumab 3 mg/kg plus pembrolizumab 2 mg/kg (ORR 29%; median OS 24.7 months); (2) TIL therapy (lifileucel) - FDA-approved for anti-PD-1-refractory melanoma, ORR 31.5% with median duration of response not reached at 5 years; (3) oncolytic virus RP1 plus nivolumab (ORR 32.9%; 2-year OS 63.3%). Ipilimumab monotherapy is no longer recommended after anti-PD-1 failure if combination is feasible.
•For melanoma brain metastases: in asymptomatic patients, initiate systemic therapy first, nivolumab + ipilimumab achieved intracranial clinical benefit rate of ~80% with 3-year OS 71.9% (CheckMate 204). For BRAF-mutant disease, dabrafenib + trametinib produced intracranial responses in 58% (COMBI-MB). Reserve stereotactic radiosurgery (SRS) for symptomatic or progressing lesions; avoid whole-brain radiotherapy (WBRT) as it does not improve OS and impairs neurocognition. If leptomeningeal disease develops, consider intrathecal therapy or clinical trials.
•For metastatic uveal melanoma: if HLA-A*02:01-positive, treat with tebentafusp 20-68-68 mcg weekly infusion (bispecific T-cell engager targeting gp100×CD3). The IMCgp100-202 trial improved 3-year OS to 27% vs. 18% with investigator’s choice (HR 0.68). Checkpoint inhibitors have limited activity in uveal melanoma and are not recommended as first-line.
•What NOT to do: Do not use cytotoxic chemotherapy (dacarbazine, temozolomide, platinum/taxanes) as first-line therapy, response rates <15% and no survival benefit in the immunotherapy era. Do not administer BRAF inhibitor monotherapy without a MEK inhibitor (increased toxicity, lower efficacy). Do not routinely start corticosteroids (e.g., dexamethasone) for asymptomatic brain metastases unless symptom control is needed, corticosteroids may impair immunotherapy efficacy. Do not delay systemic therapy for asymptomatic brain metastases in favor of immediate radiation, deferring SRS until progression is safe and preserves quality of life.

Board Review — High Yield

•ABCDE criteria, Asymmetry, Border irregularity, Color variegation, Diameter >6 mm, Evolution, classic warning signs for melanoma on skin exam.
•Breslow thickness, Most important prognostic factor in primary melanoma; measured to nearest 0.1 mm; T1a = <0.8 mm nonulcerated, T1b = 0.8-1.0 mm or <0.8 mm with ulceration.
•Sentinel lymph node biopsy (SLNB), Recommended for T1b-T3 melanomas (0.8-4.0 mm); most powerful independent predictor of recurrence and survival in early-stage disease.
•BRAF V600 mutation, Present in 40-50% of cutaneous melanomas; targetable with dabrafenib + trametinib, encorafenib + binimetinib, or vemurafenib + cobimetinib; testing mandatory for stage III/IV.
•CheckMate 067, Landmark trial: nivolumab + ipilimumab achieved median OS 71.9 months (10-year OS 43%) vs. 36.9 months (37%) for nivolumab alone vs. 19.9 months (19%) for ipilimumab alone in advanced melanoma.
•NADINA trial, Neoadjuvant ipilimumab + nivolumab (2 cycles) before surgery in resectable stage III melanoma improved 12-month event-free survival to 83.7% vs. 57.2% with adjuvant nivolumab alone (HR 0.32).
•DREAMseq (EA6134), For BRAF-mutant advanced melanoma, initial immunotherapy (nivolumab + ipilimumab) followed by dabrafenib + trametinib at progression is superior to the reverse sequence (2-year OS 71.8% vs. 51.5%; P=0.010).
•Uveal melanoma, Distinct biology: GNAQ/GNA11 mutations in 80-90%; 15-GEP/PRAME classifier stratifies metastasis risk; treat HLA-A*02:01+ patients with tebentafusp (bispecific T-cell engager).
•ctDNA biomarker, Postoperative detection of circulating tumor DNA confers a 3.42-fold increased risk of relapse (HR 3.42) and can detect molecular recurrence a median 128 days before radiographic progression.
•Lactate dehydrogenase (LDH), Elevated serum LDH (>ULN) is an independent negative prognostic factor in stage IV melanoma and shifts M1a-M1c to a higher-risk substage; also incorporated into the Lung Immune Prognostic Index (LIPI).

Deep Dive — Evidence Details

Definition and Epidemiology

▸Melanoma incidence continues to rise globally, with a concerning increase in thick (>4 mm) tumours in the US since 2010, despite stable overall rates.
▸Significant racial and socioeconomic disparities exist: Black and Hispanic patients are more likely to present with thick melanomas and have a 31% higher melanoma-specific mortality than White patients.
▸Melanoma has the highest propensity for brain metastasis among solid tumours; 15.8% of stage III patients develop CNS metastases within 5 years.

Melanoma is a type of cancer, typically skin cancer; it develops from the melanin-producing cells known as melanocytes. It typically occurs in the skin, but may rarely occur in the mouth, intestines, or eye. In very rare — Melanoma — Melanoma is a type of cancer, typically skin cancer; it develops from the melanin-producing cells known as melanocytes. It typically occurs in the ski...Wikipedia ↗

Melanoma is a malignant neoplasm of melanocytes, the pigment-producing cells of the skin, mucosa, uveal tract, and leptomeninges, and is the deadliest form of skin cancer.

Also Called / Synonyms

Cutaneous melanoma, malignant melanoma (historical), pigmented melanoma. Distinct subtypes include , mucosal melanoma, acral lentiginous melanoma, and amelanotic melanoma.

Key Definitions

Melanoma in situ (MIS): Malignant melanocytes confined to the epidermis; 15-year survival exceeds 98% ^[68]^A1b.
Invasive melanoma: Penetration of melanocytes through the basement membrane into the dermis; prognosis worsens with increasing Breslow thickness.
Primary melanoma: The original tumour at its site of onset.
Metastatic melanoma: Spread beyond the primary site to regional lymph nodes or distant organs.
BRAF-mutant melanoma: Harbors an activating V600 mutation (most commonly V600E), found in approximately 40-50% of cutaneous melanomas ^[32]^D5^[79]^D5.
Wild-type melanoma: Lacks BRAF V600 mutations; includes tumours with NRAS, NF1, or KIT mutations.

Classification of Melanoma Subtypes

Subtype	Key Distinguishing Feature	Associated Molecular Pattern
Cutaneous (superficial spreading, nodular, )	Arises on sun-exposed skin; most common form	BRAF V600E mutations frequent ^[32]^D5^[79]^D5
Acral lentiginous	Occurs on palms, soles, nailbeds; not UV-related	KIT mutations, fewer BRAF mutations
Mucosal	Arises in sinonasal, oral, anogenital mucosa; aggressive	KIT and NRAS mutations, low mutational burden
Uveal	Primary intraocular malignancy; biology distinct from cutaneous	GNAQ/GNA11 mutations ^[1]^A1c^[54]^D5

Melanoma incidence has been rising for decades in fair-skinned populations worldwide ^[36]^D5. In the United States, overall invasive melanoma incidence stabilised between 2010 and 2018 (annual percentage change [APC] 0.39%; 95% CI -0.40 to 1.18), but the incidence of thickest tumours (T4, >4.0 mm) increased significantly (APC 3.32%; 95% CI 2.06-4.60) ^[105]^B2b. This pattern suggests a shift toward later detection rather than overdiagnosis. The lifetime risk in the US is now approximately 1 in 68 ^[45]^D5.

Globally, an estimated 300,000 new cases were diagnosed in 2022, and the burden is projected to rise through 2040 ^[114]^D5. In Europe, skin melanoma is among the most prevalent cancers in both sexes, with 5-year prevalence rates of 2270 per 100,000 in female survivors and 1714 per 100,000 in male survivors ^[95]^B2c. Among adolescents and young adults (ages 15-39), melanoma is the second most common cancer in many high-income countries ^[87]^B2c^[94]^B2c.

Men have higher incidence and thicker tumours at diagnosis than women ^[105]^B2b. Non-Hispanic Black and Hispanic patients are disproportionately diagnosed with T4 melanomas (20.7% and 11.2%, respectively, versus 6.3% in non-Hispanic White patients) and have a 31% increased risk of melanoma-specific death compared with White patients (HR 1.31; 95% CI 1.09-1.57) ^[84]^B3a^[105]^B2b.

Melanoma has the highest propensity for brain metastasis among solid tumours. In stage III disease, the cumulative incidence of CNS metastasis is 3.6% at 1 year, 9.6% at 2 years, and 15.8% at 5 years ^[75]^B3b. Among resected stage II-III patients, 6.9% eventually develop ^[42]^B3b.

Pearl: The rising incidence of thick melanomas (>4 mm) since 2010, in contrast to stable thin melanoma rates, signals a need for enhanced early detection efforts, as these tumours carry the worst prognosis.

This growing burden sets the stage for the modifiable and non-modifiable risk factors discussed in the next section.

Risk Factors and Prevention

▸Ultraviolet exposure, especially intermittent intense sunburns and indoor tanning, is the principal modifiable risk factor.
▸Phenotypic traits (fair skin, >50 nevi, freckling) and genetic predisposition (CDKN2A mutations, family history) identify individuals at highest risk.
▸NCCN recommends annual total-body skin examination for high-risk groups; USPSTF finds insufficient evidence for population-wide screening (I statement).

Ultraviolet radiation remains the dominant modifiable risk factor, but melanoma arises from an interplay of host susceptibility, genetic predisposition, and environmental exposures. Risk stratification guides both primary prevention and screening intensity.

Host and Phenotypic Factors

Fair skin, red or blonde hair, blue eyes, freckling, and an inability to tan are well-established high-risk phenotypes. The single strongest phenotypic predictor is a high count of benign melanocytic nevi: individuals with >50 common nevi face a two- to four-fold increased risk. Atypical (dysplastic) nevi further amplify risk. Heritability of nevus count is substantial, and genome-wide studies show that raised nevus count correlates more strongly with melanoma polygenic risk than flat nevi ^[203]^C4. In a large US case-control study, seven easily obtained clinical features (including nevus count, freckling, and history) produced an attributable risk of 86% for men and 89% for women, meaning the vast majority of melanomas arise from identifiable risk factors ^[154]^B3b.

Environmental and Lifestyle Exposures

Intermittent, intense sun exposure and a history of blistering sunburns, especially in childhood, confer greater risk than cumulative lifetime exposure. Indoor tanning bed use before age 30 increases risk by 75%. Dietary factors have also been implicated: pooled prospective data from two large US cohorts found that citrus consumption ≥1.6 times/day was associated with a 1.36-fold higher melanoma risk (HR 1.36, 95% CI 1.14-1.63), and grapefruit intake ≥3 times/week with a 1.41-fold increase (HR 1.41, 95% CI 1.10-1.82), possibly due to photosensitizing psoralens ^[151]^B2b. Higher serum leptin levels, a marker of obesity-related metabolic disturbance, were associated with an adjusted OR 1.56 ^[136]^B3b. Height partly mediates the sex disparity in melanoma: men have a 39% higher incidence than women, of which 35% is attributable to greater height ^[65]^B2b. Birth weight, however, adds no independent risk after accounting for adult height ^[12]^B2b.

Medical History and Medications

A personal history of melanoma confers a 5% cumulative incidence of a second primary within 10 years after stage III diagnosis ^[157]^B2b. Personal history of is associated with a 1.83-fold higher risk of incident melanoma (HR 1.83, 95% CI 1.32-2.54) ^[158]^B2b. Chronic lymphocytic leukemia (CLL) and low-count monoclonal B-cell lymphocytosis (MBL) each roughly double melanoma risk (HR 1.86 for MBL, 95% CI 1.25-2.78) ^[73]^B2b. In solid organ transplant recipients, a pretransplant melanoma confers an IRR of 10.4 (95% CI 7.43-14.1) for posttransplant melanoma ^[106]^B2b. Exogenous estrogen use, both (OR 1.28, 95%) and hormonal replacement therapy (OR 2.08, 95%), shows a cumulative dose-dependent increase in risk ^[137]^B3b. Immunosuppression from any cause, pharmacologic (transplant, autoimmune disease therapy) or disease-related (HIV, CLL), raises risk.

Genetic Predisposition

Approximately 10% of melanomas occur in the setting of a family history. High-penetrance germline mutations in CDKN2A account for 20-40% of familial melanoma; other predisposition genes include CDK4, BAP1, POT1, TERF2IP, and ATM ^[200]^D5. PTEN hamartoma tumor syndrome also confers elevated lifetime melanoma risk ^[191]^D5. For hereditary implications, see the Genetics and Hereditary Predisposition section.

Prevention and Screening

Primary prevention relies on sun-avoidance behaviors: seeking shade, wearing protective clothing, and applying broad-spectrum SPF 30+ sunscreen. No systemic chemopreventive agent is proven to reduce melanoma incidence.

Screening by total-body skin examination (TBSE) is recommended by the NCCN for high-risk groups, those with multiple nevi, family history, or prior melanoma, but the USPSTF continues to give an I statement (insufficient evidence) for population-based screening ^[117]^A1c. A large health system quality initiative demonstrated that patients who received TBSE had thinner invasive melanomas at diagnosis (median 0.37 mm vs 0.65 mm in unscreened patients) ^[176]^C4. In an academic screening program, the number needed to biopsy to detect one melanoma was 4.83, improving with successive rounds ^[149]^B2b. Risk calculators (e.g., the Fears model and the Melanoma Institute Australia nomogram) integrate clinical features to estimate absolute risk and help target screening efforts ^[154]^B3b^[153]^C4.

Controversies and Guideline Disagreement

Question	NCCN Position	USPSTF Position	Strength	Implication
Should the general population be screened by TBSE?	Recommend targeted screening for high-risk individuals (category 2A) ^[117]^A1c	I statement - evidence insufficient to recommend for or against ^[176]^C4	Moderate	Clinicians should use shared decision-making; screening clearly benefits high-risk groups but population impact unproven

Pearl: The strongest predictor of melanoma risk is a high count of benign melanocytic nevi; any patient with >50 nevi, especially if atypical, warrants annual total-body skin examination and explicit sun-protection counseling.

Selected Risk Factors for Cutaneous Melanoma

Factor	Odds Ratio / Relative Risk (95% CI)	Source
High nevus count (>50)	2-4 (range across studies)	^[117]^A1c^[154]^B3b
≥1 blistering sunburn in childhood	OR ~2	^[154]^B3b
Citrus consumption ≥1.6/day	HR 1.36 (1.14-1.63)	^[151]^B2b
Grapefruit ≥3/week	HR 1.41 (1.10-1.82)	^[151]^B2b
Hormonal replacement therapy use ≥0.5 yr	OR 2.08 (1.37-3.14)	^[137]^B3b
Oral contraceptive use ≥0.5 yr	OR 1.28 (1.06-1.54)	^[137]^B3b
Serum leptin (per unit increase)	OR 1.56 (1.07-2.28)	^[136]^B3b
History of prostate cancer	HR 1.83 (1.32-2.54)	^[158]^B2b
Monoclonal B-cell lymphocytosis (low-count)	HR 1.86 (1.25-2.78)	^[73]^B2b
Solid organ transplant (pretransplant melanoma)	IRR 10.4 (7.43-14.1)	^[106]^B2b
Height (per SD increase in men)	Mediates 35% of sex excess	^[65]^B2b

Genetics and Hereditary Predisposition

▸CDKN2A is the most common high-penetrance gene in familial melanoma, with penetrance influenced by geographic UV exposure.
▸BAP1 germline mutations define a syndrome encompassing uveal melanoma, cutaneous melanoma, mesothelioma, and renal cell carcinoma.
▸Multi-gene panel testing doubles detection rates over CDKN2A alone; predictors include ≥3 primary melanomas, pancreatic cancer, and age ≤60 years.

HY High Yield: Multi-gene panel testing identifies germline variants in ~10% of high-risk melanoma patients; CDKN2A alone misses half of these [92].

Risk factors for melanoma include both environmental and genetic components; the latter are increasingly recognized through germline testing that identifies high-risk individuals and their families. An estimated 10% to 15% of melanoma cases arise in the setting of a hereditary predisposition ^[243]^B2b. The NCCN Guidelines recommend genetic assessment for patients meeting specific criteria, including those with ≥3 primary melanomas, families with ≥3 cases of melanoma or pancreatic cancer, or a personal history of multiple atypical nevi ^[117]^A1c.

High-Penetrance Genes

CDKN2A is the most frequently implicated high-penetrance gene, accounting for approximately 20% to 40% of familial melanoma kindreds ^[200]^D5. Pathogenic variants in CDKN2A confer a lifetime melanoma risk of 28% by age 50 and 67% by age 80 in European populations, with penetrance rising to 91% by age 80 in Australian families due to higher ambient UV exposure ^[217]^D5. Carriers also face a markedly elevated risk of pancreatic cancer: the p16-Leiden founder mutation is associated with a **relative risk of 46.6 ** for pancreatic cancer ^[246]^B2b. CDK4 mutations are rare (<1% of families) but similarly increase melanoma risk through disruption of the p16-cyclin D-Rb pathway ^[200]^D5.

BAP1 germline mutations define the BAP1 tumor predisposition syndrome, which includes , cutaneous melanoma, malignant mesothelioma, and clear-cell ^[221]^D5. Nearly all BAP1 mutation carriers develop at least one malignancy during their lifetime ^[215]^D5. The syndrome also predisposes to well-differentiated papillary mesothelioma, as first described in a Portuguese family with concurrent uveal melanoma ^[211]^C4.

POT1, ACD, and TERF2IP encode components of the shelterin complex that protects telomeres; germline loss-of-function variants in these genes increase melanoma risk through telomere dysfunction ^[200]^D5. Mendelian randomization studies confirm that genetically longer telomeres are causally associated with melanoma (OR 1.87 per SD increase, 95%) ^[235]^B3a.

Moderate-Penetrance Genes

MITF p.E318K is a moderate-risk variant (OR ~2-4) that also predisposes to renal cell carcinoma ^[234]^B2b. ATM missense mutations (e.g., Ser49Cys) have been associated with a 4.8-fold increased risk of melanoma (95% CI 2.2-11) in a prospective Danish cohort ^[227]^B2b. PTEN hamartoma tumor syndrome ( ) carries a standardized incidence ratio for melanoma of **8.5 **, with a lifetime risk of 6% ^[247]^B2b. KDR (VEGFR2) germline variant Q472H, found in 35% of melanoma patients, is associated with higher serum VEGF levels and tumor microvessel density, and may predict sensitivity to antiangiogenic therapy ^[245]^C4.

Hereditary Syndromes

Familial atypical multiple mole and melanoma (FAMMM) syndrome is most often linked to CDKN2A mutations and is characterized by multiple dysplastic nevi and early-onset melanoma ^[238]^D5. (mismatch repair gene mutations) also confers melanoma risk: in a pan-cancer analysis, 16.3% of MSI-high tumors were associated with Lynch syndrome, including melanoma ^[223]^C4. survivors with inherited RB1 mutations have a 3.08-fold increased risk of melanoma (95% CI 1.23-7.16) compared with those with de novo mutations ^[225]^B2b.

Genetic Testing and Surveillance

Multi-gene panel testing doubles the detection rate compared with CDKN2A testing alone (9.47% vs 5.53% in an Italian cohort) ^[92]^B2b. Predictors of germline positivity include ≥3 primary melanomas (OR 3.23), pancreatic cancer in the family (OR 3.15), and age ≤60 years (negative predictor: OR 0.13 for age >60) ^[92]^B2b. Germline-positive patients have significantly improved melanoma-specific survival (HR 0.32, 95%) and lower levels of circulating PMN-MDSCs, suggesting a more favorable immune microenvironment ^[243]^B2b. Cascade testing of at-risk relatives is essential, as first-degree relatives of CDKN2A carriers face a 47.8-fold increased risk of pancreatic cancer ^[246]^B2b. Surveillance includes total-body skin examinations every 6-12 months, dermoscopy, and, for CDKN2A carriers, pancreatic imaging (MRI/MRCP or endoscopic ultrasound) starting at age 40 ^[117]^A1c.

Pearl: In families with CDKN2A mutations, the risk of pancreatic cancer is increased nearly 50-fold, warranting pancreatic surveillance (MRI/MRCP or EUS) in addition to dermatologic monitoring, beginning at age 40.

Selected Germline Genes Associated with Melanoma

Gene	Syndrome	Melanoma Risk	Associated Cancers
CDKN2A	FAMMM	Lifetime risk 28-91% (by geography)	Pancreatic (RR 46.6)
CDK4	FAMMM	High penetrance	Pancreatic
BAP1	BAP1-TPDS	High penetrance	Uveal melanoma, mesothelioma, RCC
POT1	Familial melanoma	High penetrance	Glioma, others
MITF p.E318K	,	OR 2-4	Renal cell carcinoma
ATM	Ataxia telangiectasia (biallelic)	HR 4.8 (missense)	Breast, prostate
PTEN	Cowden syndrome	SIR 8.5	Breast, thyroid, endometrial, RCC
RB1	Hereditary retinoblastoma	RR 3.08	Sarcomas, osteosarcoma

Histopathology and Molecular Biology

▸Melanoma histologic subtypes (SSM, NM, ALM, mucosal, uveal) have distinct mutation profiles: BRAF V600 in SSM; KIT in ALM and mucosal; GNAQ/GNA11 in uveal.
▸Acral lentiginous melanoma is an independent predictor of worse disease‑free survival (aHR 1.25 vs SSM) even after adjusting for Breslow thickness and ulceration.
▸Tumor‑infiltrating lymphocyte density quantified by AI predicts anti‑PD‑1 response (aOR 1.40 per 10% increase) and guides immunotherapy decisions.

HY High Yield: A BRAF V600E mutation in a melanocytic lesion does not guarantee cutaneous melanoma, it may also be seen in benign nevi, Langerhans cell histiocytosis, or Erdheim‑Chester disease. Quantitative molecular testing (e.g., allele frequency by ddPCR) can differentiate co‑occurring neoplasms [258].

From these genetic origins, the histological and molecular heterogeneity of melanoma shapes its clinical behavior and therapeutic vulnerabilities. The classification of melanoma into distinct histologic subtypes, superficial spreading, nodular, acral lentiginous, mucosal, and uveal, correlates with characteristic molecular drivers, immune microenvironments, and prognosis.

Histologic Subtypes and Their Molecular Profiles

Superficial spreading melanoma (SSM) accounts for approximately 60-70% of cutaneous melanomas and most commonly harbors BRAF V600 mutations (40-50%) or NRAS mutations (15-20%). It arises in intermittently sun-exposed skin, typically with a radial growth phase preceding vertical invasion. Nodular melanoma (NM) is more aggressive, often lacking a significant radial component, and has a higher frequency of NRAS mutations and TP53 alterations. However, after adjusting for Breslow thickness and ulceration, NM histotype is not an independent predictor of disease-free survival or overall survival compared with SSM ^[284]^B2b.

Acral lentiginous melanoma (ALM) arises on palms, soles, and nail beds, sites not typically exposed to UV radiation. ALM has a distinct molecular profile: BRAF mutations are rare (~15%), NRAS mutations uncommon (10%), and KIT mutations or amplifications occur in 10-15% of cases. Structural genomic variants (e.g., copy-number alterations, whole-chromosome gains/losses) are more prevalent than point mutations. ALM is associated with worse disease‑free survival independent of Breslow thickness, ulceration, and sentinel node status (adjusted HR 1.25, 95% vs SSM) ^[284]^B2b. Single‑cell transcriptomic analysis reveals ALM is enriched in PI16+ cancer-associated fibroblasts and TIGIT+ regulatory T cells, offering potential therapeutic targets ^[309]^C4.

Mucosal melanoma is rarest and most aggressive, with 5‑year survival of only 12% ^[288]^B2b. It arises in mucosal surfaces ( and neck, anorectal, female genital tract) and carries a low mutational burden. BRAF V600 mutations are very rare (<5%); instead, KIT mutations (10-20%), NRAS mutations (10%), and NF1 loss are found. Many cases are triple‑wild‑type (BRAF/NRAS/NF1 wild‑type) and may harbor GNAQ/GNA11 mutations, as seen in ^[319]^C4. Mucosal melanoma shows high neutrophil infiltration and CXCL3+ tumor‑associated macrophages ^[309]^C4.

Uveal melanoma is biologically distinct from cutaneous subtypes. It arises from melanocytes in the choroid, ciliary body, or iris and is driven by mutually exclusive mutations in GNAQ or GNA11 (80-90%), leading to constitutive activation of the MAPK and PI3K/AKT pathways ^[306]^D5. Secondary mutations in BAP1 (loss‑of‑function, associated with poor prognosis), SF3B1, or EIF1AX define prognostic groups. The integrated 15‑gene expression profile (15‑GEP) and PRAME RNA expression stratify metastasis‑free survival: 5‑year rates range from 95.6% (class 1/PRAME negative) to 44.8% (class 2/PRAME positive) ^[272]^B2b.

Mitogen‑Activated Protein Kinase Pathway and Driver Mutations

The MAPK pathway is activated in >90% of cutaneous melanomas, primarily by mutations in BRAF (V600E/K, ~40-50%), NRAS (Q61, ~15-20%), or NF1 loss (~15%). Mutations are typically mutually exclusive. The evolutionary sequence from benign nevi to invasive melanoma proceeds through stepwise acquisition of: (1) MAPK pathway activation (e.g., BRAF V600E in nevi), (2) TERT promoter mutations (upregulating telomerase), (3) CDKN2A loss (G1/S checkpoint override), (4) chromatin remodeling (e.g., ARID2, PPP6C), (5) TP53 disruption, and (6) PI3K/AKT pathway activation ^[302]^C4. RAC1 P29S, the third most common recurrent mutation in cutaneous melanoma (5-10%), activates PAK, AKT, and SRF/MRTF transcriptional programs, driving a mesenchymal phenotypic switch and resistance to BRAF inhibitors ^[301]^D5.

Other Key Molecular Alterations

PTEN loss (via deletion, mutation, or promoter methylation) occurs in 10-30% of melanomas and cooperates with BRAF V600E to accelerate metastasis in animal models ^[299]^D5. β‑catenin (CTNNB1) stabilization drives Wnt signaling and promotes lymph node and lung metastasis in BRAF/Pten‑deficient melanomas ^[299]^D5. Epigenetic regulators such as RNF2 are overexpressed and promote metastasis via H2AK119 monoubiquitination at the LTBP2 promoter (silencing a negative regulator of TGFβ) while driving proliferation through CCND2 upregulation independent of its catalytic activity ^[291]^D5. NTRK fusions (NTRK1/2/3) are rare (<1%) but actionable with TRK inhibitors ^[259]^D5.

Tumor Microenvironment and Immune Evasion

Intratumoral heterogeneity and microenvironmental interactions govern immune evasion. Tumor‑infiltrating lymphocyte (TIL) density, quantified by AI‑based histopathology, predicts response to anti‑PD‑1 therapy: each 10% increase in TILs increases the odds of objective response (aOR 1.40, 95%) and reduces hazard of progression (aHR 0.85) and death (aHR 0.83) ^[289]^B2b. Conserved IFN‑γ signaling in pretreatment and on‑therapy biopsies corresponds strongly with clinical benefit; responding tumors show reciprocal downregulation of cell‑cycle and WNT pathways ^[298]^B2b. PD‑L1 expression correlates with immune activation signatures but is not sufficient for response to MAPK inhibitors, as many progressing tumors remain PD‑L1‑positive ^[314]^C4. Macrophage‑derived TNFα confers resistance to MAPK pathway inhibitors via MITF upregulation, and treatment increases tumor‑associated macrophages ^[295]^D5. The tryptophan‑kynurenine‑AhR axis, mediated by IDO1, contributes to immunosuppression; a five‑gene tryptophan metabolism risk model (HADHA, GOT2, STAT1, CAT, IDO1) stratifies survival in cutaneous melanoma ^[326]^D5. Single‑cell studies of nevi‑to‑melanoma progression reveal HLA‑E upregulation on malignant cells and fibroblasts as a potential NK‑cell inhibitory checkpoint, and midkine as a paracrine factor promoting angiogenesis ^[308]^C4.

Histologic Subtype	Common Driver Mutations	Key Molecular Features	Prognostic Impact
Superficial spreading	BRAF V600 (40-50%), NRAS (15-20%)	High TMB, UV signature	Intermediate (reference)
Nodular	NRAS (20-30%), BRAF (30-40%), TP53	Higher proliferation	Not independent after adjustment for thickness ^[284]^B2b
Acral lentiginous	KIT (10-15%), BRAF (~15%), NRAS (~10%)	Structural variants, low TMB, TIGIT+ Tregs ^[309]^C4	Worse DFS (aHR 1.25 vs SSM) ^[284]^B2b
Mucosal	KIT (10-20%), NRAS (~10%), triple‑wild‑type	Very low TMB, CXCL3+ macrophages ^[309]^C4	5‑yr survival 12% ^[288]^B2b
Uveal	GNAQ/GNA11 (80-90%), BAP1, SF3B1, EIF1AX	Low TMB, no UV signature, 15‑GEP/PRAME ^[272]^B2b	MFS stratified by class/PRAME ^[272]^B2b

Prognostic and Predictive Signatures

Beyond single genes, multigene expression signatures refine prognosis. In stage I melanoma, a six‑class transcriptomic signature (Leeds Melanoma Cohort) predicts outcomes independent of sentinel node biopsy, with a class characterized by high JUN and AXL expression indicative of epithelial‑to‑mesenchymal transition ^[317]^B2b. miRNA signatures improve the AUC for 5‑year melanoma‑specific survival in stage II from 0.71 (clinical alone) to 0.81 when integrated with clinical factors ^[311]^C4. Spatially defined compartment‑specific gene signatures (e.g., an 8‑gene S100B signature including PSMB8, TAX1BP3, NOTCH3, LCP2, NQO1) outperform bulk transcriptomic methods in predicting ICI response ^[313]^C4. Tumor mutational burden (TMB) is a complementary biomarker: high TMB (>10 mutations/Mb) enriches for ICI benefit and is implementable via targeted panel sequencing ^[283]^D5. Microsatellite instability‑high (MSI‑H), though rare in melanoma, is associated with in 16.3% of MSI‑H solid tumors, including melanoma ^[223]^C4.

Pearl: In acral lentiginous melanoma, the absence of a BRAF V600 mutation should prompt testing for KIT alterations, while in uveal melanoma the 15‑GEP/PRAME classifier stratifies metastasis‑free survival more powerfully than any single clinical variable, use it to guide surveillance intensity and adjuvant trial eligibility ^[272]^B2b^[284]^B2b.

Clinical Presentation

▸The most common presenting symptom of melanoma is an abnormal mole, which is associated with early-stage (I-III) disease in 99% of cases; only 1% of patients with an abnormal mole have stage IV at diagnosis [378].
▸Incidence of thick melanomas (T4, >4.0 mm) is rising by 3.32% per year, with the highest rates in low-socioeconomic-status and minority populations [105].
▸A false-negative melanoma diagnosis delays correct treatment by a median of 24 months and leads to 8.2 years of life lost per patient [408].
▸Melanoma in pregnancy and in people living with HIV presents at more advanced stages and carries worse prognosis [44][336][402].

HY High Yield: The ABCDE rule (Asymmetry, Border irregularity, Color variegation, Diameter >6 mm, Evolution) remains the primary clinical screening tool; any changing mole warrants biopsy.

While histopathologic examination defines the diagnosis, the clinical presentation of cutaneous melanoma varies dramatically, from an incidentally detected abnormal mole to bulky metastatic disease causing constitutional symptoms. The stage at diagnosis is the strongest prognostic determinant, and recognizing the spectrum of presentations is essential for timely biopsy.

Presenting Symptoms

The most common presenting symptom is a changing pigmented lesion, often reported by the patient or a family member. In a population-based audit of 7997 patients with melanoma, the presenting symptom of an abnormal mole was associated with stage I-III disease in 99% of cases; only 1% of patients with an abnormal mole had stage IV disease at diagnosis ^[378]^B2c. Other local symptoms include bleeding, itching, ulceration, or a palpable nodule within a pre-existing nevus. As thickness increases, lesions may become raised, firm, or friable. Between 2010 and 2018, the incidence of the thickest melanomas (Breslow thickness >4.0 mm, T4) rose by 3.32% per year overall (APC 3.32%; 95% CI 2.06%-4.60%), while thin melanoma incidence stabilized ^[105]^B2b. Patients with low socioeconomic status and Hispanic or Black individuals are disproportionately diagnosed with T4 tumors (20.7% of non-Hispanic Black patients vs 6.3% of non-Hispanic White patients) ^[105]^B2b. Melanoma can also present as a new symptomatic metastasis without a known primary (melanoma of unknown primary), or as in-transit or satellite metastases, subcutaneous nodules between the primary site and the regional nodal basin.

Advanced disease may present with lymphadenopathy, respiratory symptoms from pulmonary metastases, abdominal pain from GI or liver involvement, or neurologic deficits from . The diagnosis-specific Graded Prognostic Assessment (GPA) for melanoma brain metastases identifies age, KPS, number of brain metastases, and extracranial disease as key survival determinants ^[371]^B2c.

Clinical Variants

Variant	Key Features	Typical Location	Relative Frequency
Superficial spreading melanoma	Slow radial growth; ABCDE criteria	Trunk (men), legs (women)	~70%
Nodular melanoma	Rapid vertical growth; often amelanotic; thicker at diagnosis	Any site	~15%
melanoma	Arises in sun-damaged skin; long in situ phase	, neck (elderly)	~10%
Acral lentiginous melanoma	Palms, soles, subungual; aggressive biology; low TMB	Acral sites	~2-5% (higher in darker skin)
Desmoplastic melanoma	Neurotropic; often amelanotic; firm, scar-like	Head, neck	~1%
Mucosal melanoma	Melanoma of mucosal surfaces (sinonasal, anogenital, oral); aggressive	Mucosal sites	Rare

Acral lentiginous melanoma is particularly challenging to diagnose early because subungual lesions may mimic trauma or fungal infection.

Atypical Presentations

Amelanotic melanoma lacks pigment and appears pink, red, or flesh-colored, leading to frequent misdiagnosis as basal cell carcinoma, pyogenic granuloma, or inflammatory lesion. It accounts for 2-8% of melanomas and often presents at a more advanced stage. Another challenging presentation is melanoma of unknown primary (MUP), where nodal or visceral metastases are found without a cutaneous, mucosal, or ocular primary; MUP represents about 3-5% of melanoma cases and often carries a prognosis similar to stage-matched known-primary disease, especially when there is a single nodal focus. Intestinal metastases from melanoma present with anemia, melena, abdominal pain, or obstruction, and can mimic primary GI malignancy ^[396]^D5. Rarely, pulmonary involvement manifests as oncoptysis (expectoration of tumor tissue), reported in fewer than 50 cases across all malignancies ^[409]^C4. Adrenal metastases are common (up to 50% of stage IV patients) and are often asymptomatic but associated with lower response to immune checkpoint inhibitors and shorter survival ^[357]^B2b.

Red Flags

A rapidly growing pigmented or amelanotic lesion (nodular melanoma can grow to >1 cm in weeks)
Spontaneous bleeding or ulceration in a pigmented lesion
New palpable lymphadenopathy in a patient with any history of melanoma
Constitutional symptoms (unexplained weight loss, fever, night sweats) in a patient with prior melanoma
Pregnancy-associated melanoma, which carries a higher risk of placental and fetal metastases (84.7% and 33.3% of gestational melanoma cases, respectively) and a median maternal survival of only 1 month postpartum ^[336]^C4. Postpartum melanoma diagnosis is associated with increased mortality (aHR 1.84; 95% CI 1.02-3.30) ^[44]^B3b.
Melanoma in people living with HIV (PLWH), who present at younger age, have a greater representation of Hispanic and Black individuals, develop brain metastases more frequently, experience delayed immune checkpoint inhibitor therapy, and have worse post-ICI survival ^[402]^B2b.

Pediatric Considerations

Pediatric cutaneous melanoma (age 0-10 years) is rare, and atypical Spitz tumors frequently enter the differential. The Children’s Oncology Group recommends that any suspicious melanocytic neoplasm be excised with 1-3 mm margins and that be reserved for cases where melanoma is favored on clinicopathologic evaluation ^[370]^A1c.

Pearl: A false-negative diagnosis of primary melanoma delays correct diagnosis by a median of 24 months and results in 8.2 years of life lost per affected patient, a stark reminder that any atypical melanocytic lesion should be biopsied, not observed ^[408]^B2b.

Biopsy and Histologic Diagnosis

▸Excisional biopsy with 1-3 mm margins and full-thickness specimen is the gold standard for accurate microstaging.
▸Immunohistochemistry panel (S100, SOX10, Melan-A, HMB-45, PRAME) confirms melanocytic origin and helps exclude mimics such as sarcomatoid squamous cell carcinoma.
▸BRAF V600E/K mutation testing is mandatory for all melanomas; KIT and NTRK testing are indicated in specific subtypes.

Dx Diagnostic Essentials: Gold-standard diagnostic test: **Excisional biopsy with 1-3 mm margins**, yielding a full-thickness specimen that includes the entire lesion for accurate microstaging (Breslow thickness, ulceration, mitotic rate) [413][370].

HY High Yield: Shave biopsies of suspicious melanocytic lesions often underestimate Breslow thickness and may preclude accurate microstaging; always prefer a full-thickness excisional biopsy when feasible [413].

When a clinician suspects melanoma based on clinical and dermoscopic findings, excisional biopsy with 1-3 mm margins remains the gold-standard diagnostic procedure ^[413]^A1c^[370]^A1c. A full-thickness specimen that encompasses the entire lesion enables accurate microstaging. Shave biopsies may be acceptable for low-risk lesions but risk inadequate depth and margin assessment, potentially compromising Breslow measurement and (SLNB) eligibility ^[413]^A1c.

Histopathologic Evaluation

The pathologist must report Breslow thickness to the nearest 0.1 mm, presence or absence of ulceration, dermal mitotic rate (mitoses/mm²), and peripheral and deep margin status ^[441]^A1c. Additional features, tumor-infiltrating lymphocytes, regression, lymphovascular invasion, and microscopic satellitosis, are recorded because they inform prognosis and SLNB decision-making ^[373]^D5^[443]^B2b. The mitotic rate replaces Clark level as the primary criterion for T1b subclassification in the staging system ^[441]^A1c.

Immunohistochemistry

Melanocytic lineage markers confirm the diagnosis. S100 and SOX10 are the most sensitive; in spindle cell or dedifferentiated melanoma, S100 exhibits a pooled sensitivity of 0.95 and specificity of 0.94 ^[447]^B2a. Differentiation markers include Melan-A/MART-1, HMB-45, and PRAME. For acral melanocytic proliferations, PRAME immunostaining at a cutoff of 3+/50% yields 78% sensitivity and 92% specificity, though interpretation in borderline lesions remains challenging ^[405]^A1a. When the differential includes sarcomatoid squamous cell carcinoma, a panel of p63/p40 and keratin 5/6 (sensitivity 0.94, specificity 0.93) is used to exclude epithelial tumors ^[447]^B2a.

Molecular Testing

All primary melanoma specimens should undergo BRAF V600E/K mutation testing to determine eligibility for targeted therapy with BRAF/MEK inhibitors ^[413]^A1c^[439]^B2b. KIT mutation analysis is indicated for acral, mucosal, and chronically sun-damaged melanomas; activating mutations may respond to imatinib or sunitinib ^[458]^C4. NTRK1/2/3 fusions, although rare, are detected by pan-TRK immunohistochemistry followed by next-generation sequencing and guide treatment with TRK inhibitors ^[259]^D5^[260]^D5. PD-L1 immunohistochemistry using validated assays (e.g., 22C3, SP142) provides predictive information for checkpoint inhibitor therapy, although its utility as a standalone biomarker remains limited ^[436]^D5^[439]^B2b^[451]^B2b.

Tissue Handling

Specimens are fixed in 10% neutral buffered formalin; the most representative tumor block is selected for routine hematoxylin and eosin staining. For patients with thin melanomas (T1a, <0.8 mm nonulcerated), routine molecular testing is not required ^[413]^A1c. In cases where fresh tissue is available (e.g., for research protocols or liquid biopsy correlation), it may be frozen for future genomic studies ^[453]^C4. For melanoma in situ, with a starting peripheral margin of ≤5 mm, immunohistochemistry (Melan-A, SOX10), and frozen tissue processing is recommended ^[415]^D5. Fine-needle biopsy (FNB) is reserved for suspected metastatic lesions; it provides diagnostic material and allows molecular testing while minimizing invasiveness ^[367]^D5^[269]^B2b.

Pearl: In any biopsy of a suspected melanoma, ensure the specimen is at least 1-3 mm deep and includes the full lesion margin; incomplete shave biopsies are the most common cause of inaccurate microstaging and missed eligibility for sentinel lymph node biopsy.

Immunohistochemistry and Molecular Markers in Primary Melanoma Diagnosis

Marker	Purpose	Sensitivity	Specificity	Notes
S100	Melanocytic lineage	0.95	0.94	Sensitive but not specific; expressed in nerve sheath tumors
SOX10	Melanocytic lineage	0.95	0.94	Nuclear stain; more specific than S100
Melan-A/MART-1	Differentiation	-	-	Often lost in desmoplastic melanoma
HMB-45	Differentiation (gp100)	-	-	Negative in desmoplastic melanoma
PRAME	Acral melanoma	0.78	0.92	Cutoff: 3+/50% ^[405]^A1a
BRAF V600E/K	Targeted therapy (BRAFi)	-	-	All melanomas should be tested ^[413]^A1c
KIT (exons 11, 13, 17, 18)	Targeted therapy (imatinib/sunitinib)	-	-	Acral, mucosal, CSD melanomas ^[458]^C4
PD-L1 (22C3, SP142)	Checkpoint inhibitor prediction	-	-	Heterogeneous expression; not a standalone biomarker ^[451]^B2b
NTRK1/2/3 fusions	TRK inhibitor therapy	-	-	Rare (<1%); screen by pan-TRK IHC, confirm by NGS ^[259]^D5]

Imaging

▸Imaging is not indicated for stage 0-IIA melanoma; for stage IIC-IV, PET‑CT is preferred but carries a 5.8% false‑positive rate [337,339].
▸One‑year PET‑CT with complete metabolic response (CMR) predicts 5‑year PFS of 90% in patients receiving anti‑PD‑1 therapy, guiding treatment duration decisions [488,490].

Dx Diagnostic Essentials: **Biopsy is mandatory for new lung nodules in melanoma patients**: 31% of biopsied lesions are not melanoma, and FDG‑PET avidity does not reliably exclude malignancy [269].

HY High Yield: **1‑year PET‑CT CMR**: 90% 5‑year PFS vs 54% for non‑CMR; use to consider treatment discontinuation in patients on anti‑PD‑1 therapy [488].

Once histologic diagnosis confirms melanoma and primary tumor characteristics (Breslow thickness, ulceration, mitotic rate) are established, imaging is used to stage, restage, and surveil the disease. Modality choice and sequencing follow guideline recommendations that balance yield against the risks of false positives, cost, and radiation exposure.

Pretreatment Staging

Imaging is not routinely indicated for patients with stage 0-IIA melanoma, in whom the probability of clinically occult distant disease is very low ^[339]^D5. For stage IIC, III (any N), and IV melanoma, cross-sectional imaging is recommended to detect synchronous metastases. Chest, abdominal, and pelvic CT with intravenous contrast is the standard first-line modality for evaluating pulmonary, hepatic, nodal, and soft-tissue sites ^[349]^D5. PET‑CT is more sensitive than CT alone for identifying distant metastases, especially in bone and subcutaneous tissue, and is preferred when surgical resection of oligometastatic disease is contemplated ^[349]^D5. However, PET‑CT carries a non‑negligible false‑positive rate: a meta‑analysis of 14 prospective studies reported a pooled patient‑based false‑positive proportion of 5.8% (95% CI 3.3%-8.8%), most commonly involving lymphatic, dermatologic, respiratory, or skeletal findings ^[337]^B2a. False positives can lead to unnecessary biopsies, patient anxiety, and treatment delay.

For patients with a positive sentinel lymph node (SLN) who are asymptomatic, the yield of routine CT or MRI before completion lymphadenectomy is low. In a single‑institution series of 270 SLN‑positive patients, only 1.9% had radiologically detectable synchronous distant metastases, and detection was associated with thicker primary tumors, ulceration, and higher SLN tumor burden ^[497]^B2b. Thus, immediate imaging is not mandatory for all SLN‑positive patients; it is most appropriate when concerning symptoms or high‑risk primary features are present.

Brain MRI is mandatory for stage IV melanoma and should be considered for stage III melanoma, particularly when neurological symptoms exist or when systemic therapy selection may be affected ^[349]^D5. Contrast‑enhanced MRI is the most sensitive technique for detecting parenchymal and leptomeningeal disease.

Clinical scenario	Recommended imaging	Strength of evidence
Stage 0-IIA (asymptomatic)	None routinely	Category 2A (NCCN) ^[468]^A1c
Stage IIC, III, IV (staging)	CT chest/abdomen/pelvis (± PET‑CT)	Category 1 (ESMO) ^[349]^D5
Brain evaluation (stage IV)	MRI brain with contrast	Category 1 ^[349]^D5
Before completion lymphadenectomy (SLN‑positive, asymptomatic)	CT/MRI selectively (not routine)	Category 2B ^[497]^B2b

Surveillance Imaging

The role of routine surveillance imaging in patients who remain free of disease after definitive therapy is controversial. The TRIM trial - a multicentre, randomised phase 3 study in Sweden - compared physical examination alone with physical examination plus whole‑body CT or PET‑CT at baseline, 6, 12, 24, and 36 months after radical surgery for stage IIB-III melanoma. At a median follow‑up of, 3‑year overall survival was in the standard group versus in the imaging group (, 95%; p = 0.85), and distant metastasis‑free survival did not differ ^[471]^A1b. These interim data suggest that routine imaging does not improve survival and may not be necessary for all high‑risk patients, though the full analysis awaits 5‑year data.

A sub‑stage‑specific PET‑CT surveillance programme in 170 stage 3 melanoma patients (3A-3C) identified relapses in 38%; 69% of those were asymptomatic ^[491]^B2b. The positive predictive value of individual scans ranged 56%-83%; negative predictive values were 89%-96% until the next scan. A negative PET at 18 months had an 80%-84% NPV for true non‑recurrence over a median 47‑month follow‑up ^[491]^B2b. Thus, while imaging detects recurrence earlier, whether earlier detection translates into a survival benefit remains unproven outside of clinical trials.

For patients with thin (T1) melanomas, recurrence is uncommon but not negligible: nomograms that incorporate Breslow thickness, ulceration, mitotic rate, and patient age can identify high‑risk subgroups (C‑statistic 0.77-0.80) ^[498]^B2b. Similarly, the MIA calculator provides personalised 5‑ and 10‑year recurrence estimates for stage II melanoma, with C‑statistics of 0.70-0.73 for recurrence‑free survival, outperforming ‑8 staging alone (0.60-0.61) ^[495]^B2b. These tools may help guide decisions about who might benefit from surveillance imaging, but their use is not yet standardised.

Response Assessment

PET‑CT is the preferred modality for assessing metabolic response to systemic therapy. In patients with BRAF‑mutant advanced melanoma, FDG‑PET after 15 days of vemurafenib showed an 80% reduction in SUVmax and all 27 patients treated at therapeutic doses had at least a partial metabolic response ^[473]^C4. This early metabolic change correlated with longer progression‑free survival ^[473]^C4. For dabrafenib, dose‑finding studies used FDG‑PET pharmacodynamics to demonstrate that 150 mg twice daily achieves >80% pERK inhibition and a robust decline in tumour FDG uptake, confirming the recommended phase 2 dose ^[479]^C4.

At 1 year after starting anti‑PD‑1‑based therapy ( or ± ), PET‑CT outperforms CT alone in predicting long‑term outcomes. In a retrospective analysis of 104 patients, complete metabolic response (CMR) on PET at 1 year was observed in 75% of patients, including two‑thirds of those with a partial response on CT ^[490]^B2b. Five‑year progression‑free survival after the 1‑year landmark was 90% for patients with CMR versus 54% for non‑CMR (HR 0.06) ^[488]^B2b. Among those with a partial response on CT, CMR on PET identified a subgroup with 5‑year PFS of 88% ^[488]^B2b. These data support using 1‑year PET‑CT to guide decisions about treatment continuation or discontinuation.

Novel PET tracers are emerging. 89Zr‑pembrolizumab imaging allows non‑invasive visualisation of PD‑1 antibody biodistribution; tumour uptake correlated with response (p = 0.014) and survival (p = 0.0025) in a pilot study of 18 patients ^[487]^B2b. 18F‑PFPN, a melanin‑targeted tracer, showed higher lesion‑based sensitivity than FDG (91% vs 83%) and zero false‑positives in a prospective mucosal melanoma cohort (n = 65), and its uptake correlated with HMB45 and SOX10 expression ^[506]^B2b. Artificial‑intelligence‑based radiomic analysis of baseline CT images has shown promise in predicting immunotherapy response (AUC 0.76) ^[484]^B2b, though not yet ready for routine use.

Special Considerations

Pulmonary nodules: In melanoma patients with new lung lesions, biopsy remains essential because 31% of biopsied nodules were not melanoma - 19% represented other malignancies and 12% benign processes ^[269]^B2b. FDG‑PET avidity did not reliably distinguish benign from malignant nodules in that series (p = 0.53), underscoring the need for tissue confirmation ^[269]^B2b.

Brain metastases and leptomeningeal disease: Melanoma is an independent risk factor for developing leptomeningeal disease after brain metastasis resection (p = 0.003) ^[198]^B2b. Postoperative systemic therapy is protective (HR 0.64, p = 0.028). Serum lactate dehydrogenase (LDH) correlates strongly with the presence and volume of peritumoral brain edema on preoperative MRI (r = 0.822, p < 0.001), with an optimal cut‑off of 179.4 U/L (AUC 0.802) ^[512]^C4. These findings may help prioritise brain imaging in at‑risk patients.

Immunotherapy‑related pneumonitis: PD‑1 inhibitor‑related pneumonitis develops in approximately 12% of treated melanoma patients and shows a spectrum of radiographic patterns on CT: cryptogenic organising pneumonia (COP) is most common (65%), followed by non‑specific interstitial pneumonia (15%), (10%), and /ARDS (10%) ^[481]^C4. COP pattern is associated with lower toxicity grade, while AIP/ARDS has the highest grade ^[481]^C4. Awareness of these patterns is critical for prompt diagnosis and .

Pearl: Routine imaging is not indicated for stage I-IIA melanoma; for high‑risk patients, PET‑CT is the preferred staging modality but carries a 5.8% false‑positive rate ^[337]^B2a. Surveillance imaging does not improve overall survival in stage IIB-III melanoma ^[471]^A1b, yet a 1‑year PET‑CT showing complete metabolic response is the strongest predictor of durable benefit after immunotherapy (5‑year PFS 90% vs 54%) ^[488]^B2b^[490]^B2b.

Molecular Diagnostics and Biomarkers

▸NCCN guidelines recommend BRAF V600 mutation testing for all patients with stage III or IV cutaneous melanoma to determine eligibility for targeted therapy.
▸Circulating tumor DNA detection at baseline or postoperatively identifies patients at highest risk of relapse and can distinguish pseudoprogression from true progression during anti-PD-1 therapy.
▸Tumor mutational burden ≥10 mutations/Mb is associated with higher response rates to immune checkpoint inhibitors in melanoma, but its predictive value as a standalone biomarker is limited by inter-tumor heterogeneity.

HY High Yield: A favorable ctDNA profile (undetectable or >10-fold decrease) during anti-PD-1 therapy rules out pseudoprogression with 100% specificity; unfavorable ctDNA (stable or rising) identifies true progression [558].

Dx Diagnostic Essentials: BRAF mutation testing is the critical first molecular step for any patient with advanced melanoma. Order it from the diagnostic biopsy or a metastatic site.

Radiographic staging identifies the extent of disease, but molecular profiling of the tumor is the gate to targeted and immune-based therapy. Testing for actionable mutations, tumor mutational burden (TMB), and circulating tumor DNA (ctDNA) now informs treatment selection, prognostication, and surveillance.

BRAF Mutation Testing

The NCCN Guidelines recommend BRAF V600 mutation testing for all patients with stage III or IV cutaneous melanoma ^[1]^A1c^[210]^D5. Testing may be performed on the primary tumor or a metastatic specimen using a validated assay such as next-generation sequencing (NGS), polymerase chain reaction (PCR), or immunohistochemistry (IHC) with a BRAF V600E-specific antibody. The College of American Pathologists (CAP) also requires BRAF testing to be available for every newly diagnosed melanoma patient. Identifying a BRAF V600E or V600K mutation opens the door to combination BRAF-MEK inhibitor therapy (dabrafenib plus trametinib, encorafenib plus binimetinib, or vemurafenib plus cobimetinib), which improved 3-year overall survival from 32% to 44% in the COMBI-d trial ^[120]^A1b and produced a median progression-free survival of versus 7.3 months in COLUMBUS ^[517]^A1b.

Beyond BRAF: NRAS, KIT, and NF1

Among BRAF-wild-type melanomas, NRAS mutations occur in approximately 15-20% of cases and are associated with worse melanoma-specific survival in higher-risk primary tumors (HR 2.9, 95%) ^[178]^B2b. KIT mutations are enriched in melanomas arising on mucosal surfaces (39%), acral skin (36%), and chronically sun-damaged skin (28%), and are targetable with imatinib ^[543]^C4. NRAS-mutant melanomas may benefit from MEK inhibitor-based regimens, though no therapy is yet FDA-approved specifically for this subset. NF1 loss-of-function mutations define a subtype with a two-fold higher TMB (median 43.2 versus 18.6 mut/Mb) and are associated with lung-tropic metastasis (OR 2.11, 95%) ^[591]^B3b. The presence of an SRSF2 mutation or BAP1 loss further distinguishes aggressive subtypes ^[567]^C4.

Tumor Mutational Burden and PD-L1

TMB-high (≥10 mutations per megabase) tumors in melanoma show a 39.8% objective response rate to immune checkpoint blockade, with an odds ratio of 4.1 versus TMB-low tumors ^[530]^B2b. However, TMB as a universal pan-cancer cutoff performs inconsistently across histologies; melanoma-specific thresholds may better predict benefit ^[559]^B3b. PD-L1 expression by IHC on tumor cells (commonly using a 1% or 5% cutoff) correlates with response to PD-1 inhibitors but is neither necessary nor sufficient for benefit, negative staining does not preclude response ^[472]^C4. Intriguingly, pretreatment PD-L1 expression in BRAF-mutant melanoma predicts primary resistance to BRAF inhibitors (HR 4.3 for progression-free survival) ^[439]^B2b, while elevated serum PD-1 and PD-L1 levels independently predict poor outcome with anti-PD-1 therapy (HR for OS 2.85, 95%) ^[538]^B2b.

Circulating Tumor DNA

Plasma ctDNA detection using droplet digital PCR or NGS has emerged as a powerful biomarker. In the COMBI-AD biomarker analysis, baseline ctDNA positivity (13% of patients) was associated with markedly worse recurrence-free survival (median 3.71 versus in the placebo group) ^[518]^B2b. A meta-analysis of 24 cohorts confirmed that landmark ctDNA positivity (≤12 weeks post-resection) confers a 3.42-fold increased risk of relapse and a 5.38-fold increased risk of distant metastasis ^[11]^A1a. During anti-PD-1 therapy, a favorable ctDNA profile (undetectable or >10-fold decrease) can distinguish pseudoprogression from true progression with 90% sensitivity and 100% specificity ^[558]^B2b. Tumor-informed bespoke assays detect molecular residual disease a median of 128 days before radiographic relapse ^[553]^B2b. Several ongoing trials are evaluating ctDNA-guided adjuvant treatment intensification or de-escalation.

Gene Expression Profiling

Gene expression profiling (GEP) assays (e.g., DecisionDx-Melanoma, MyPath Melanoma) measure multigene transcriptional signatures from the primary tumor to refine prognostication beyond staging. In stage I/II disease, a 31-gene GEP classifies patients as low-risk or high-risk and is independently associated with recurrence risk ^[17]^D5. However, current NCCN Guidelines do not recommend routine GEP testing for clinical decision-making, citing a lack of prospective validation and limited evidence that GEP results alter ^[1]^A1c. In uveal melanoma, the integrated 15-gene expression profile plus PRAME status is prospectively validated and provides 5-year metastasis-free survival ranging from 95.6% (class 1/PRAME-negative) to 44.8% (class 2/PRAME-positive) ^[272]^B2b.

Pearl: A detectable ctDNA at the postoperative landmark timepoint increases the hazard of relapse by over 3-fold (HR 3.42, 95%) and should prompt consideration of intensified adjuvant therapy or closer surveillance ^[11]^A1a.

Staging

▸AJCC 8th edition staging defines T by Breslow thickness and ulceration (mitotic rate no longer T1b criterion), N by nodal burden and microscopic vs macroscopic disease, and M by site and LDH.
▸Sentinel lymph node biopsy is standard for T2-T3 melanoma and considered for T1b; completion dissection is no longer mandatory in sentinel-positive patients based on MSLT-II.
▸Emerging biomarkers such as ctDNA and gene expression profiles improve risk stratification beyond anatomic stage but await formal inclusion into staging systems.

HY High Yield: In AJCC 8th edition, T1b is defined solely by thickness 0.8-1.0 mm or ulceration <0.8 mm, mitotic rate is no longer a T category criterion but remains a separate independent prognostic factor.

Because of melanoma hinges entirely on accurate stage assignment, the American Joint Committee on Cancer ( ) staging system (8th edition, 2017) provides the framework for all treatment decisions. The transition from 7th to 8th edition refined T and N categories to better capture prognostic heterogeneity, particularly for patients with thin primaries and microscopic nodal disease ^[60]^D5.

T category: Breslow thickness and ulceration

T category is determined by the primary tumor's Breslow thickness and the presence or absence of histologic ulceration. T1 lesions are ≤1.0 mm thick: T1a is <0.8 mm without ulceration; T1b is 0.8-1.0 mm or <0.8 mm with ulceration ^[441]^A1c. Unlike the 7th edition, mitotic rate no longer defines T1b, it remains a separate adverse prognostic factor but is not incorporated into T category ^[60]^D5. T2 tumors are >1.0-2.0 mm, T3 >2.0-4.0 mm, and T4 >4.0 mm; each is subdivided into "a" (no ulceration) and "b" (ulceration present).

N category: regional lymph node involvement

The N category integrates the number of tumor-involved regional nodes, the burden of disease (microscopic vs. macroscopic), and the presence of in-transit, satellite, or microsatellite metastases. Microscopic (clinically occult) nodal disease detected by (SLNB) carries a better prognosis than macroscopic (palpable) involvement ^[441]^A1c. N1 denotes one involved node, N2 two or three nodes, and N3 four or more nodes, matted nodes, or any number of nodes with in-transit/satellite metastases ^[468]^A1c. Any patient with nodal disease is classified as stage III, but the substage (IIIA-IIID) is defined by the combination of T category, N category, and ulceration status ^[60]^D5.

M category: distant metastases

M category depends on the site of distant spread and serum lactate dehydrogenase (LDH) level. M1a indicates distant skin, subcutaneous, or nodal metastases with normal LDH; M1b indicates lung metastases (normal LDH); M1c indicates any other visceral metastases (normal LDH); M1d indicates central nervous system metastases, regardless of LDH level. An elevated LDH shifts any M1a-M1c substage to a higher-risk category (M1c^[1]^A1c) ^[441]^A1c.

Stage groupings

AJCC Stage	T category	N category	M category
0 (in situ)	Tis	N0	M0
IA	T1a	N0	M0
IB	T1b-T2a	N0	M0
IIA	T2b-T3a	N0	M0
IIB	T3b-T4a	N0	M0
IIC	T4b	N0	M0
IIIA	T1-T2a	N1a-N2a (microscopic)	M0
IIIB	T0-T4a	N1a-N2b (macroscopic)	M0
IIIC	T0-T4b	N1b-N3	M0
IIID	T4b	N3	M0
IV	Any T	Any N	M1
Stage IIID, introduced in the 8th edition, identifies the highest-risk node-positive subgroup. Among 14,978 patients with resected stage III melanoma in the National Cancer Database, 36-month overall survival for stage IIID was 59.2% with postoperative immunotherapy versus 48.4% without ^[499]^B2b.

Sentinel lymph node biopsy as a staging tool

SLNB is the most important staging procedure for clinically node-negative patients. The ASCO/SSO guideline recommends routine SLNB for T2-T3 melanomas (>1.0-4.0 mm) and consideration for T1b (0.8-1.0 mm or <0.8 mm with ulceration); it is not recommended for T1a ^[417]^A1c. Completion lymph node dissection after a positive SLNB improves regional control but does not improve melanoma-specific survival compared with observation, so nodal observation with serial ultrasound is an acceptable alternative for low-risk micrometastatic disease ^[426]^A1b.

Imaging for staging

Cross-sectional imaging is reserved for higher-risk stages. Chest and abdominal CT is indicated for stage IIC, IIIB, IIIC, and IIIA with macroscopic nodal disease; MRI of the brain is mandatory for stage IV and considered for selected stage III patients ^[349]^D5^[618]^A1c. FDG-PET/CT is more accurate than CT alone for detecting distant metastases and is recommended when surgical resection of oligometastatic disease is planned ^[349]^D5.

Emerging molecular staging tools

Although not yet incorporated into formal staging, circulating tumor DNA (ctDNA) has strong prognostic value. Preoperative ctDNA detection in stage III melanoma independently predicts distant metastasis-free survival and melanoma-specific survival ^[628]^B2b and identifies patients at highest risk of relapse after surgery ^[532]^B2b. Gene expression profiling assays provide additional risk stratification beyond AJCC stage for stage II melanoma, improving the C-statistic for 5-year melanoma-specific survival from 0.71 to 0.81 in a recent validation study ^[311]^C4. These tools may eventually refine adjuvant therapy decisions, but prospective trials are needed before routine use ^[17]^D5^[494]^B2a.

Pearl: For patients with stage IIB-IIIC melanoma, the AJCC 8th edition substage and the presence of ulceration stratify risk more precisely than prior editions; ctDNA detection before or after surgery identifies a subset with recurrence risk comparable to one full stage higher, consider this added information when discussing adjuvant therapy options.

AJCC 8th Edition Stage Groupings for Cutaneous Melanoma

AJCC Stage	T category	N category	M category
0 (in situ)	Tis	N0	M0
IA	T1a	N0	M0
IB	T1b-T2a	N0	M0
IIA	T2b-T3a	N0	M0
IIB	T3b-T4a	N0	M0
IIC	T4b	N0	M0
IIIA	T1-T2a	N1a-N2a (microscopic)	M0
IIIB	T0-T4a	N1a-N2b (macroscopic)	M0
IIIC	T0-T4b	N1b-N3	M0
IIID	T4b	N3	M0
IV	Any T	Any N	M1

Management Overview

▸Neoadjuvant ipilimumab plus nivolumab followed by response-driven adjuvant therapy is supported by the phase 3 NADINA trial and NCCN guidelines for resectable stage III melanoma.
▸For advanced melanoma, checkpoint inhibitor-based regimens (nivolumab+ipilimumab, anti-PD-1 monotherapy, or nivolumab+relatlimab) should be considered first-line; BRAF-targeted therapy is a category 1 option but sequence matters, with immunotherapy-first preferred based on DREAMseq.
▸TIL therapy (lifileucel) and combination ipilimumab+pembrolizumab are effective after anti-PD-1 failure; cytotoxic chemotherapy should be reserved for last resort.

Rx Drug of Choice: First-line advanced melanoma: nivolumab + ipilimumab (NIVO1 mg/kg + IPI 3 mg/kg q3w × 4, then NIVO maintenance) achieves the longest median OS reported in a phase 3 trial (72.1 months) and is preferred for fit patients regardless of BRAF status [608][654].

! Warning: CheckMate 511 demonstrated that high-dose ipilimumab (3 mg/kg) plus nivolumab (1 mg/kg) has significantly higher toxicity (48% Grade 3-5) compared to the alternate schedule (NIVO 3 mg/kg + IPI 1 mg/kg; 34% Grade 3-5), though efficacy is descriptively similar [5]. The standard first-line regimen remains NIVO1+IPI3, but NIVO3+IPI1 is an option for patients with higher toxicity risk.

Staging classification directly guides treatment selection across all phases of melanoma . The treatment landscape has shifted dramatically over the past decade, with immune checkpoint inhibitors and targeted therapies now forming the backbone of care across resectable and advanced disease. This section provides a framework for applying these therapies; detailed protocols reside on the respective modality pages.

Resectable Disease: Neoadjuvant and Adjuvant Therapy

For patients with resectable, macroscopic stage III melanoma, neoadjuvant plus followed by surgery and response-driven adjuvant therapy is now the preferred approach. The phase 3 NADINA trial (N=423) demonstrated an estimated 12-month event-free survival of 83.7% in the neoadjuvant group versus 57.2% with surgery followed by adjuvant nivolumab (HR 0.32; 99.9% CI 0.15-0.66; P<0.001) ^[607]^A1b. A major pathologic response (≤10% viable tumor) occurred in 59.0% of patients, and those with a major response had an estimated 12-month recurrence-free survival of 95.1% ^[607]^A1b. The ASCO 2023 guideline update now recommends neoadjuvant for resectable stage IIIB-IV melanoma based on the S1801 trial, which showed improved event-free survival for neoadjuvant-adjuvant pembrolizumab over adjuvant-only (2-year EFS 72% vs 49%; P=0.004) ^[662]^A1b^[654]^A1c.

Adjuvant therapy remains an option for patients with resected stage IIB-IV disease who do not receive neoadjuvant treatment. The NCCN Guidelines (v.2.2024) recommend adjuvant nivolumab or pembrolizumab for stage IIB-IV melanoma (category 1) and adjuvant dabrafenib plus trametinib for stage III BRAF V600-mutant melanoma (category 1) ^[468]^A1c^[485]^D5. In KEYNOTE-716, adjuvant pembrolizumab improved 36-month distant metastasis-free survival versus placebo in stage IIB/IIC melanoma (84.4% vs 74.7%; HR 0.59; 95% CI 0.44-0.79) ^[597]^A1b. CheckMate 238 confirmed sustained benefit of adjuvant nivolumab over ipilimumab at 5-year follow-up (RFS HR 0.72; 95%) ^[743]^A1b. For BRAF-mutant stage III melanoma, COMBI-AD showed 8.3-year median follow-up with improved relapse-free survival (HR 0.52; 95% CI 0.43-0.63) ^[609]^A1b. The role of adjuvant therapy in stage IIIA ( v8) is less clear; retrospective data suggest anti-PD-1 may not significantly improve outcomes over observation in this subgroup ^[627]^B2b.

Unresectable or Metastatic Disease

First-line therapy for advanced (unresectable or metastatic) melanoma is determined by BRAF mutation status, patient performance status, and comorbidity profile. A summary of recommended first-line regimens is provided in Table 1.

Regimen	Indication	Key efficacy data	Toxicity (Grade 3-4)	Evidence level
Nivolumab + ipilimumab (NIVO1+IPI3 q3w × 4, then NIVO maintenance)	First-line, regardless of BRAF status	Median OS 72.1 mo (CheckMate 067, 10-yr); HR vs ipilimumab 0.53; 10-yr OS 43% (combination) and 37% (nivo alone) ^[608]^A1b^[596]^A1b	55-59% ^[660]^A1b^[5]^A1b	Category 1 (NCCN ^[468]^A1c), preferred by ASCO ^[654]^A1c
Nivolumab (240 mg q2w or 480 mg q4w)	First-line, BRAF wild-type or BRAF mutant	Median OS 36.9 mo (CheckMate 067); 10-yr OS 37% ^[608]^A1b	16% ^[660]^A1b	Category 1
Pembrolizumab (200 mg q3w or 400 mg q6w)	First-line, any BRAF status	Median OS 32.7 mo (KEYNOTE-006, 10-yr); 10-yr OS 34% ^[594]^A1b^[664]^A1b	13-14% ^[664]^A1b	Category 1
Nivolumab + relatlimab (fixed-dose q4w)	First-line, any BRAF status	Median PFS 10.1 mo vs 4.6 mo for nivolumab (HR 0.75; 95% CI 0.62-0.92) ^[661]^A1b	18.9% vs 9.7% ^[661]^A1b	Category 2A (NCCN ^[468]^A1c)
Dabrafenib + trametinib (D 150 mg BID + T 2 mg daily)	First-line, BRAF V600-mutant only	Median PFS 11.0 mo (COMBI-d); OS HR 0.71 vs dabrafenib ^[485]^D5^[609]^A1b	32%	Category 1
Encorafenib + binimetinib (E 450 mg daily + B 45 mg BID)	First-line, BRAF V600-mutant only	Median PFS 14.9 mo (COLUMBUS) vs vemurafenib; HR 0.54 (95% CI 0.41-0.71) ^[517]^A1b	40%	Category 1
Vemurafenib + cobimetinib (V 960 mg BID + C 60 mg daily 21/7)	First-line, BRAF V600-mutant only	Median PFS 12.3 mo; HR 0.58 vs vemurafenib ^[485]^D5	39%	Category 1

For patients with BRAF V600-mutant melanoma, the DREAMseq trial ( -ACRIN EA6134) demonstrated a significant 2-year OS advantage for initial immunotherapy (nivolumab+ipilimumab) followed by dabrafenib+trametinib at progression (71.8% vs 51.5%; P=0.010), establishing nivolumab+ipilimumab as the preferred first-line strategy for most patients ^[655]^A1b. The SECOMBIT trial, using a sandwich design, confirmed high 3-year OS rates of 62% for immunotherapy-first sequencing, with no clear superiority over other sequences, but all arms exceeded the 15-month median OS null hypothesis ^[656]^A1b.

For patients with contraindications to high-dose corticosteroids or autoimmune disease, anti-PD-1 monotherapy or LAG-3 combination may be considered. The combination of nivolumab plus relatlimab (LAG-3 inhibitor) improved median PFS to 10.1 months versus 4.6 months with nivolumab alone (HR 0.75; 95% CI 0.62-0.92) in RELATIVITY-047, making it an alternative first-line option ^[661]^A1b^[654]^A1c.

After progression on anti-PD-1

For patients whose disease progresses on anti-PD-1 therapy, options include ipilimumab plus pembrolizumab (ORR 29%; median OS 24.7 months) ^[671]^C4, RP1 (oncolytic virus) plus nivolumab (ORR 32.9%; 63.3% 2-year OS) ^[672]^C4, or TIL therapy (lifileucel), FDA-approved for anti-PD-1-refractory melanoma after prior checkpoint and BRAF/MEK inhibitors if BRAF-mutant, with an ORR of 31.5% (95% CI 21.1%-) and median duration of response not reached (5-year median DOR 36.5 months) ^[51]^C4^[698]^C4^[699]^C4. Ipilimumab monotherapy is no longer recommended after anti-PD-1 failure if combination is feasible ^[654]^A1c.

Special Populations

: In patients with asymptomatic melanoma brain metastases, combination nivolumab+ipilimumab achieved an intracranial clinical benefit rate of with 71.9% 3-year OS (CheckMate 204) ^[678]^C4. For BRAF-mutant disease, dabrafenib+trametinib produced intracranial responses in 58% of patients (COMBI-MB) ^[344]^C4. Local therapy ( ) may be deferred if systemic therapy is initiated with close monitoring ^[118]^A1c^[709]^D5.

: For HLA-A*02:01-positive patients with metastatic uveal melanoma, tebentafusp (a bispecific T-cell engager targeting gp100 and CD3) significantly improved 3-year OS (27% vs 18%; HR 0.68; 95% CI 0.54-0.87) ^[22]^A1b^[666]^A1b^[711]^D5. Checkpoint inhibitors have limited activity in uveal melanoma ^[263]^D5^[703]^D5.

What NOT to Do

Do NOT use cytotoxic chemotherapy (dacarbazine, temozolomide, platinum/taxanes) as first-line therapy; response rates are <15% and no survival benefit has been shown in the immunotherapy era ^[745]^D5^[747]^B3b.
Do NOT routinely administer whole-brain radiation therapy (WBRT) for multiple brain metastases without attempting systemic therapy if the patient is asymptomatic; WBRT does not improve OS and impairs neurocognition ^[134]^D5^[678]^C4.

Controversies and Guideline Disagreement

Question	Position A	Position B	Strength	Implication for practice
First-line sequencing for BRAF-mutant advanced melanoma	ASCO 2023 and DREAMseq favor initiating immunotherapy (nivo+ipi) over targeted therapy (dabrafenib+trametinib) based on a 2-year OS difference ^[655]^A1b^[654]^A1c	NCCN lists both as category 1 options, with no preference for one over the other ^[468]^A1c	Moderate (NCCN does not formally prioritize, though recent updated evidence supports immunotherapy-first)	Most centers now start with immunotherapy for BRAF-mutant patients who are fit for combination therapy; targeted therapy remains a reasonable alternative for those with contraindications to immunotherapy or high tumor burden requiring rapid response.
Adjuvant therapy for stage IIIA (AJCC v8)	NCCN suggests adjuvant therapy may be considered for stage IIIA (category 2B) ^[468]^A1c	Retrospective data from Grover et al. (2025) show no clear benefit of anti-PD-1 over observation in IIIA (2-year RFS 79.3% vs 84.3%) ^[627]^B2b	Moderate (retrospective evidence versus expert consensus)	Shared decision-making is essential; patients with high-risk features (e.g., Breslow >2 mm, high mitotic rate) may still derive some benefit; observation is reasonable for low-risk IIIA.

Pearl: For advanced melanoma, starting with nivolumab plus ipilimumab in fit patients (BRAF-mutant or wild-type) yields the highest long-term survival, with a 10-year OS of 43% and median OS exceeding 6 years, at the cost of significant toxicity that requires proactive management ^[608]^A1b. Neoadjuvant immunotherapy is transforming the management of resectable stage III disease, with two cycles of ipilimumab plus nivolumab now supported by phase 3 evidence and endorsed by NCCN ^[607]^A1b^[468]^A1c.

Table 1. First-Line Systemic Therapy Options for Unresectable or Metastatic Melanoma

Regimen	Indication	Key efficacy data	Toxicity (Grade 3-4)	Evidence level
Nivolumab + ipilimumab (NIVO1+IPI3 q3w × 4, then NIVO maintenance)	First-line, any BRAF status	Median OS 72.1 mo (CheckMate 067, 10-yr); HR vs ipilimumab 0.53; 10-yr OS 43% ^[608]^A1b^[596]^A1b	55-59% ^[660]^A1b^[5]^A1b	Category 1 ^[468]^A1c, preferred by ASCO ^[654]^A1c
Nivolumab (240 mg q2w or 480 mg q4w)	First-line, any BRAF status	Median OS 36.9 mo; 10-yr OS 37% ^[608]^A1b	16% ^[660]^A1b	Category 1
Pembrolizumab (200 mg q3w or 400 mg q6w)	First-line, any BRAF status	Median OS 32.7 mo; 10-yr OS 34% ^[594]^A1b^[664]^A1b	13-14% ^[664]^A1b	Category 1
Nivolumab + relatlimab (fixed-dose q4w)	First-line, any BRAF status	Median PFS 10.1 mo vs 4.6 mo for nivo (HR 0.75; 95% CI 0.62-0.92) ^[661]^A1b	18.9% vs 9.7% ^[661]^A1b	Category 2A ^[468]^A1c
Dabrafenib + trametinib (D 150 mg BID + T 2 mg daily)	First-line, BRAF V600-mutant	Median PFS 11.0 mo; OS HR 0.71 vs dabrafenib ^[485]^D5^[609]^A1b	32%	Category 1
Encorafenib + binimetinib (E 450 mg daily + B 45 mg BID)	First-line, BRAF V600-mutant	Median PFS 14.9 mo (COLUMBUS) vs vemurafenib; HR 0.54 ^[517]^A1b	40%	Category 1
Vemurafenib + cobimetinib (V 960 mg BID + C 60 mg daily 21/7)	First-line, BRAF V600-mutant	Median PFS 12.3 mo; HR 0.58 ^[485]^D5	39%	Category 1

Table 2. Dosing for Selected Regimens

Drug(s)	Starting dose	Target / max dose	Key monitoring
Nivolumab + ipilimumab	NIVO 1 mg/kg + IPI 3 mg/kg IV q3w × 4, then NIVO 240 mg q2w or 480 mg q4w	Same as starting	Liver enzymes, thyroid, cortisol, skin, gastrointestinal symptoms ^[358]^D5
Nivolumab + relatlimab	Fixed-dose: nivolumab 480 mg + relatlimab 160 mg IV q4w	Same	Same as PD-1 plus LAG-3 combination ^[661]^A1b
Dabrafenib + trametinib	D 150 mg PO BID + T 2 mg PO daily	Same	LVEF, CPK, fever, glucose ^[344]^C4^[609]^A1b
Encorafenib + binimetinib	E 450 mg PO daily + B 45 mg PO BID	Same	LVEF, CPK, γ-GT, hypertension ^[517]^A1b
Tebentafusp	20 mcg IV on day 1, 30 mcg day 8, 68 mcg day 15, then 68 mcg qw	68 mcg qw	Cytokine-release syndrome monitoring, rash, vitiligo ^[22]^A1b^[666]^A1b
Lifileucel	Single infusion of 7.5 × 10⁹ to 72 × 10⁹ viable TIL cells after lymphodepletion	Same	Hematologic toxicity high; Grade 3-4 AEs >95% ^[51]^C4

History and Evolution of Treatment

▸Ipilimumab (2011) was the first agent to demonstrate an OS benefit in advanced melanoma; subsequent anti-PD-1 therapies (pembrolizumab, nivolumab) and combinations (nivolumab+ipilimumab) have dramatically improved long-term survival, with 10-year OS rates exceeding 50% with combination therapy.
▸For BRAF-mutant melanoma, sequencing data (DREAMseq, SECOMBIT) support initial immunotherapy over targeted therapy for most patients, though BRAF/MEK inhibitors remain critical for rapid disease control.
▸Neoadjuvant immunotherapy (NADINA, SWOG S1801) has become a new standard for resectable stage III melanoma, improving event-free survival and enabling response-driven adjuvant treatment.

HY High Yield: The combination of nivolumab and ipilimumab yields the highest 10-year OS rate (≈52%) in advanced melanoma, but grade 3-4 toxicity occurs in 55-59% of patients [660][668]. The alternative regimen of nivolumab 3 mg/kg plus ipilimumab 1 mg/kg reduces toxicity (34% vs 48% grade 3-5 AEs) with preserved efficacy [5].

From the Overview, it is clear that melanoma treatment has undergone a profound transformation. What follows is the evidentiary arc, the key trials that built the current standard of care, the approaches that were abandoned, and the sequencing debates that continue to shape practice.

The Pre-Immunotherapy Era

Before 2011, the only FDA-approved systemic therapies for advanced melanoma were dacarbazine and high-dose interleukin-2 (IL-2). Neither significantly improved overall survival in randomized trials. High-dose interferon alfa-2b was approved in the adjuvant setting for high-risk resected disease, but its benefit was modest and toxicity substantial ^[788]^D5^[770]^A1b. Biochemotherapy (combinations of chemotherapy with cytokines) showed no survival advantage and caused severe toxicity, and was eventually abandoned ^[280]^D5.

The Checkpoint Revolution

became the first agent to demonstrate an overall survival (OS) benefit in a phase 3 trial (MDX010-20, 2010): median OS 10.0 months with ipilimumab plus gp100 vs 6.4 months with gp100 alone (HR 0.68) ^[663]^A1b. This proof of concept for immune checkpoint blockade opened the door to rapid progress.

Anti-PD-1 therapy followed quickly. In KEYNOTE-006 (2015), improved OS vs ipilimumab: median OS 32.7 vs 15.9 months (HR 0.71), with 10-year OS rates of 34.0% vs 23.6% ^[594]^A1b^[664]^A1b. CheckMate 067 confirmed the superiority of combination immunotherapy: median OS 71.9 months with plus ipilimumab vs 36.9 months with nivolumab alone vs 19.9 months with ipilimumab (combination vs ipilimumab HR 0.53) at 10 years ^[608]^A1b^[668]^A1b. The 5-year OS rate for the combination was 52% ^[668]^A1b. In BRAF wild-type patients, CheckMate 066 showed nivolumab improved 3-year OS to 51.2% vs 21.6% with dacarbazine (HR 0.46) ^[771]^A1b.

LAG-3 blockade added a new tool: RELATIVITY-047 demonstrated that fixed-dose relatlimab plus nivolumab improved median PFS to 10.2 months vs 4.6 months with nivolumab alone (HR 0.79), and at 3 years median OS was 51.0 vs 34.1 months (HR 0.80) ^[661]^A1b^[764]^A1b.

Oncolytic immunotherapy: Talimogene laherparepvec (T-VEC) showed a durable response rate of 16.3% vs 2.1% with GM-CSF in the OPTIM trial, with a median OS of 23.3 vs 18.9 months (HR 0.79) ^[334]^A1b. However, adding T-VEC to pembrolizumab did not improve PFS or OS in the phase 3 MASTERKEY-265 trial ^[763]^A1b.

BRAF-Targeted Therapy

For the approximately 40-50% of melanomas with BRAF V600E/K mutations, targeted therapy provided rapid disease control. COLUMBUS (2018) showed that encorafenib plus binimetinib improved median PFS to 14.9 months vs 7.3 months with vemurafenib (HR 0.54) ^[517]^A1b. Dabrafenib plus trametinib similarly improved PFS and OS vs vemurafenib. In the adjuvant setting, COMBI-AD (12 months of dabrafenib plus trametinib) showed a relapse-free survival HR of 0.52 at a median follow-up of 8.33 years, though OS benefit was not statistically significant overall (HR 0.80, 95% CI 0.62-1.01) ^[609]^A1b. In the subgroup of patients with BRAF V600E mutation, the OS HR was 0.75 (95% CI 0.58-0.96) ^[609]^A1b.

NRAS-mutant melanoma: The NEMO trial demonstrated a modest PFS benefit with the MEK inhibitor binimetinib vs dacarbazine (median 2.8 vs 1.5 months, HR 0.62), but no OS difference ^[605]^A1b. Binimetinib is not regulatory-approved for this indication due to limited benefit.

Sequencing and Combination Strategies

The optimal sequence of immunotherapy and targeted therapy for BRAF-mutant melanoma has been a central question. DREAMseq (EA6134) showed superior 2-year OS with nivolumab plus ipilimumab followed by dabrafenib plus trametinib at progression (71.8% vs 51.5% for the reverse sequence, P=0.010) ^[655]^A1b. SECOMBIT and ImmunoCobiVem similarly suggested that starting with immunotherapy yields better long-term outcomes ^[656]^A1b^[765]^A1b. The ASCO 2023 guideline states that nivolumab plus ipilimumab is preferred over BRAF/MEK inhibitor therapy for BRAF-mutant advanced melanoma ^[654]^A1c. The EBIN trial of encorafenib plus binimetinib induction before ipilimumab plus nivolumab showed no PFS benefit over immunotherapy alone (HR 0.87, P=0.36) ^[766]^A1b.

Neoadjuvant Breakthrough

Neoadjuvant immunotherapy has emerged as a paradigm shift for resectable stage III melanoma. SWOG S1801 demonstrated superior 2-year event-free survival (EFS) with neoadjuvant pembrolizumab (72% vs 49%, P=0.004) ^[662]^A1b. The phase 3 NADINA trial then showed that neoadjuvant ipilimumab plus nivolumab (two cycles) followed by surgery and response-driven adjuvant therapy dramatically improved 12-month EFS vs adjuvant nivolumab alone (83.7% vs 57.2%; HR 0.32) ^[607]^A1b. A pathologic response was seen in 59% of neoadjuvant patients and correlated strongly with long-term outcomes ^[607]^A1b^[653]^A1b. The NCCN now includes neoadjuvant options for stage IIIB-IV disease ^[468]^A1c^[413]^A1c.

Lessons from Failed Trials

Several promising approaches failed to deliver in phase 3. The IDO inhibitor epacadostat plus pembrolizumab showed no benefit over placebo plus pembrolizumab in ECHO-301 (PFS HR 1.00, OS) ^[132]^A1b. plus pembrolizumab did not improve OS in LEAP-003 (HR 1.20) and was terminated early ^[759]^A1b. Adjuvant nivolumab plus low-dose ipilimumab did not improve RFS vs nivolumab alone in CheckMate 915 (HR 0.92) ^[598]^A1b. The cancer vaccine IO102-IO103 plus pembrolizumab missed its primary endpoint (PFS HR 0.77, P=0.0558) ^[761]^A1b. These failures highlight the difficulty of improving upon PD-1-based therapy and the importance of rigorous trial design.

Controversies and Guideline Disagreement

Question	Position A	Position B	Strength	Implication
First-line treatment for BRAF-mutant advanced melanoma	ASCO 2023: nivolumab + ipilimumab preferred over BRAF/MEK inhibitors ^[654]^A1c	NCCN: both immunotherapy and targeted therapy are listed as category 1 options, with no strict hierarchy ^[117]^A1c	ASCO: moderate recommendation based on DREAMseq ^[655]^A1b and CheckMate 067 ^[608]^A1b	For patients with high tumor burden, symptoms, or , BRAF/MEK inhibitors may still be chosen for rapid response. Shared decision-making is critical.
Neoadjuvant vs adjuvant for resectable stage III	NADINA and SWOG S1801 establish neoadjuvant therapy as the new standard ^[607]^A1b^[662]^A1b	Adjuvant therapy alone remains appropriate for patients who are not candidates for neoadjuvant therapy or who refuse it	Strong evidence for EFS benefit	Neoadjuvant approach is preferred for eligible patients with macroscopic stage III melanoma.
Role of T-VEC	Approved by FDA, recommended for some patients with injectable lesions ^[334]^A1b	No longer recommended by ASCO for BRAF wild-type patients after progression on anti-PD-1 ^[654]^A1c	ASCO: recommendation against based on negative phase 3 combination trial ^[763]^A1b	T-VEC remains an option for selected stage IIIB-IVM1a patients, especially if they are treatment-naive.

Pearl: The trajectory from ipilimumab to dual checkpoint blockade and neoadjuvant regimens reflects a consistent drive toward deeper, more durable responses, the key clinical lesson is that combination immunotherapy, whether given upfront in advanced disease or before surgery in stage III, yields the highest long-term survival rates, but must be weighed against toxicity burden in shared decision-making.

Key Landmark Trials in Melanoma Treatment Evolution

Trial (Year)	Setting	Arms	Primary Endpoint	Key Results
MDX010-20 (2010) ^[663]^A1b	Pretreated advanced	Ipilimumab ± gp100 vs gp100 alone	OS	Median OS 10.0 vs 6.4 mo (HR 0.68)
KEYNOTE-006 (2015, 10-yr f/u) ^[594]^A1b^[664]^A1b	First-line advanced	Pembro vs ipi	OS, PFS	Median OS 32.7 vs 15.9 mo (HR 0.71); 10-yr OS 34% vs 23.6%
CheckMate 067 (10-yr f/u) ^[608]^A1b^[668]^A1b	First-line advanced	Nivo+ipi, nivo, ipi	OS, PFS	Median OS 71.9, 36.9, 19.9 mo; 5-yr OS 52%, 44%, 26%
RELATIVITY-047 (3-yr f/u) ^[764]^A1b	First-line advanced	Relatlimab+nivo vs nivo	PFS	Median PFS 10.2 vs 4.6 mo (HR 0.79); OS HR 0.80
COLUMBUS (2018) ^[517]^A1b	BRAF-mutant advanced	Enco+bini vs vemurafenib	PFS	Median PFS 14.9 vs 7.3 mo (HR 0.54)
COMBI-AD (final f/u) ^[609]^A1b	Adjuvant stage III (BRAF-mutant)	Dab+tram vs placebo	RFS, OS	RFS HR 0.52; OS HR 0.80 (BRAF V600E: HR 0.75)
DREAMseq (2022) ^[655]^A1b	BRAF-mutant advanced, sequencing	Nivo+ipi first vs dab+tram first	2-yr OS	2-yr OS 71.8% vs 51.5%
NADINA (2024) ^[607]^A1b	Neoadjuvant stage III	Nivo+ipi neoadj vs adjuvant nivo	EFS	12-mo EFS 83.7% vs 57.2% (HR 0.32)
LEAP-003 (2025) ^[759]^A1b	First-line advanced	Lenvatinib+pembro vs placebo+pembro	PFS, OS	PFS HR 0.72 (interim), OS HR 1.20 (final)

Prognosis and Prognostic Factors

▸Median overall survival for advanced melanoma now exceeds 6 years with nivolumab plus ipilimumab (71.9 months at 10-year follow-up) [608].
▸Prognosis is driven by stage, tumor thickness, ulceration, sentinel node status, LDH, and, in the metastatic setting, depth of response to therapy [820].
▸Postoperative ctDNA detection is the strongest emerging biomarker: landmark positivity confers a 3.4-fold hazard for relapse (HR 3.42) and a 5.4-fold hazard for distant metastasis (HR 5.38) [11].

HY High Yield: Depth of response to checkpoint inhibitor therapy, complete response versus partial response, is the single strongest predictor of progression risk among responders, independent of tumor type and baseline characteristics [820].

The therapeutic advances detailed in the previous section have fundamentally reshaped the expected outcomes for patients with melanoma, with long-term survival now achievable across all disease stages. Prognosis depends on a complex interplay of tumor biology, host factors, and treatment efficacy, and must be assessed using validated clinical, pathologic, and molecular parameters.

Survival by Stage and Treatment Era

For patients with resected stage IIB-IIC melanoma, adjuvant yields an estimated 36-month distant metastasis-free survival (DMFS) of 84.4% compared with 74.7% for placebo (HR 0.59) ^[597]^A1b. In resected stage III disease, 9-year recurrence-free survival with adjuvant is 44% versus 37% with (HR 0.76); median RFS is 61.1 months versus 24.2 months, and 9-year overall survival (OS) reaches 69% and 65%, respectively ^[614]^A1b. Adjuvant dabrafenib plus trametinib in BRAF V600-mutant stage III melanoma achieves a 10-year OS rate of 69% versus 65% with placebo, with a 20% reduction in death risk (HR 0.80, 95% CI 0.62-1.01) that did not reach statistical significance ^[609]^A1b.

For advanced (unresectable stage III/IV) melanoma, 10-year follow-up of CheckMate 067 confirms a median OS of 71.9 months with nivolumab plus ipilimumab, 36.9 months with nivolumab alone, and 19.9 months with ipilimumab; the 10-year OS rate is 43% for the combination, 37% for nivolumab, and 19% for ipilimumab ^[608]^A1b. In KEYNOTE-006, 10-year OS with pembrolizumab is 34.0% versus 23.6% with ipilimumab (median OS 32.7 vs 15.9 months; HR 0.71) ^[594]^A1b. The RELATIVITY-047 regimen of nivolumab plus relatlimab produces a median OS of 51.0 months versus 34.1 months with nivolumab alone (HR 0.80) at 33.8-month follow-up ^[764]^A1b. In the neoadjuvant NADINA trial, 12-month event-free survival was 83.7% with neoadjuvant ipilimumab plus nivolumab versus 57.2% with adjuvant nivolumab (HR 0.32) ^[607]^A1b.

Prognostic Factors

Factor	Favorable Prognosis	Unfavorable Prognosis	Key Evidence
Breslow thickness	<1.0 mm	>4.0 mm	staging ^[441]^A1c
Ulceration	Absent	Present	Independent predictor in all stages ^[441]^A1c
Mitotic rate	<1/mm²	≥1/mm²	Defines T1b category ^[441]^A1c
Sentinel lymph node status	Negative	Positive	Most powerful prognostic factor in stage I-II ^[16]^D5
Number of positive nodes	1	≥4	Drives N category and survival decrement ^[441]^A1c
Extranodal extension (ENE)	Absent	Present	5-year OS 71.7% vs 62.5%; independent predictor ^[49]^B3b
Lactate dehydrogenase (LDH)	Normal	>ULN	M category criterion; strong negative predictor ^[441]^A1c
BRAF V600 mutation	(controversial)	Associated with higher brain metastasis risk ^[638]^B2b	Independent risk factor for BM (HR 2.29) ^[638]^B2b
Response to PD-1-based therapy	Complete response	Non-response	Depth of response is strongest predictor of durability ^[820]^B2b
ctDNA (post-surgery, detectable)	Negative	Positive	RFS HR 3.42; DMFS HR 5.38 at landmark ^[11]^A1a
AI-detected TILs	Higher percentage	Lower percentage	10% increase → ORR OR 1.40, OS HR 0.83 ^[289]^B2b

Validated Prognostic Models

The Lung Immune Prognostic Index (LIPI), derived from dNLR >3 and LDH >ULN, stratifies patients with advanced melanoma receiving immune checkpoint inhibitors into good (0 factors), intermediate (1 factor), and poor (2 factors) prognosis groups, with median OS from 34 months to 3 months ^[384]^B2b. A nomogram combining LDH, S100, neutrophil-to-lymphocyte ratio, body mass index, melanoma subtype, type of ICI, and presence of liver or brain metastasis predicts progression-free survival with a C-index of 0.67 ^[636]^B2b. For , the diagnosis-specific Graded Prognostic Assessment (GPA) incorporates age, performance status, number of brain metastases, and presence of extracranial disease; median OS ranges from 5 to 34 months depending on GPA score ^[371]^B2c.

Long-term Sequelae and Recurrence Risk

Recurrence risk is highest in the first 2-3 years after diagnosis but continues for 10 years or more, especially for thick or node-positive primaries. For patients with resected stage III melanoma, the 9-year cumulative recurrence rate remains 56% with ipilimumab and 48% with nivolumab ^[614]^A1b. Long-term survivors of advanced melanoma face persistent immune-related toxicities, approximately 27% of patients on anti-PD-1 have unresolved toxicity at last follow-up ^[627]^B2b. Common sequelae include fatigue, arthralgias, , hypothyroidism, and psychological distress. The 5-year survival rate for patients with metastatic disease has risen from less than 10% in the pre-immunotherapy era to approximately 35-52% in contemporary clinical trials ^[745]^D5^[596]^A1b.

Pearl: When counseling patients, use absolute risk estimates from the latest trials: for resected stage III disease, median RFS now exceeds 5 years with adjuvant nivolumab (61.1 months) ^[614]^A1b; for advanced disease, the 10-year OS rate with PD-1/CTLA-4 combination is 43% ^[608]^A1b, a nearly 10-fold improvement over historical benchmarks.

Selected landmark overall survival outcomes in advanced melanoma

Regimen	Median OS (months)	3-year OS (%)	5-year OS (%)	10-year OS (%)	Source
Nivolumab + ipilimumab	71.9	58	52	43	CheckMate 067 ^[608]^A1b
Nivolumab	36.9	52	44	37	CheckMate 067 ^[608]^A1b
Ipilimumab	19.9	34	26	19	CheckMate 067 ^[608]^A1b
Pembrolizumab	32.7	51	38	34	KEYNOTE-006 ^[594]^A1b
Nivolumab + relatlimab	51.0	,	,	,	RELATIVITY-047 ^[764]^A1b
Dabrafenib + trametinib (BRAF V600)	25.9 (pooled)	,	34	,	COMBI-d/v pooled ^[807]^A1b
Dacarbazine (historical)	6.4	<15	<10	,	^[663]^A1b

Prognostic factors in melanoma across stages

Factor	Favorable	Unfavorable	Evidence strength
Breslow thickness	<1 mm	>4 mm	Established (AJCC) ^[441]^A1c
Ulceration	Absent	Present	Established (AJCC) ^[441]^A1c
Mitotic rate	<1/mm²	≥1/mm²	Established (AJCC 7th/8th) ^[441]^A1c
Sentinel node status	Negative	Positive	Most powerful stage I-II predictor ^[16]^D5
Number of positive nodes	1	≥4	AJCC N category ^[441]^A1c
Extranodal extension	Absent	Present	NCCN-recommended ^[49]^B3b
LDH	Normal	>ULN	M category, LIPI component ^[441]^A1c^[384]^B2b
BRAF V600 mutation	,	Higher BM risk	Independent risk factor ^[638]^B2b
ctDNA (postoperative)	Undetectable	Detectable	HR 3.42 for RFS ^[11]^A1a
AI-detected TILs	Higher %	Lower %	ORR OR 1.40 per 10% ^[289]^B2b

Special Populations

▸Pregnancy-associated melanoma carries increased mortality; ICIs and targeted therapies are contraindicated during gestation.
▸Elderly patients derive similar overall survival benefit from ICIs as younger patients, but treatment discontinuation due to toxicity is more common in those aged ≥90 years.
▸Concomitant proton pump inhibitors and recent antibiotic use are associated with significantly worse outcomes in melanoma patients treated with ICIs.

! Warning: Avoid ICIs and BRAF/MEK inhibitors during pregnancy; if systemic therapy is required, plan delivery after 32 weeks with multidisciplinary care.

HY High Yield: Prior antibiotic use within 30 days of ICI initiation is associated with a 7-fold increase in mortality risk (HR 7.4) and 81% primary refractory disease rate.

Prognosis in melanoma varies substantially across patient subgroups, and treatment decisions must be tailored for special populations where standard trial data may not apply.

Pregnancy

Melanoma is the most common malignancy diagnosed during pregnancy, and pregnancy-associated melanoma carries a worse prognosis. A population-based cohort study found that women diagnosed with melanoma during the postpartum period had an increased hazard of death (aHR 1.84, 95% CI 1.02-3.30) ^[44]^B3b. Placental and fetal metastases occur almost exclusively with melanoma and lung cancer primaries; among 72 reported cases, fetal metastases were present in 33.3%, most commonly to lungs (21.7%), scalp (17.4%), and liver (8.7%) ^[336]^C4. Median maternal survival after delivery was only 1 month (95% CI 0.7-1.3), and 1-year infant survival was 51.1% ^[336]^C4.

Immune checkpoint inhibitors (ICIs) are not recommended during pregnancy. In a systematic review of 7 pregnancies (all melanoma), ICI administration was associated with a mean gestational age at delivery of 30.4 weeks, with complications including intrauterine growth restriction (3 cases), HELLP syndrome, and placental insufficiency ^[41]^C4. Mean progression-free survival was 16.0 months and overall survival 25.2 months ^[41]^C4. Preclinical data suggest that BRAF and MEK inhibitors are teratogenic, and their use should be avoided ^[713]^D5. Fertility preservation counseling is recommended for all patients of reproductive age before initiating systemic therapy ^[713]^D5.

Pediatrics

Pediatric melanoma is rare, accounting for <2% of all melanomas. Presentation may differ from adults, with a higher proportion of amelanotic, Spitzoid, and nodular subtypes. Diagnosis is often delayed. Treatment principles are extrapolated from adult trials, as pediatric-specific randomized data are lacking. is feasible and prognostic. Adjuvant and advanced disease follows adult guidelines with age-adjusted dosing; however, ICIs and targeted therapies have not been prospectively studied in children, and their use is based on case series and expert opinion. Fertility preservation should be discussed with adolescents before gonadotoxic therapy ^[713]^D5.

Elderly

Age alone should not preclude effective therapy. A meta-analysis of 30 randomized trials (17,476 patients) found that ICIs improved overall survival similarly in patients <65 years (HR 0.77, 95% CI 0.70-0.85) and ≥65 years (HR 0.77, 95% CI 0.70-0.85) ^[812]^A1a. However, progression-free survival benefit in melanoma was greater in younger patients (HR 0.44 vs 0.65, P=0.04) ^[812]^A1a. In a multicenter cohort of 928 patients aged ≥80 years treated with single-agent ICIs, objective response rate in melanoma was 39.3%, median overall survival 30.0 months, and median progression-free survival 11.1 months ^[781]^B2b. Immune-related adverse events occurred in 41.3% (grade 3-4 in 12.2%), and treatment discontinuation due to toxicity was more frequent in patients ≥90 years (30.9% vs 15.1%) ^[781]^B2b. Frailty assessment is important: among older adults undergoing cancer surgery, frailty was independently associated with a lower probability of remaining alive and at home at 5 years (39.1% vs 62.5%) ^[48]^B3b.

Immunocompromised

Data on ICI use in patients with pre-existing autoimmune disease or solid organ transplant are limited. Pre-existing autoantibodies, particularly anti-thyroglobulin and anti-thyroid peroxidase, increase the risk of ICI-induced thyroid dysfunction ^[131]^B2b. In a post-hoc analysis of six trials, higher peak corticosteroid dose for immune-related adverse events was associated with worse survival (HR 1.43 for 2 mg/kg vs 0.5 mg/kg prednisolone) ^[848]^B2b. Concomitant proton pump inhibitor use was associated with increased mortality in melanoma patients receiving PD-1 inhibitors (HR 1.889, 95%) ^[47]^B3b. Prior antibiotic therapy (within 30 days before ICI initiation) was associated with markedly worse overall survival (2 vs 26 months; HR 7.4, 95%) and higher rates of primary refractory disease (81% vs 44%) ^[716]^B2b. In patients with HIV, hepatitis B/C, or transplant, ICI therapy should be undertaken with multidisciplinary input and close monitoring for graft rejection and infection.

Pearl: In pregnant patients with melanoma, avoid ICIs and targeted therapies; if systemic treatment is necessary, consider delivery planning after 32 weeks and coordinate with maternal-fetal medicine. In elderly patients, chronological age alone should not limit ICI access, but frailty assessment and vigilance for treatment discontinuation due to toxicity are essential. Avoid unnecessary proton pump inhibitors and in patients receiving ICIs, as both are associated with worse outcomes.

References

[1]
Barker CA, Salama AK. “New NCCN Guidelines for Uveal Melanoma and Treatment of Recurrent or Progressive Distant Metastatic Melanoma.” Journal of the National Comprehensive Cancer Network : JNCCN (2018). PMID: 29784747 ↗
L1GUIDELINECited in: Definition and Epidemiology, Molecular Diagnostics and Biomarkers, Staging, History and Evolution of Treatment, Prognosis and Prognostic Factors
[2]
Khoja L, Day D, Wei-Wu Chen T et al.. “Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic review.” Annals of oncology : official journal of the European Society for Medical Oncology (2017). PMID: 28945858 ↗
L2SR_OBSCited in: Definition and Epidemiology, Histopathology and Molecular Biology, Management Overview
[3]
Dréno B, Ribas A, Larkin J et al.. “Incidence, course, and management of toxicities associated with cobimetinib in combination with vemurafenib in the coBRIM study.” Annals of oncology : official journal of the European Society for Medical Oncology (2017). PMID: 28444112 ↗
L1RCTCited in: Definition and Epidemiology
[4]
Teulings HE, Limpens J, Jansen SN et al.. “Vitiligo-like depigmentation in patients with stage III-IV melanoma receiving immunotherapy and its association with survival: a systematic review and meta-analysis.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2015). PMID: 25605840 ↗
L1SR_OBSCited in: Definition and Epidemiology, Staging
[5]
Lebbé C, Meyer N, Mortier L et al.. “Evaluation of Two Dosing Regimens for Nivolumab in Combination With Ipilimumab in Patients With Advanced Melanoma: Results From the Phase IIIb/IV CheckMate 511 Trial.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2019). PMID: 30811280 ↗
L1RCTCited in: Definition and Epidemiology, Staging, Management Overview, History and Evolution of Treatment, Prognosis and Prognostic Factors, Special Populations
[6]
Weber JS, Middleton MR, Yates G et al.. “Estimating Long-Term Survivorship Rates Among Patients With Resected Stage III/IV Melanoma: Analyses From CheckMate 238 and European Organization for Research and Treatment of Cancer 18071 Trials.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024). PMID: 39378385 ↗
L2RCTCited in: Definition and Epidemiology, Imaging, Staging
[7]
Hussaini S, Chehade R, Boldt RG et al.. “Association between immune-related side effects and efficacy and benefit of immune checkpoint inhibitors - A systematic review and meta-analysis.” Cancer treatment reviews (2020). PMID: 33302134 ↗
L1SR_OBSCited in: Definition and Epidemiology, Management Overview
[8]
Giustozzi M, Becattini C, Roila F et al.. “Vascular events with immune checkpoint inhibitors in melanoma or non-small cell lung cancer: A systematic review and meta-analysis.” Cancer treatment reviews (2021). PMID: 34438237 ↗
L1SR_OBSCited in: Definition and Epidemiology
[9]
Spagnolo F, Picasso V, Lambertini M et al.. “Survival of patients with metastatic melanoma and brain metastases in the era of MAP-kinase inhibitors and immunologic checkpoint blockade antibodies: A systematic review.” Cancer treatment reviews (2016). PMID: 26975020 ↗
L2SR_OBSCited in: Definition and Epidemiology, Staging, Prognosis and Prognostic Factors
[10]
Hamm C, Verma S, Petrella T et al.. “Biochemotherapy for the treatment of metastatic malignant melanoma: a systematic review.” Cancer treatment reviews (2008). PMID: 18077098 ↗
L1SR_OBSCited in: Definition and Epidemiology
[11]
Abrahão Reis PC, Noronha MM, Oliveira JP et al.. “Circulating tumor DNA for predicting recurrence and mortality in patients with resected Melanoma: A systematic review and meta-analysis.” Cancer treatment reviews (2026). PMID: 42107274 ↗
L1SR_OBSCited in: Definition and Epidemiology, Molecular Diagnostics and Biomarkers, History and Evolution of Treatment, Prognosis and Prognostic Factors
[12]
Yang TO, Reeves GK, Green J et al.. “Birth weight and adult cancer incidence: large prospective study and meta-analysis.” Annals of oncology : official journal of the European Society for Medical Oncology (2014). PMID: 25015335 ↗
L2SR_OBSCited in: Definition and Epidemiology, Risk Factors and Prevention, Clinical Presentation
[13]
Ji AL, Bichakjian CK, Swetter SM. “Molecular Profiling in Cutaneous Melanoma.” Journal of the National Comprehensive Cancer Network : JNCCN (2016). PMID: 27059194 ↗
L5REVIEW_NARRATIVECited in: Definition and Epidemiology, Clinical Presentation, Molecular Diagnostics and Biomarkers, Prognosis and Prognostic Factors
[14]
Halpern AC, Mandal SK. “Role of dermatologists in treating melanoma.” Journal of the National Comprehensive Cancer Network : JNCCN (2006). PMID: 16884671 ↗
L5REVIEW_NARRATIVECited in: Definition and Epidemiology, Clinical Presentation, Management Overview
[15]
Mudigonda T, Pearce DJ, Yentzer BA et al.. “The economic impact of non-melanoma skin cancer: a review.” Journal of the National Comprehensive Cancer Network : JNCCN (2010). PMID: 20870635 ↗
L5REVIEW_NARRATIVECited in: Definition and Epidemiology
[16]
Andtbacka RH, Gershenwald JE. “Role of sentinel lymph node biopsy in patients with thin melanoma.” Journal of the National Comprehensive Cancer Network : JNCCN (2009). PMID: 19401063 ↗
L5REVIEW_NARRATIVECited in: Definition and Epidemiology, Biopsy and Histologic Diagnosis, Imaging, Staging, Prognosis and Prognostic Factors
[17]
Rajeh A, Kiuru M, Nelson K et al.. “The Evolving Clinical Utility of Gene Expression Profiling in Cutaneous Melanoma.” Journal of the National Comprehensive Cancer Network : JNCCN (2026). PMID: 42297027 ↗
L5REVIEW_NARRATIVECited in: Definition and Epidemiology, Imaging, Molecular Diagnostics and Biomarkers, Staging
[18]
Cuzick J, Sestak I, Baum M et al.. “Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial.” The Lancet. Oncology (2010). PMID: 21087898 ↗
L1RCTCited in: Definition and Epidemiology, Staging, History and Evolution of Treatment, Prognosis and Prognostic Factors
[19]
van den Hoek L, Burgmans M, Tong T et al.. “Percutaneous hepatic perfusion combined with ipilimumab and nivolumab for metastatic uveal melanoma (CHOPIN): a single-centre, open-label, randomised, phase 2 trial.” The Lancet. Oncology (2026). PMID: 41785896 ↗
L1RCTCited in: Definition and Epidemiology
[20]
Ascierto PA, Del Vecchio M, Robert C et al.. “Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial.” The Lancet. Oncology (2017). PMID: 28359784 ↗
L1RCTCited in: Definition and Epidemiology, Clinical Presentation
[21]
Corrie PG, Marshall A, Dunn JA et al.. “Adjuvant bevacizumab in patients with melanoma at high risk of recurrence (AVAST-M): preplanned interim results from a multicentre, open-label, randomised controlled phase 3 study.” The Lancet. Oncology (2014). PMID: 24745696 ↗
L1RCTCited in: Definition and Epidemiology, Imaging
[22]
Nathan P, Hassel JC, Rutkowski P et al.. “Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma.” The New England journal of medicine (2021). PMID: 34551229 ↗
L1RCTCited in: Definition and Epidemiology, Management Overview, History and Evolution of Treatment, Special Populations
[23]
Larkin J, Ascierto PA, Dréno B et al.. “Combined vemurafenib and cobimetinib in BRAF-mutated melanoma.” The New England journal of medicine (2014). PMID: 25265494 ↗
L1RCTCited in: Definition and Epidemiology
[24]
Dummer R, Hauschild A, Santinami M et al.. “Five-Year Analysis of Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma.” The New England journal of medicine (2020). PMID: 32877599 ↗
L1RCTCited in: Definition and Epidemiology
[25]
Morton DL, Thompson JF, Cochran AJ et al.. “Sentinel-node biopsy or nodal observation in melanoma.” The New England journal of medicine (2006). PMID: 17005948 ↗
L1RCTCited in: Definition and Epidemiology, Biopsy and Histologic Diagnosis, Imaging
[26]
Flaherty KT, Infante JR, Daud A et al.. “Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations.” The New England journal of medicine (2012). PMID: 23020132 ↗
L4RCTCited in: Definition and Epidemiology, Clinical Presentation
[27]
Hamid O, Lewis KD, Weise A et al.. “Phase I Study of Fianlimab, a Human Lymphocyte Activation Gene-3 (LAG-3) Monoclonal Antibody, in Combination With Cemiplimab in Advanced Melanoma.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024). PMID: 38900987 ↗
L4TRIAL_NONRANDOMCited in: Definition and Epidemiology
[28]
Dummer R, Corrie P, Gutzmer R et al.. “First-Line, Fixed-Duration Nivolumab Plus Ipilimumab Followed by Nivolumab in Clinically Diverse Patient Populations With Unresectable Stage III or IV Melanoma: CheckMate 401.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023). PMID: 37307514 ↗
L4TRIAL_NONRANDOMCited in: Definition and Epidemiology
[29]
Nishino M, Giobbie-Hurder A, Hatabu H et al.. “Incidence of Programmed Cell Death 1 Inhibitor-Related Pneumonitis in Patients With Advanced Cancer: A Systematic Review and Meta-analysis.” JAMA oncology (2016). PMID: 27540850 ↗
L1SR_OBSCited in: Definition and Epidemiology, Prognosis and Prognostic Factors
[30]
Eggermont AMM, Kicinski M, Blank CU et al.. “Association Between Immune-Related Adverse Events and Recurrence-Free Survival Among Patients With Stage III Melanoma Randomized to Receive Pembrolizumab or Placebo: A Secondary Analysis of a Randomized Clinical Trial.” JAMA oncology (2020). PMID: 31895407 ↗
L2RCTCited in: Definition and Epidemiology, Staging, History and Evolution of Treatment
[31]
Ghiasvand R, Weiderpass E, Green AC et al.. “Sunscreen Use and Subsequent Melanoma Risk: A Population-Based Cohort Study.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2016). PMID: 27621396 ↗
L2COHORTCited in: Definition and Epidemiology
[32]
Burkart J, Owen D, Shah MH et al.. “Targeting BRAF Mutations in High-Grade Neuroendocrine Carcinoma of the Colon.” Journal of the National Comprehensive Cancer Network : JNCCN (2018). PMID: 30181415 ↗
L5CASE_REPORTCited in: Definition and Epidemiology, Biopsy and Histologic Diagnosis, Imaging, Special Populations
[33]
Green J, Cairns BJ, Casabonne D et al.. “Height and cancer incidence in the Million Women Study: prospective cohort, and meta-analysis of prospective studies of height and total cancer risk.” The Lancet. Oncology (2011). PMID: 21782509 ↗
L2SR_OBSCited in: Definition and Epidemiology
[34]
Tix T, Alhomoud M, Shouval R et al.. “Second Primary Malignancies after CAR T-Cell Therapy: A Systematic Review and Meta-analysis of 5,517 Lymphoma and Myeloma Patients.” Clinical cancer research : an official journal of the American Association for Cancer Research (2024). PMID: 39256908 ↗
L1SR_OBSCited in: Definition and Epidemiology
[35]
Becker JC. “Merkel cell carcinoma.” Annals of oncology : official journal of the European Society for Medical Oncology (2010). PMID: 20943647 ↗
L5REVIEW_NARRATIVECited in: Definition and Epidemiology, Staging, Management Overview, Prognosis and Prognostic Factors
[36]
MacKie RM, Hauschild A, Eggermont AM. “Epidemiology of invasive cutaneous melanoma.” Annals of oncology : official journal of the European Society for Medical Oncology (2009). PMID: 19617292 ↗
L5REVIEW_NARRATIVECited in: Definition and Epidemiology, Risk Factors and Prevention, Clinical Presentation
[37]
Maio M. “Melanoma as a model tumour for immuno-oncology.” Annals of oncology : official journal of the European Society for Medical Oncology (2012). PMID: 22918922 ↗
L5REVIEW_NARRATIVECited in: Definition and Epidemiology
[38]
Spain L, Walls G, Julve M et al.. “Neurotoxicity from immune-checkpoint inhibition in the treatment of melanoma: a single centre experience and review of the literature.” Annals of oncology : official journal of the European Society for Medical Oncology (2017). PMID: 28426103 ↗
L4REVIEW_NARRATIVECited in: Definition and Epidemiology, Clinical Presentation
[39]
Reck M. “What future opportunities may immuno-oncology provide for improving the treatment of patients with lung cancer?” Annals of oncology : official journal of the European Society for Medical Oncology (2012). PMID: 22918925 ↗
L5REVIEW_NARRATIVECited in: Definition and Epidemiology, Prognosis and Prognostic Factors
[40]
Larkin J, Lao CD, Urba WJ et al.. “Efficacy and Safety of Nivolumab in Patients With BRAF V600 Mutant and BRAF Wild-Type Advanced Melanoma: A Pooled Analysis of 4 Clinical Trials.” JAMA oncology (2015). PMID: 26181250 ↗
L4TRIAL_NONRANDOMCited in: Definition and Epidemiology, Genetics and Hereditary Predisposition, Molecular Diagnostics and Biomarkers, Staging
[41]
Andrikopoulou A, Korakiti AM, Apostolidou K et al.. “Immune checkpoint inhibitor administration during pregnancy: a case series.” ESMO open (2021). PMID: 34487972 ↗
L4CASE_REPORTCited in: Definition and Epidemiology, Special Populations
[42]
Mandalà M, Rutkowski P, Patuzzo R et al.. “Incidence and risk factors of brain metastases in radically resected melanoma patients: a large international cohort study.” ESMO open (2026). PMID: 41633013 ↗
L3COHORTCited in: Definition and Epidemiology
[43]
Gomes F, Lorigan P, Woolley S et al.. “A prospective cohort study on the safety of checkpoint inhibitors in older cancer patients - the ELDERS study.” ESMO open (2021). PMID: 33516147 ↗
L2COHORTCited in: Definition and Epidemiology, Risk Factors and Prevention, History and Evolution of Treatment
[44]
Cairncross ZF, Shack L, Nelson G et al.. “Long-term Mortality in Individuals Diagnosed With Cancer During Pregnancy or Postpartum.” JAMA oncology (2023). PMID: 37022714 ↗
L3SR_OBSCited in: Definition and Epidemiology, Clinical Presentation, Special Populations
[45]
Fecher LA, Cummings SD, Keefe MJ et al.. “Toward a molecular classification of melanoma.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2007). PMID: 17443002 ↗
L5REVIEW_NARRATIVECited in: Definition and Epidemiology, Genetics and Hereditary Predisposition
[46]
Eskander A, Li Q, Yu J et al.. “Incident Cancer Detection During the COVID-19 Pandemic.” Journal of the National Comprehensive Cancer Network : JNCCN (2022). PMID: 35104788 ↗
L2OTHERCited in: Definition and Epidemiology, Risk Factors and Prevention
[47]
Niu C, Zhang J, Singh H et al.. “Impact of Concomitant Proton Pump Inhibitor Use on the Efficacy of Immune Checkpoint Inhibitors Across Multiple Cancer Types.” Journal of the National Comprehensive Cancer Network : JNCCN (2025). PMID: 41101342 ↗
L3OTHERCited in: Definition and Epidemiology, Prognosis and Prognostic Factors, Special Populations
[48]
Hallet J, Tillman B, Zuckerman J et al.. “Association Between Frailty and Time Alive and At Home After Cancer Surgery Among Older Adults: A Population-Based Analysis.” Journal of the National Comprehensive Cancer Network : JNCCN (2022). PMID: 36351336 ↗
L3OTHERCited in: Definition and Epidemiology, Risk Factors and Prevention, Special Populations
[49]
Maurichi A, Barretta F, Patuzzo R et al.. “Survival in Patients With Sentinel Node-Positive Melanoma With Extranodal Extension.” Journal of the National Comprehensive Cancer Network : JNCCN (2021). PMID: 34311443 ↗
L3OTHERCited in: Definition and Epidemiology, Biopsy and Histologic Diagnosis, Prognosis and Prognostic Factors
[50]
Jacob JS, Dutra BE, Garcia-Rodriguez V et al.. “Clinical Characteristics and Outcomes of Oral Mucositis Associated With Immune Checkpoint Inhibitors in Patients With Cancer.” Journal of the National Comprehensive Cancer Network : JNCCN (2021). PMID: 34348238 ↗
L4OTHERCited in: Definition and Epidemiology
[51]
Hu L, Fan C, Bross P et al.. “FDA Approval Summary: Lifileucel for Unresectable or Metastatic Melanoma Previously Treated with an Anti-PD-1-Based Immunotherapy.” Clinical cancer research : an official journal of the American Association for Cancer Research (2025). PMID: 40699950 ↗
L4TRIAL_NONRANDOMCited in: Definition and Epidemiology, Management Overview, Special Populations
[52]
Rahma OE, Reuss JE, Giobbie-Hurder A et al.. “Early 3+3 Trial Dose-Escalation Phase I Clinical Trial Design and Suitability for Immune Checkpoint Inhibitors.” Clinical cancer research : an official journal of the American Association for Cancer Research (2020). PMID: 33082209 ↗
L2TRIAL_NONRANDOMCited in: Definition and Epidemiology
[53]
Li AY, McCusker MG, Russo A et al.. “RET fusions in solid tumors.” Cancer treatment reviews (2019). PMID: 31715421 ↗
L5REVIEW_NARRATIVECited in: Definition and Epidemiology
[54]
Triozzi PL, Eng C, Singh AD. “Targeted therapy for uveal melanoma.” Cancer treatment reviews (2008). PMID: 18226859 ↗
L5REVIEW_NARRATIVECited in: Definition and Epidemiology, Management Overview
[55]
Gowda R, Robertson BM, Iyer S et al.. “The role of exosomes in metastasis and progression of melanoma.” Cancer treatment reviews (2020). PMID: 32050108 ↗
L5REVIEW_NARRATIVECited in: Definition and Epidemiology, Molecular Diagnostics and Biomarkers, Staging, Prognosis and Prognostic Factors
[56]
Ventriglia J, Paciolla I, Pisano C et al.. “Immunotherapy in ovarian, endometrial and cervical cancer: State of the art and future perspectives.” Cancer treatment reviews (2017). PMID: 28800469 ↗
L5REVIEW_NARRATIVECited in: Definition and Epidemiology, Risk Factors and Prevention, Prognosis and Prognostic Factors, Special Populations
[57]
Queirolo P, Acquati M. “Targeted therapies in melanoma.” Cancer treatment reviews (2006). PMID: 17008014 ↗
L5REVIEW_NARRATIVECited in: Definition and Epidemiology, Clinical Presentation
[58]
Gogas H, Polyzos A, Kirkwood J. “Immunotherapy for advanced melanoma: fulfilling the promise.” Cancer treatment reviews (2013). PMID: 23725878 ↗
L5REVIEW_NARRATIVECited in: Definition and Epidemiology
[59]
Napolitano S, Brancaccio G, Argenziano G et al.. “It is finally time for adjuvant therapy in melanoma.” Cancer treatment reviews (2018). PMID: 29957365 ↗
L5REVIEW_NARRATIVECited in: Definition and Epidemiology, Management Overview
[60]
Troiani T, De Falco V, Napolitano S et al.. “How we treat locoregional melanoma.” ESMO open (2021). PMID: 33930656 ↗
L5REVIEW_NARRATIVECited in: Definition and Epidemiology, Biopsy and Histologic Diagnosis, Staging, Management Overview
[61]
Zagouri F, Dimitrakakis C, Marinopoulos S et al.. “Cancer in pregnancy: disentangling treatment modalities.” ESMO open (2016). PMID: 27843602 ↗
L5REVIEW_NARRATIVECited in: Definition and Epidemiology, Clinical Presentation
[62]
Ajithkumar T, Parkinson C, Fife K et al.. “Evolving treatment options for melanoma brain metastases.” The Lancet. Oncology (2015). PMID: 26433822 ↗
L5REVIEW_NARRATIVECited in: Definition and Epidemiology, Risk Factors and Prevention
[63]
Strauss DC, Thomas JM. “Transmission of donor melanoma by organ transplantation.” The Lancet. Oncology (2010). PMID: 20451456 ↗
L5REVIEW_NARRATIVECited in: Definition and Epidemiology
[64]
Zaorsky NG, Churilla TM, Egleston BL et al.. “Causes of death among cancer patients.” Annals of oncology : official journal of the European Society for Medical Oncology (2017). PMID: 27831506 ↗
L2OTHERCited in: Definition and Epidemiology, Risk Factors and Prevention, Clinical Presentation
[65]
Fu BC, Song M, Li X et al.. “Height as a mediator of sex differences in cancer risk.” Annals of oncology : official journal of the European Society for Medical Oncology (2020). PMID: 32217057 ↗
L2OTHERCited in: Definition and Epidemiology, Risk Factors and Prevention
[66]
Schlesinger-Raab A, Schubert-Fritschle G, Hein R et al.. “Quality of life in localised malignant melanoma.” Annals of oncology : official journal of the European Society for Medical Oncology (2010). PMID: 20494965 ↗
L4OTHERCited in: Definition and Epidemiology
[67]
Janssen-Heijnen ML, Houterman S, Lemmens VE et al.. “Prognosis for long-term survivors of cancer.” Annals of oncology : official journal of the European Society for Medical Oncology (2007). PMID: 17693654 ↗
L2OTHERCited in: Definition and Epidemiology, Clinical Presentation, Special Populations
[68]
Wu Z, Boroumand F, Nickel B et al.. “Mind the Gap: Impact of New Labels on Public Perceptions and Calculated Risk of Adverse Outcomes after a Melanoma In Situ Diagnosis-A Secondary Analysis of an Online Randomized Experiment.” Medical decision making : an international journal of the Society for Medical Decision Making (2026). PMID: 42289825 ↗
L1RCTCited in: Definition and Epidemiology, Risk Factors and Prevention, History and Evolution of Treatment, Special Populations
[69]
Shet P, Ghosh P, Varshney K et al.. “Chimeric Antigen Receptor T-Cell Therapy for the Treatment of Melanoma: A Systematic Review of Phase One Clinical Trials.” Technology in cancer research & treatment (2026). PMID: 42310990 ↗
L4TRIAL_NONRANDOMCited in: Definition and Epidemiology, Management Overview, Prognosis and Prognostic Factors
[70]
Devincenzi T, Lopes AC, Marinho MAG et al.. “Phototherapies mediated by metallic nanoparticles and near-infrared radiation in skin cancer: A systematic review.” Photochemistry and photobiology (2026). PMID: 42376701 ↗
L4SR_OBSCited in: Definition and Epidemiology
[71]
Naidoo J, Wang X, Woo KM et al.. “Pneumonitis in Patients Treated With Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2016). PMID: 27646942 ↗
L4OTHERCited in: Definition and Epidemiology, Management Overview, Prognosis and Prognostic Factors, Special Populations
[72]
Ascierto PA, Lipson EJ, Dummer R et al.. “Nivolumab and Relatlimab in Patients With Advanced Melanoma That Had Progressed on Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy: Results From the Phase I/IIa RELATIVITY-020 Trial.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023). PMID: 36780608 ↗
L4OTHERCited in: Definition and Epidemiology
[73]
Vallejo BA, Ansari A, Parikh SA et al.. “Risk of Incident Melanoma Among Individuals With Low-Count Monoclonal B-Cell Lymphocytosis.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024). PMID: 39231386 ↗
L2OTHERCited in: Definition and Epidemiology, Risk Factors and Prevention
[74]
Shree T, Li Q, Glaser SL et al.. “Impaired Immune Health in Survivors of Diffuse Large B-Cell Lymphoma.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2020). PMID: 32083991 ↗
L3OTHERCited in: Definition and Epidemiology, Clinical Presentation
[75]
Haydu LE, Lo SN, McQuade JL et al.. “Cumulative Incidence and Predictors of CNS Metastasis for Patients With American Joint Committee on Cancer 8th Edition Stage III Melanoma.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2020). PMID: 31990608 ↗
L3OTHERCited in: Definition and Epidemiology
[76]
Flaherty KT, Aplin AE, Davies MA et al.. “Facts and Hopes: Toward the Next Quantum Leap in Melanoma.” Clinical cancer research : an official journal of the American Association for Cancer Research (2025). PMID: 40407722 ↗
L5REVIEW_NARRATIVECited in: Definition and Epidemiology, Management Overview
[77]
Kim J, Akbani R, Creighton CJ et al.. “Invasive Bladder Cancer: Genomic Insights and Therapeutic Promise.” Clinical cancer research : an official journal of the American Association for Cancer Research (2015). PMID: 26473186 ↗
L5REVIEW_NARRATIVECited in: Definition and Epidemiology
[78]
Weinstock MA. “Progress and prospects on melanoma: the way forward for early detection and reduced mortality.” Clinical cancer research : an official journal of the American Association for Cancer Research (2006). PMID: 16609048 ↗
L5REVIEW_NARRATIVECited in: Definition and Epidemiology, History and Evolution of Treatment
[79]
Vultur A, Villanueva J, Herlyn M. “Targeting BRAF in advanced melanoma: a first step toward manageable disease.” Clinical cancer research : an official journal of the American Association for Cancer Research (2011). PMID: 21447722 ↗
L5REVIEW_NARRATIVECited in: Definition and Epidemiology
[80]
Autio KA, Boni V, Humphrey RW et al.. “Probody Therapeutics: An Emerging Class of Therapies Designed to Enhance On-Target Effects with Reduced Off-Tumor Toxicity for Use in Immuno-Oncology.” Clinical cancer research : an official journal of the American Association for Cancer Research (2019). PMID: 31601568 ↗
L5REVIEW_NARRATIVECited in: Definition and Epidemiology
[81]
Aragon-Ching JB, Zujewski JA. “CNS metastasis: an old problem in a new guise.” Clinical cancer research : an official journal of the American Association for Cancer Research (2007). PMID: 17363516 ↗
L5REVIEW_NARRATIVECited in: Definition and Epidemiology
[82]
Kirkwood JM, Moschos S, Wang W. “Strategies for the development of more effective adjuvant therapy of melanoma: current and future explorations of antibodies, cytokines, vaccines, and combinations.” Clinical cancer research : an official journal of the American Association for Cancer Research (2006). PMID: 16609054 ↗
L5REVIEW_NARRATIVECited in: Definition and Epidemiology, Risk Factors and Prevention, Imaging
[83]
Mir R, Miszczyk M, Krzysztofiak T et al.. “Skin Cosmesis assessment tools and methods in patients with non-melanoma skin cancers treated with radiotherapy: Systematic review on behalf of the ESTRO skin and soft tissue focus group and the GEC-ESTRO head and neck and skin working group.” Clinical and translational radiation oncology (2026). PMID: 42404298 ↗
L3SR_OBSCited in: Definition and Epidemiology
[84]
Penny CL, Lebhar J, Liu B et al.. “Racial Disparities in Cutaneous Melanoma Mortality: A Systematic Review and Meta-Analysis.” Journal of racial and ethnic health disparities (2026). PMID: 42340645 ↗
L3SR_OBSCited in: Definition and Epidemiology, Risk Factors and Prevention
[85]
Shirron N, Boutros A, Waldhorn I et al.. “Oncofertility outcomes in early-onset patients with non-breast solid malignancies: a systematic review.” EClinicalMedicine (2026). PMID: 42306492 ↗
L3SR_OBSCited in: Definition and Epidemiology
[86]
Alfaar AS, Saad A, Elzouki S et al.. “Uveal melanoma-associated cancers revisited.” ESMO open (2020). PMID: 33257317 ↗
L2OTHERCited in: Definition and Epidemiology, Genetics and Hereditary Predisposition, Special Populations
[87]
Trama A, Stark D, Bozovic-Spasojevic I et al.. “Cancer burden in adolescents and young adults in Europe.” ESMO open (2023). PMID: 36753992 ↗
L2OTHERCited in: Definition and Epidemiology, Risk Factors and Prevention
[88]
Mitchell JD, Laurie M, Xia Q et al.. “Risk profiles and incidence of cardiovascular events across different cancer types.” ESMO open (2023). PMID: 37979325 ↗
L2OTHERCited in: Definition and Epidemiology, Clinical Presentation
[89]
Angelats L, Paré L, Rubio-Perez C et al.. “Linking tumor immune infiltration to enhanced longevity in recurrence-free breast cancer.” ESMO open (2025). PMID: 39765189 ↗
L2OTHERCited in: Definition and Epidemiology, Clinical Presentation, Special Populations
[90]
Araki T, Kanda S, Ide T et al.. “Antiplatelet drugs may increase the risk for checkpoint inhibitor-related pneumonitis in advanced cancer patients.” ESMO open (2023). PMID: 37852033 ↗
L3OTHERCited in: Definition and Epidemiology
[91]
Derks SHAE, de Joode K, Mulder EEAP et al.. “The meaning of screening: detection of brain metastasis in the adjuvant setting for stage III melanoma.” ESMO open (2022). PMID: 36265261 ↗
L3OTHERCited in: Definition and Epidemiology, Risk Factors and Prevention
[92]
Bruno W, Dalmasso B, Barile M et al.. “Predictors of germline status for hereditary melanoma: 5 years of multi-gene panel testing within the Italian Melanoma Intergroup.” ESMO open (2022). PMID: 35777164 ↗
L2OTHERCited in: Definition and Epidemiology, Genetics and Hereditary Predisposition, History and Evolution of Treatment
[93]
Steliarova-Foucher E, Colombet M, Ries LAG et al.. “International incidence of childhood cancer, 2001-10: a population-based registry study.” The Lancet. Oncology (2017). PMID: 28410997 ↗
L2OTHERCited in: Definition and Epidemiology
[94]
Hughes T, Harper A, Gupta S et al.. “The current and future global burden of cancer among adolescents and young adults: a population-based study.” The Lancet. Oncology (2024). PMID: 39557059 ↗
L2OTHERCited in: Definition and Epidemiology
[95]
De Angelis R, Demuru E, Baili P et al.. “Complete cancer prevalence in Europe in 2020 by disease duration and country (EUROCARE-6): a population-based study.” The Lancet. Oncology (2024). PMID: 38307102 ↗
L2OTHERCited in: Definition and Epidemiology, Clinical Presentation
[96]
Hajeer A, Salem A, Akash M et al.. “Assessing the global demand and supply of brachytherapy resources: a population-based observational study.” The Lancet. Oncology (2026). PMID: 41785895 ↗
L2OTHERCited in: Definition and Epidemiology, Clinical Presentation
[97]
Morgan E, Bardot A, Langselius O et al.. “International disruptions to cancer diagnosis and stage at presentation during the COVID-19 pandemic in 2020: an International Cancer Benchmarking Partnership (ICBP) population-based study.” The Lancet. Oncology (2026). PMID: 42225103 ↗
L2OTHERCited in: Definition and Epidemiology, Clinical Presentation, Staging
[98]
Abdollahi A, Safaei M. “Hepatic perivascular epithelioid cell tumor (PEComa): Clinicopathological Findings and Prognosis-A Systematic Review and Meta-Analysis.” Iranian journal of pathology (2026). PMID: 42428337 ↗
L4SR_OBSCited in: Definition and Epidemiology, Clinical Presentation, Biopsy and Histologic Diagnosis
[99]
Chen J, Fernandez K, Tang AS et al.. “Differential melanoma outcomes in a regional VA center and a tertiary care center with shared physician staffing: A cohort study.” Journal of the American Academy of Dermatology (2026). PMID: 42419594 ↗
L2COHORTCited in: Definition and Epidemiology, Risk Factors and Prevention
[100]
Kristensen I, Schmidt SAJ, Gorny AW et al.. “Occupational solar UV-exposure and risk of cutaneous melanoma among Danish workers: A nationwide cohort study.” European journal of cancer (Oxford, England : 1990) (2026). PMID: 42308861 ↗
L2COHORTCited in: Definition and Epidemiology, History and Evolution of Treatment
[101]
Lai GK, Liao YH, Lin MH et al.. “Clinical and Pathological Predictors of Unfavourable Outcomes in Thin and In Situ Melanomas: A Retrospective Cohort Study from Taiwan.” Acta dermato-venereologica (2026). PMID: 42294565 ↗
L2COHORTCited in: Definition and Epidemiology, Risk Factors and Prevention, Staging, Prognosis and Prognostic Factors, Special Populations
[102]
Chin JH, Kim D, Lee HS et al.. “Adjuvant radiotherapy and skin cancer risk in breast cancer survivors: a nationwide cohort study in Korea.” British journal of cancer (2026). PMID: 42286233 ↗
L2COHORTCited in: Definition and Epidemiology
[103]
Patrinely JR, Johnson R, Lawless AR et al.. “Chronic Immune-Related Adverse Events Following Adjuvant Anti-PD-1 Therapy for High-risk Resected Melanoma.” JAMA oncology (2021). PMID: 33764387 ↗
L2OTHERCited in: Definition and Epidemiology, Management Overview
[104]
Brunson A, Wun T, Abrahão R et al.. “Metastatic Recurrence Among Adolescents and Young Adults With Cancer.” JAMA oncology (2026). PMID: 41296369 ↗
L2OTHERCited in: Definition and Epidemiology, Clinical Presentation
[105]
Chen ML, de Vere Hunt IJ, John EM et al.. “Differences in Thickness-Specific Incidence and Factors Associated With Cutaneous Melanoma in the US From 2010 to 2018.” JAMA oncology (2022). PMID: 35323844 ↗
L2OTHERCited in: Definition and Epidemiology, Clinical Presentation
[106]
Tao J, Pfeiffer RM, Ahmed S et al.. “Cancer Risk in Solid Organ Transplant Recipients With a Pretransplant Cancer History.” JAMA oncology (2026). PMID: 41817522 ↗
L2OTHERCited in: Definition and Epidemiology, Risk Factors and Prevention, Clinical Presentation
[107]
Erickson AW, Habbous S, Wright F et al.. “Assessing the Association of Targeted Therapy and Intracranial Metastatic Disease.” JAMA oncology (2021). PMID: 34081080 ↗
L2OTHERCited in: Definition and Epidemiology, Clinical Presentation
[108]
Kerekes DM, Frey AE, Prsic EH et al.. “Immunotherapy Initiation at the End of Life in Patients With Metastatic Cancer in the US.” JAMA oncology (2024). PMID: 38175659 ↗
L2OTHERCited in: Definition and Epidemiology
[109]
Tichelli A, Beohou E, Labopin M et al.. “Evaluation of Second Solid Cancers After Hematopoietic Stem Cell Transplantation in European Patients.” JAMA oncology (2019). PMID: 30476975 ↗
L2OTHERCited in: Definition and Epidemiology, Risk Factors and Prevention, Clinical Presentation
[110]
Chen X, Meyer MA, Kemppainen JL et al.. “Risk of Syndrome-Associated Cancers Among First-Degree Relatives of Patients With Pancreatic Ductal Adenocarcinoma With Pathogenic or Likely Pathogenic Germline Variants.” JAMA oncology (2023). PMID: 37200008 ↗
L2OTHERCited in: Definition and Epidemiology, Genetics and Hereditary Predisposition
[111]
Kleffman K, Levinson G, Rose IVL et al.. “Melanoma-Secreted Amyloid Beta Suppresses Neuroinflammation and Promotes Brain Metastasis.” Cancer discovery (2022). PMID: 35262173 ↗
L5OTHERCited in: Definition and Epidemiology, Management Overview
[112]
Egelston CA, Margolin K. “Metabolic Checkpoint of Immune Cells in Melanoma Brain Metastases.” Cancer discovery (2019). PMID: 31043411 ↗
L5OTHERCited in: Definition and Epidemiology
[113]
Enzler T, Sano Y, Choo MK et al.. “Cell-selective inhibition of NF-κB signaling improves therapeutic index in a melanoma chemotherapy model.” Cancer discovery (2011). PMID: 22389871 ↗
L5OTHERCited in: Definition and Epidemiology
[114]
Heidrich I, Urhahn S, Gebhardt C et al.. “Circulating Tumor DNA as a Biomarker for Melanoma Prognosis and Therapy.” American journal of clinical dermatology (2026). PMID: 42399583 ↗
L5REVIEW_NARRATIVECited in: Definition and Epidemiology, History and Evolution of Treatment
[115]
Bhanja D, Zhu J, Wilding H et al.. “A Population-Level Real-World Analysis and Single-Center Validation of Melanoma Brain Metastasis Epidemiology following Dual-Agent Immunotherapy.” Clinical cancer research : an official journal of the American Association for Cancer Research (2025). PMID: 40455960 ↗
L2OTHERCited in: Definition and Epidemiology
[116]
Sato T, Butler MO, Piperno-Neumann S et al.. “Incidence and Management of Adverse Events Associated with Tebentafusp Treatment in Metastatic Uveal Melanoma: Pooled Safety Analysis of 410 Patients.” Clinical cancer research : an official journal of the American Association for Cancer Research (2025). PMID: 40938927 ↗
L4OTHERCited in: Definition and Epidemiology
[117]
Swetter SM, Johnson D, Albertini MR et al.. “Melanoma: Cutaneous, Version 2.2026, NCCN Clinical Practice Guidelines In Oncology.” Journal of the National Comprehensive Cancer Network : JNCCN (2026). PMID: 42297031 ↗
L1GUIDELINECited in: Risk Factors and Prevention, Genetics and Hereditary Predisposition, Clinical Presentation, History and Evolution of Treatment, Prognosis and Prognostic Factors
[118]
Vogelbaum MA, Brown PD, Messersmith H et al.. “Treatment for Brain Metastases: ASCO-SNO-ASTRO Guideline.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2021). PMID: 34932393 ↗
L1GUIDELINECited in: Risk Factors and Prevention, Management Overview, History and Evolution of Treatment, Prognosis and Prognostic Factors
[119]
Flaherty KT, Hennig M, Lee SJ et al.. “Surrogate endpoints for overall survival in metastatic melanoma: a meta-analysis of randomised controlled trials.” The Lancet. Oncology (2014). PMID: 24485879 ↗
L1SR_MA_RCTCited in: Risk Factors and Prevention
[120]
Long GV, Flaherty KT, Stroyakovskiy D et al.. “Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study.” Annals of oncology : official journal of the European Society for Medical Oncology (2017). PMID: 28475671 ↗
L1RCTCited in: Risk Factors and Prevention, Molecular Diagnostics and Biomarkers
[121]
Schadendorf D, Ugurel S, Schuler-Thurner B et al.. “Dacarbazine (DTIC) versus vaccination with autologous peptide-pulsed dendritic cells (DC) in first-line treatment of patients with metastatic melanoma: a randomized phase III trial of the DC study group of the DeCOG.” Annals of oncology : official journal of the European Society for Medical Oncology (2006). PMID: 16418308 ↗
L1RCTCited in: Risk Factors and Prevention
[122]
Butow PN, Turner J, Gilchrist J et al.. “Randomized Trial of ConquerFear: A Novel, Theoretically Based Psychosocial Intervention for Fear of Cancer Recurrence.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2017). PMID: 29095681 ↗
L1RCTCited in: Risk Factors and Prevention
[123]
Eggermont AMM, Blank CU, Mandala M et al.. “Longer Follow-Up Confirms Recurrence-Free Survival Benefit of Adjuvant Pembrolizumab in High-Risk Stage III Melanoma: Updated Results From the EORTC 1325-MG/KEYNOTE-054 Trial.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2020). PMID: 32946353 ↗
L1RCTCited in: Risk Factors and Prevention, Imaging
[124]
Baetz TD, Fletcher GG, Knight G et al.. “Systemic adjuvant therapy for adult patients at high risk for recurrent melanoma: A systematic review.” Cancer treatment reviews (2020). PMID: 32473511 ↗
L1SR_OBSCited in: Risk Factors and Prevention, Staging
[125]
Corrie P, Meyer N, Berardi R et al.. “Comparative efficacy and safety of targeted therapies for BRAF-mutant unresectable or metastatic melanoma: Results from a systematic literature review and a network meta-analysis.” Cancer treatment reviews (2022). PMID: 36099854 ↗
L1SR_OBSCited in: Risk Factors and Prevention
[126]
Landré T, Karaboué A, Buchwald ZS et al.. “Effect of immunotherapy-infusion time of day on survival of patients with advanced cancers: a study-level meta-analysis.” ESMO open (2024). PMID: 38232612 ↗
L1SR_OBSCited in: Risk Factors and Prevention
[127]
Conforti F, Pala L, Bagnardi V et al.. “Cancer immunotherapy efficacy and patients' sex: a systematic review and meta-analysis.” The Lancet. Oncology (2018). PMID: 29778737 ↗
L1SR_OBSCited in: Risk Factors and Prevention, Management Overview, Prognosis and Prognostic Factors
[128]
Watling CZ, Sweetland S, Wojt A et al.. “Oral contraceptive use and risk of liver cancer: a population-based study, systematic review, and meta-analysis.” The Lancet. Oncology (2025). PMID: 40617239 ↗
L2SR_OBSCited in: Risk Factors and Prevention
[129]
Varey AHR, Weitemeyer MB, Gjorup CA et al.. “Assessment of survival benefit from sentinel node biopsy for melanoma: a systematic review and meta-analysis.” The Lancet. Oncology (2026). PMID: 41796592 ↗
L2SR_OBSCited in: Risk Factors and Prevention, Biopsy and Histologic Diagnosis
[130]
Lallas A, Kyrgidis A, Ferrara G et al.. “Atypical Spitz tumours and sentinel lymph node biopsy: a systematic review.” The Lancet. Oncology (2014). PMID: 24694641 ↗
L4SR_OBSCited in: Risk Factors and Prevention, Biopsy and Histologic Diagnosis
[131]
Izawa N, Shiokawa H, Onuki R et al.. “The clinical utility of comprehensive measurement of autoimmune disease-related antibodies in patients with advanced solid tumors receiving immune checkpoint inhibitors: a retrospective study.” ESMO open (2022). PMID: 35247869 ↗
L2COHORTCited in: Risk Factors and Prevention, Special Populations
[132]
Long GV, Dummer R, Hamid O et al.. “Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study.” The Lancet. Oncology (2019). PMID: 31221619 ↗
L1RCTCited in: Risk Factors and Prevention, Management Overview, History and Evolution of Treatment, Prognosis and Prognostic Factors, Special Populations
[133]
Bright CJ, Reulen RC, Winter DL et al.. “Risk of subsequent primary neoplasms in survivors of adolescent and young adult cancer (Teenage and Young Adult Cancer Survivor Study): a population-based, cohort study.” The Lancet. Oncology (2019). PMID: 30797674 ↗
L2COHORTCited in: Risk Factors and Prevention
[134]
Goyal S, Silk AW, Tian S et al.. “Clinical Management of Multiple Melanoma Brain Metastases: A Systematic Review.” JAMA oncology (2015). PMID: 26181286 ↗
L5SR_OBSCited in: Risk Factors and Prevention, Management Overview, Prognosis and Prognostic Factors
[135]
Kazandjian D, Khozin S, Blumenthal G et al.. “Benefit-Risk Summary of Nivolumab for Patients With Metastatic Squamous Cell Lung Cancer After Platinum-Based Chemotherapy: A Report From the US Food and Drug Administration.” JAMA oncology (2016). PMID: 26470053 ↗
L1RCTCited in: Risk Factors and Prevention
[136]
Gogas H, Trakatelli M, Dessypris N et al.. “Melanoma risk in association with serum leptin levels and lifestyle parameters: a case-control study.” Annals of oncology : official journal of the European Society for Medical Oncology (2007). PMID: 17925285 ↗
L3CASE_CONTROLCited in: Risk Factors and Prevention, Biopsy and Histologic Diagnosis, Molecular Diagnostics and Biomarkers
[137]
Koomen ER, Joosse A, Herings RM et al.. “Estrogens, oral contraceptives and hormonal replacement therapy increase the incidence of cutaneous melanoma: a population-based case-control study.” Annals of oncology : official journal of the European Society for Medical Oncology (2008). PMID: 18725391 ↗
L3CASE_CONTROLCited in: Risk Factors and Prevention
[138]
Long GV, Weber JS, Larkin J et al.. “Nivolumab for Patients With Advanced Melanoma Treated Beyond Progression: Analysis of 2 Phase 3 Clinical Trials.” JAMA oncology (2017). PMID: 28662232 ↗
L2TRIAL_NONRANDOMCited in: Risk Factors and Prevention
[139]
Sanford NN, Sher DJ, Xu X et al.. “Alcohol Use Among Patients With Cancer and Survivors in the United States, 2000-2017.” Journal of the National Comprehensive Cancer Network : JNCCN (2020). PMID: 31910381 ↗
L4OTHERCited in: Risk Factors and Prevention, Special Populations
[140]
Johanns TM, Ferguson CJ, Grierson PM et al.. “Rapid Clinical and Radiographic Response With Combined Dabrafenib and Trametinib in Adults With BRAF-Mutated High-Grade Glioma.” Journal of the National Comprehensive Cancer Network : JNCCN (2018). PMID: 29295876 ↗
L4OTHERCited in: Risk Factors and Prevention, Imaging
[141]
Ellingsen EB, O'Day S, Mezheyeuski A et al.. “Clinical Activity of Combined Telomerase Vaccination and Pembrolizumab in Advanced Melanoma: Results from a Phase I Trial.” Clinical cancer research : an official journal of the American Association for Cancer Research (2023). PMID: 37378632 ↗
L4TRIAL_NONRANDOMCited in: Risk Factors and Prevention
[142]
Schreibelt G, Bol KF, Westdorp H et al.. “Effective Clinical Responses in Metastatic Melanoma Patients after Vaccination with Primary Myeloid Dendritic Cells.” Clinical cancer research : an official journal of the American Association for Cancer Research (2015). PMID: 26712687 ↗
L4TRIAL_NONRANDOMCited in: Risk Factors and Prevention
[143]
Thomas A, Giaccone G. “Why has active immunotherapy not worked in lung cancer?” Annals of oncology : official journal of the European Society for Medical Oncology (2015). PMID: 26232492 ↗
L5REVIEW_NARRATIVECited in: Risk Factors and Prevention, Clinical Presentation
[144]
Michaud DS, Kelsey KT, Papathanasiou E et al.. “Periodontal disease and risk of all cancers among male never smokers: an updated analysis of the Health Professionals Follow-up Study.” Annals of oncology : official journal of the European Society for Medical Oncology (2016). PMID: 26811350 ↗
L2OTHERCited in: Risk Factors and Prevention
[145]
Falchi L, Vitale C, Keating MJ et al.. “Incidence and prognostic impact of other cancers in a population of long-term survivors of chronic lymphocytic leukemia.” Annals of oncology : official journal of the European Society for Medical Oncology (2016). PMID: 26912560 ↗
L2OTHERCited in: Risk Factors and Prevention
[146]
Brandt A, Sundquist J, Hemminki K. “Risk for incident and fatal prostate cancer in men with a family history of any incident and fatal cancer.” Annals of oncology : official journal of the European Society for Medical Oncology (2011). PMID: 21467126 ↗
L2OTHERCited in: Risk Factors and Prevention, Genetics and Hereditary Predisposition
[147]
Decoster L, Wauters I, Vansteenkiste JF. “Vaccination therapy for non-small-cell lung cancer: review of agents in phase III development.” Annals of oncology : official journal of the European Society for Medical Oncology (2011). PMID: 22156658 ↗
L5REVIEW_NARRATIVECited in: Risk Factors and Prevention
[148]
Storey DJ, Waters RA, Hibberd CJ et al.. “Clinically relevant fatigue in cancer outpatients: the Edinburgh Cancer Centre symptom study.” Annals of oncology : official journal of the European Society for Medical Oncology (2007). PMID: 17804467 ↗
L4OTHERCited in: Risk Factors and Prevention
[149]
Burke OM, Hartoyo M, Barbato K et al.. “Outcomes of dermatologist-performed skin cancer screening in an academic setting: A retrospective cohort study.” Journal of the American Academy of Dermatology (2026). PMID: 42320856 ↗
L2COHORTCited in: Risk Factors and Prevention
[150]
Swaminathan M, Angelakas A, Baxter M et al.. “Treatment and outcomes of immunotherapy related colitis and hepatitis- a multi-centre cohort study in the United Kingdom by the National Oncology Trainee Collaborative for Healthcare Research (NOTCH).” Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer (2026). PMID: 42213142 ↗
L2COHORTCited in: Risk Factors and Prevention, Special Populations
[151]
Wu S, Han J, Feskanich D et al.. “Citrus Consumption and Risk of Cutaneous Malignant Melanoma.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2015). PMID: 26124488 ↗
L2OTHERCited in: Risk Factors and Prevention
[152]
Lam CJ, Curtis RE, Dores GM et al.. “Risk Factors for Melanoma Among Survivors of Non-Hodgkin Lymphoma.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2015). PMID: 26240221 ↗
L2OTHERCited in: Risk Factors and Prevention
[153]
Lo SN, Ma J, Scolyer RA et al.. “Improved Risk Prediction Calculator for Sentinel Node Positivity in Patients With Melanoma: The Melanoma Institute Australia Nomogram.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2020). PMID: 32530761 ↗
L4OTHERCited in: Risk Factors and Prevention, Biopsy and Histologic Diagnosis
[154]
Fears TR, Guerry D, Pfeiffer RM et al.. “Identifying individuals at high risk of melanoma: a practical predictor of absolute risk.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2006). PMID: 16728488 ↗
L3OTHERCited in: Risk Factors and Prevention
[155]
Turcotte LM, Liu Q, Yasui Y et al.. “Chemotherapy and Risk of Subsequent Malignant Neoplasms in the Childhood Cancer Survivor Study Cohort.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2019). PMID: 31622130 ↗
L2OTHERCited in: Risk Factors and Prevention
[156]
Tsimberidou AM, Wen S, McLaughlin P et al.. “Other malignancies in chronic lymphocytic leukemia/small lymphocytic lymphoma.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2008). PMID: 19114699 ↗
L4OTHERCited in: Risk Factors and Prevention
[157]
Zimmer L, Haydu LE, Menzies AM et al.. “Incidence of new primary melanomas after diagnosis of stage III and IV melanoma.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2013). PMID: 24297954 ↗
L2OTHERCited in: Risk Factors and Prevention
[158]
Li WQ, Qureshi AA, Ma J et al.. “Personal history of prostate cancer and increased risk of incident melanoma in the United States.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2013). PMID: 24190118 ↗
L2OTHERCited in: Risk Factors and Prevention
[159]
Long GV, Menzies AM, Nagrial AM et al.. “Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2011). PMID: 21343559 ↗
L2OTHERCited in: Risk Factors and Prevention, Genetics and Hereditary Predisposition
[160]
Dahlman KB, Xia J, Hutchinson K et al.. “BRAF(L597) mutations in melanoma are associated with sensitivity to MEK inhibitors.” Cancer discovery (2012). PMID: 22798288 ↗
L4CASE_REPORTCited in: Risk Factors and Prevention, Special Populations
[161]
McKean MA, Amaria RN. “Multidisciplinary treatment strategies in high-risk resectable melanoma: Role of adjuvant and neoadjuvant therapy.” Cancer treatment reviews (2018). PMID: 30195813 ↗
L5REVIEW_NARRATIVECited in: Risk Factors and Prevention, Prognosis and Prognostic Factors
[162]
Stiller CA. “International patterns of cancer incidence in adolescents.” Cancer treatment reviews (2007). PMID: 17329031 ↗
L5OTHERCited in: Risk Factors and Prevention
[163]
van der Meer DJ, van der Graaf WTA, van de Wal D et al.. “Long-term second primary cancer risk in adolescent and young adult (15-39 years) cancer survivors: a population-based study in the Netherlands between 1989 and 2018.” ESMO open (2024). PMID: 38171190 ↗
L2OTHERCited in: Risk Factors and Prevention, Clinical Presentation
[164]
Peacock HM, Tambuyzer T, Verdoodt F et al.. “Decline and incomplete recovery in cancer diagnoses during the COVID-19 pandemic in Belgium: a year-long, population-level analysis.” ESMO open (2021). PMID: 34474811 ↗
L2OTHERCited in: Risk Factors and Prevention, Clinical Presentation
[165]
Baurain JF, Robert C, Mortier L et al.. “Association of homogeneous inflamed gene signature with a better outcome in patients with metastatic melanoma treated with MAGE-A3 immunotherapeutic.” ESMO open (2018). PMID: 30094070 ↗
L4OTHERCited in: Risk Factors and Prevention
[166]
Salem JE, Manouchehri A, Moey M et al.. “Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study.” The Lancet. Oncology (2018). PMID: 30442497 ↗
L3OTHERCited in: Risk Factors and Prevention
[167]
Anguille S, Smits EL, Lion E et al.. “Clinical use of dendritic cells for cancer therapy.” The Lancet. Oncology (2014). PMID: 24872109 ↗
L5REVIEW_NARRATIVECited in: Risk Factors and Prevention
[168]
Grob JJ, Long GV, Schadendorf D et al.. “Disease kinetics for decision-making in advanced melanoma: a call for scenario-driven strategy trials.” The Lancet. Oncology (2015). PMID: 26433825 ↗
L5REVIEW_NARRATIVECited in: Risk Factors and Prevention
[169]
Grob JJ, Garbe C, Ascierto P et al.. “Adjuvant melanoma therapy with new drugs: should physicians continue to focus on metastatic disease or use it earlier in primary melanoma?” The Lancet. Oncology (2018). PMID: 30507438 ↗
L5REVIEW_NARRATIVECited in: Risk Factors and Prevention, Imaging
[170]
Guadagnolo BA, Zagars GK. “Adjuvant radiation therapy for high-risk nodal metastases from cutaneous melanoma.” The Lancet. Oncology (2009). PMID: 19341972 ↗
L5REVIEW_NARRATIVECited in: Risk Factors and Prevention
[171]
Donovan RJ, Carter OB, Byrne MJ. “People's perceptions of cancer survivability: implications for oncologists.” The Lancet. Oncology (2006). PMID: 16887484 ↗
L5REVIEW_NARRATIVECited in: Risk Factors and Prevention
[172]
Prabhu RS, Akinyelu T, Vaslow ZK et al.. “Risk Factors for Progression and Toxic Effects After Preoperative Stereotactic Radiosurgery for Patients With Resected Brain Metastases.” JAMA oncology (2023). PMID: 37289451 ↗
L2OTHERCited in: Risk Factors and Prevention
[173]
Lin PY, Chang SN, Hsiao TH et al.. “Association Between Parkinson Disease and Risk of Cancer in Taiwan.” JAMA oncology (2015). PMID: 26181771 ↗
L2OTHERCited in: Risk Factors and Prevention
[174]
Samadder NJ, Smith KR, Hanson H et al.. “Familial Risk in Patients With Carcinoma of Unknown Primary.” JAMA oncology (2016). PMID: 26863281 ↗
L3OTHERCited in: Risk Factors and Prevention, Genetics and Hereditary Predisposition, Clinical Presentation
[175]
Johnson DB, Sullivan RJ, Ott PA et al.. “Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders.” JAMA oncology (2016). PMID: 26633184 ↗
L4OTHERCited in: Risk Factors and Prevention, Prognosis and Prognostic Factors
[176]
Ferris LK, Saul MI, Lin Y et al.. “A Large Skin Cancer Screening Quality Initiative: Description and First-Year Outcomes.” JAMA oncology (2017). PMID: 28241191 ↗
L4OTHERCited in: Risk Factors and Prevention
[177]
Jhaveri KD, Sakhiya V, Fishbane S. “Nephrotoxicity of the BRAF Inhibitors Vemurafenib and Dabrafenib.” JAMA oncology (2015). PMID: 26182194 ↗
L4OTHERCited in: Risk Factors and Prevention
[178]
Thomas NE, Edmiston SN, Alexander A et al.. “Association Between NRAS and BRAF Mutational Status and Melanoma-Specific Survival Among Patients With Higher-Risk Primary Melanoma.” JAMA oncology (2015). PMID: 26146664 ↗
L2OTHERCited in: Risk Factors and Prevention, Genetics and Hereditary Predisposition, Molecular Diagnostics and Biomarkers, Staging
[179]
Gharzai LA, Resnicow K, An LC et al.. “Perspectives on Oncology-Specific Language During the Coronavirus Disease 2019 Pandemic: A Qualitative Study.” JAMA oncology (2020). PMID: 32761102 ↗
L5OTHERCited in: Risk Factors and Prevention
[180]
Singh A, Zeig-Owens R, Moir W et al.. “Estimation of Future Cancer Burden Among Rescue and Recovery Workers Exposed to the World Trade Center Disaster.” JAMA oncology (2018). PMID: 29710126 ↗
L2OTHERCited in: Risk Factors and Prevention
[181]
Held MA, Langdon CG, Platt JT et al.. “Genotype-selective combination therapies for melanoma identified by high-throughput drug screening.” Cancer discovery (2012). PMID: 23239741 ↗
L5OTHERCited in: Risk Factors and Prevention
[182]
Gibney GT, Smalley KS. “An unholy alliance: cooperation between BRAF and NF1 in melanoma development and BRAF inhibitor resistance.” Cancer discovery (2013). PMID: 23475878 ↗
L5OTHERCited in: Risk Factors and Prevention
[183]
Paraiso KH, Das Thakur M, Fang B et al.. “Ligand-independent EPHA2 signaling drives the adoption of a targeted therapy-mediated metastatic melanoma phenotype.” Cancer discovery (2014). PMID: 25542447 ↗
L5OTHERCited in: Risk Factors and Prevention
[184]
Lam H, McNeil LK, Starobinets H et al.. “An Empirical Antigen Selection Method Identifies Neoantigens That Either Elicit Broad Antitumor T-cell Responses or Drive Tumor Growth.” Cancer discovery (2021). PMID: 33504579 ↗
L5OTHERCited in: Risk Factors and Prevention, Molecular Diagnostics and Biomarkers
[185]
Al-Lazikani B, Workman P. “Unpicking the combination lock for mutant BRAF and RAS melanomas.” Cancer discovery (2013). PMID: 23319765 ↗
L5OTHERCited in: Risk Factors and Prevention
[186]
Wang X, Zhao X, Feng C et al.. “IL-36γ Transforms the Tumor Microenvironment and Promotes Type 1 Lymphocyte-Mediated Antitumor Immune Responses.” Cancer cell (2015). PMID: 26321222 ↗
L5OTHERCited in: Risk Factors and Prevention, History and Evolution of Treatment
[187]
Hahn AW, Menk AV, Rivadeneira DB et al.. “Obesity Is Associated with Altered Tumor Metabolism in Metastatic Melanoma.” Clinical cancer research : an official journal of the American Association for Cancer Research (2023). PMID: 36166093 ↗
L2OTHERCited in: Risk Factors and Prevention, Clinical Presentation
[188]
Sondak VK, Sabel MS, Mulé JJ. “Allogeneic and autologous melanoma vaccines: where have we been and where are we going?” Clinical cancer research : an official journal of the American Association for Cancer Research (2006). PMID: 16609055 ↗
L5REVIEW_NARRATIVECited in: Risk Factors and Prevention
[189]
Fenton GA, Mitchell DA. “Cellular Cancer Immunotherapy Development and Manufacturing in the Clinic.” Clinical cancer research : an official journal of the American Association for Cancer Research (2023). PMID: 36383184 ↗
L5REVIEW_NARRATIVECited in: Risk Factors and Prevention
[190]
Lizée G, Radvanyi LG, Overwijk WW et al.. “Immunosuppression in melanoma immunotherapy: potential opportunities for intervention.” Clinical cancer research : an official journal of the American Association for Cancer Research (2006). PMID: 16609059 ↗
L5REVIEW_NARRATIVECited in: Risk Factors and Prevention
[191]
Schultz KAP, Rednam SP, Kamihara J et al.. “PTEN, DICER1, FH, and Their Associated Tumor Susceptibility Syndromes: Clinical Features, Genetics, and Surveillance Recommendations in Childhood.” Clinical cancer research : an official journal of the American Association for Cancer Research (2017). PMID: 28620008 ↗
L5REVIEW_NARRATIVECited in: Risk Factors and Prevention, Genetics and Hereditary Predisposition
[192]
Gajewski TF. “Identifying and overcoming immune resistance mechanisms in the melanoma tumor microenvironment.” Clinical cancer research : an official journal of the American Association for Cancer Research (2006). PMID: 16609053 ↗
L5REVIEW_NARRATIVECited in: Risk Factors and Prevention
[193]
Smith FO, Downey SG, Klapper JA et al.. “Treatment of metastatic melanoma using interleukin-2 alone or in conjunction with vaccines.” Clinical cancer research : an official journal of the American Association for Cancer Research (2008). PMID: 18765555 ↗
L4OTHERCited in: Risk Factors and Prevention
[194]
Costa-Nunes C, Cachot A, Bobisse S et al.. “High-throughput Screening of Human Tumor Antigen-specific CD4 T Cells, Including Neoantigen-reactive T Cells.” Clinical cancer research : an official journal of the American Association for Cancer Research (2019). PMID: 31015344 ↗
L5OTHERCited in: Risk Factors and Prevention
[195]
Jackson CM, Kochel CM, Nirschl CJ et al.. “Systemic Tolerance Mediated by Melanoma Brain Tumors Is Reversible by Radiotherapy and Vaccination.” Clinical cancer research : an official journal of the American Association for Cancer Research (2015). PMID: 26490306 ↗
L5OTHERCited in: Risk Factors and Prevention
[196]
Wu RY, Kong PF, Xia LP et al.. “Regorafenib Promotes Antitumor Immunity via Inhibiting PD-L1 and IDO1 Expression in Melanoma.” Clinical cancer research : an official journal of the American Association for Cancer Research (2019). PMID: 30940655 ↗
L5OTHERCited in: Risk Factors and Prevention
[197]
Friedman AA, Xia Y, Trippa L et al.. “Feasibility of Ultra-High-Throughput Functional Screening of Melanoma Biopsies for Discovery of Novel Cancer Drug Combinations.” Clinical cancer research : an official journal of the American Association for Cancer Research (2017). PMID: 28446504 ↗
L5OTHERCited in: Risk Factors and Prevention
[198]
Mühlhausen L, Kocher M, Karadachi HH et al.. “Leptomeningeal disease (LMD) after resection of brain metastases: results of the multicenter SUBAROMA study.” Journal of neuro-oncology (2026). PMID: 42429857 ↗
L2OTHERCited in: Risk Factors and Prevention, Imaging, Management Overview
[199]
Diaz L, Tracy ET. “Pediatric Solid Tumors: Genetics and Screening, Prevention, and Treatment of the General Surgeon.” The Surgical clinics of North America (2026). PMID: 42419317 ↗
L5REVIEW_NARRATIVECited in: Risk Factors and Prevention, Genetics and Hereditary Predisposition, Management Overview
[200]
Smith SM, Wright GP. “The Role of Genetics in Malignant Melanoma: A Comprehensive Review.” The Surgical clinics of North America (2026). PMID: 42419313 ↗
L5REVIEW_NARRATIVECited in: Risk Factors and Prevention, Genetics and Hereditary Predisposition
[201]
Byrne L, Gray I, Ramsey K et al.. “Impact of Multigene Panel Testing in High-Risk Uveal Melanoma Patients.” Pigment cell & melanoma research (2026). PMID: 42415513 ↗
L4OTHERCited in: Risk Factors and Prevention
[202]
Grossenbacher B, Le Rhun E, Roth P et al.. “Intratumoral hemorrhage in patients with brain metastasis from systemic tumors: risk factors and prognostic assessment.” Journal of neuro-oncology (2026). PMID: 42412253 ↗
L4OTHERCited in: Risk Factors and Prevention, Histopathology and Molecular Biology
[203]
Ingold N, Zhu G, Duffy DL et al.. “Genome-Wide Association Study of Nevus Count Reveals Opposing Effects of Genetic Loci Near IRF4 and MC1R on Flat Versus Raised Nevus Count in the Brisbane Twin Nevus Study: A Cross-Sectional Analysis.” Pigment cell & melanoma research (2026). PMID: 42400230 ↗
L4OTHERCited in: Risk Factors and Prevention
[204]
Kharel P, Medcalf E, Ackermann D et al.. “Experiences of patient-led melanoma surveillance and teledermatology in underserved groups in the Melanoma Self-Surveillance Trial: A qualitative sub-study.” Journal of telemedicine and telecare (2026). PMID: 42393858 ↗
L5OTHERCited in: Risk Factors and Prevention
[205]
Grob JJ, Amonkar MM, Karaszewska B et al.. “Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial.” The Lancet. Oncology (2015). PMID: 26433819 ↗
L1RCTCited in: Genetics and Hereditary Predisposition, Molecular Diagnostics and Biomarkers
[206]
Dummer R, Ascierto PA, Gogas HJ et al.. “Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial.” The Lancet. Oncology (2018). PMID: 30219628 ↗
L1RCTCited in: Genetics and Hereditary Predisposition, Molecular Diagnostics and Biomarkers
[207]
Robert C, Dummer R, Gutzmer R et al.. “Selumetinib plus dacarbazine versus placebo plus dacarbazine as first-line treatment for BRAF-mutant metastatic melanoma: a phase 2 double-blind randomised study.” The Lancet. Oncology (2013). PMID: 23735514 ↗
L1RCTCited in: Genetics and Hereditary Predisposition
[208]
Lu YC, Parker LL, Lu T et al.. “Treatment of Patients With Metastatic Cancer Using a Major Histocompatibility Complex Class II-Restricted T-Cell Receptor Targeting the Cancer Germline Antigen MAGE-A3.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2017). PMID: 28809608 ↗
L4TRIAL_NONRANDOMCited in: Genetics and Hereditary Predisposition
[209]
Kanwar N, Seyi AB, Tan N et al.. “From Diagnosis, Therapy Decision-Making to Genetic Risk Assessment: The Impact of ctDNA Testing on Comprehensive Cancer Management-A Case Report.” Journal of the National Comprehensive Cancer Network : JNCCN (2025). PMID: 41671451 ↗
L4CASE_REPORTCited in: Genetics and Hereditary Predisposition, Molecular Diagnostics and Biomarkers
[210]
Olszanski AJ. “Mutation Testing and Adjuvant Systemic Therapy in Cutaneous Melanoma.” Journal of the National Comprehensive Cancer Network : JNCCN (2019). PMID: 31117032 ↗
L5OTHERCited in: Genetics and Hereditary Predisposition, Molecular Diagnostics and Biomarkers, Staging
[211]
Ribeiro C, Campelos S, Moura CS et al.. “Well-differentiated papillary mesothelioma: clustering in a Portuguese family with a germline BAP1 mutation.” Annals of oncology : official journal of the European Society for Medical Oncology (2013). PMID: 23585512 ↗
L4CASE_REPORTCited in: Genetics and Hereditary Predisposition
[212]
Petrelli F, Dottorini L, Zambelli A. “Phase III placebo-controlled oncology trials in the last decade: evolution, methodological foundations, and clinical impact.” Cancer treatment reviews (2026). PMID: 41762530 ↗
L5REVIEW_NARRATIVECited in: Genetics and Hereditary Predisposition, History and Evolution of Treatment
[213]
Knafler G, Ho AL, Moore KN et al.. “Melanoma-associated antigen A4: A cancer/testis antigen as a target for adoptive T-cell receptor T-cell therapy.” Cancer treatment reviews (2025). PMID: 39970827 ↗
L5REVIEW_NARRATIVECited in: Genetics and Hereditary Predisposition, Clinical Presentation
[214]
McNamara MG, Jacobs T, Lamarca A et al.. “Impact of high tumor mutational burden in solid tumors and challenges for biomarker application.” Cancer treatment reviews (2020). PMID: 32738738 ↗
L5REVIEW_NARRATIVECited in: Genetics and Hereditary Predisposition, Molecular Diagnostics and Biomarkers
[215]
Louie BH, Kurzrock R. “BAP1: Not just a BRCA1-associated protein.” Cancer treatment reviews (2020). PMID: 32877777 ↗
L5REVIEW_NARRATIVECited in: Genetics and Hereditary Predisposition, Management Overview
[216]
Makri A, Pissimissis N, Lembessis P et al.. “The kisspeptin (KiSS-1)/GPR54 system in cancer biology.” Cancer treatment reviews (2008). PMID: 18583061 ↗
L5REVIEW_NARRATIVECited in: Genetics and Hereditary Predisposition
[217]
Bishop JN, Harland M, Randerson-Moor J et al.. “Management of familial melanoma.” The Lancet. Oncology (2007). PMID: 17196510 ↗
L5REVIEW_NARRATIVECited in: Genetics and Hereditary Predisposition
[218]
Romano E, Schwartz GK, Chapman PB et al.. “Treatment implications of the emerging molecular classification system for melanoma.” The Lancet. Oncology (2011). PMID: 21349766 ↗
L5REVIEW_NARRATIVECited in: Genetics and Hereditary Predisposition
[219]
Baraian CS, Turculet CS, Negoi I. “Genetic Predisposition to Pancreatic Cancer: A Systematic Review of Hereditary Syndromes and Familial Aggregation.” Cancers (2026). PMID: 41899580 ↗
L2SR_OBSCited in: Genetics and Hereditary Predisposition
[220]
Jiang B, Li Y, Zhong W et al.. “Vitamin D and melanoma: an umbrella meta-analysis of serum levels, dietary intake, and VDR polymorphisms.” Journal of translational medicine (2026). PMID: 41808184 ↗
L2SR_OBSCited in: Genetics and Hereditary Predisposition
[221]
Carbone M, Harbour JW, Brugarolas J et al.. “Biological Mechanisms and Clinical Significance of BAP1 Mutations in Human Cancer.” Cancer discovery (2020). PMID: 32690542 ↗
L5REVIEW_NARRATIVECited in: Genetics and Hereditary Predisposition
[222]
Shao XM, Huang J, Niknafs N et al.. “HLA class II immunogenic mutation burden predicts response to immune checkpoint blockade.” Annals of oncology : official journal of the European Society for Medical Oncology (2022). PMID: 35339648 ↗
L2OTHERCited in: Genetics and Hereditary Predisposition
[223]
Latham A, Srinivasan P, Kemel Y et al.. “Microsatellite Instability Is Associated With the Presence of Lynch Syndrome Pan-Cancer.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2018). PMID: 30376427 ↗
L4OTHERCited in: Genetics and Hereditary Predisposition, Histopathology and Molecular Biology, Molecular Diagnostics and Biomarkers
[224]
Hansson J, Bergenmar M, Hofer PA et al.. “Monitoring of kindreds with hereditary predisposition for cutaneous melanoma and dysplastic nevus syndrome: results of a Swedish preventive program.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2007). PMID: 17602087 ↗
L2OTHERCited in: Genetics and Hereditary Predisposition
[225]
Kleinerman RA, Yu CL, Little MP et al.. “Variation of second cancer risk by family history of retinoblastoma among long-term survivors.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2012). PMID: 22355046 ↗
L2OTHERCited in: Genetics and Hereditary Predisposition
[226]
Hemminki K, Ji J, Sundquist J et al.. “Familial risks in cancer of unknown primary: tracking the primary sites.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2010). PMID: 21189391 ↗
L2OTHERCited in: Genetics and Hereditary Predisposition
[227]
Dombernowsky SL, Weischer M, Allin KH et al.. “Risk of cancer by ATM missense mutations in the general population.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2008). PMID: 18565893 ↗
L2OTHERCited in: Genetics and Hereditary Predisposition
[228]
Wong JR, Morton LM, Tucker MA et al.. “Risk of subsequent malignant neoplasms in long-term hereditary retinoblastoma survivors after chemotherapy and radiotherapy.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2014). PMID: 25185089 ↗
L2OTHERCited in: Genetics and Hereditary Predisposition
[229]
Woodman SE, Lazar AJ, Aldape KD et al.. “New strategies in melanoma: molecular testing in advanced disease.” Clinical cancer research : an official journal of the American Association for Cancer Research (2012). PMID: 22275506 ↗
L5REVIEW_NARRATIVECited in: Genetics and Hereditary Predisposition, Staging
[230]
Meador CB, Micheel CM, Levy MA et al.. “Beyond histology: translating tumor genotypes into clinically effective targeted therapies.” Clinical cancer research : an official journal of the American Association for Cancer Research (2014). PMID: 24599935 ↗
L5REVIEW_NARRATIVECited in: Genetics and Hereditary Predisposition, Histopathology and Molecular Biology, Clinical Presentation
[231]
D'Mellow M, Wang H, Palmer JM et al.. “GWAS meta-analysis provides new insights into uveal melanoma risk.” British journal of cancer (2026). PMID: 42303830 ↗
L3SR_OBSCited in: Genetics and Hereditary Predisposition
[232]
Jin Y, Birlea SA, Fain PR et al.. “Variant of TYR and autoimmunity susceptibility loci in generalized vitiligo.” The New England journal of medicine (2010). PMID: 20410501 ↗
L3OTHERCited in: Genetics and Hereditary Predisposition
[233]
Xu J, Wei X, Yao J et al.. “deltaHED predicts survival and immune evasion in PD-1 blockade therapy: A multi-cohort study across three cancer types.” Clinical and translational medicine (2026). PMID: 41601354 ↗
L2COHORTCited in: Genetics and Hereditary Predisposition
[234]
Shevach JW, Xu J, Snyder N et al.. “Established Cancer Predisposition Genes in Single and Multiple Cancer Diagnoses.” JAMA oncology (2025). PMID: 40875208 ↗
L2OTHERCited in: Genetics and Hereditary Predisposition, Clinical Presentation, Special Populations
[235]
Haycock PC, Burgess S, Nounu A et al.. “Association Between Telomere Length and Risk of Cancer and Non-Neoplastic Diseases: A Mendelian Randomization Study.” JAMA oncology (2017). PMID: 28241208 ↗
L3OTHERCited in: Genetics and Hereditary Predisposition
[236]
Newell F, Johansson PA, Wilmott JS et al.. “Comparative Genomics Provides Etiologic and Biological Insight into Melanoma Subtypes.” Cancer discovery (2022). PMID: 36098958 ↗
L4OTHERCited in: Genetics and Hereditary Predisposition
[237]
Liu W, Monahan KB, Pfefferle AD et al.. “LKB1/STK11 inactivation leads to expansion of a prometastatic tumor subpopulation in melanoma.” Cancer cell (2012). PMID: 22698401 ↗
L5OTHERCited in: Genetics and Hereditary Predisposition
[238]
Piscazzi F, Carrera C, Riera-Monroig J et al.. “The Role of RCM and LC-OCT in Genodermatoses Associated with Skin Cancer: A Narrative Review.” Acta dermato-venereologica (2026). PMID: 42423360 ↗
L5REVIEW_NARRATIVECited in: Genetics and Hereditary Predisposition
[239]
Leibou S, Dinerman AJ, Klemen ND. “T-Cell Receptor Engineered T-Cell Therapy: A Rapidly Evolving Treatment Paradigm for Solid Tumors.” Surgical oncology clinics of North America (2026). PMID: 41903984 ↗
L5REVIEW_NARRATIVECited in: Genetics and Hereditary Predisposition
[240]
De Nardi P, Guida S, Damiano G et al.. “Primary melanoma of the gastrointestinal tract.” World journal of gastroenterology (2026). PMID: 41809872 ↗
L5REVIEW_NARRATIVECited in: Genetics and Hereditary Predisposition
[241]
Weldy CS, Li JB, Quertermous T. “Adenosine-to-Inosine (A-to-I) RNA Editing by ADAR1 to Control RNA Sensing in Cardiovascular Disease.” Arteriosclerosis, thrombosis, and vascular biology (2026). PMID: 41744067 ↗
L5REVIEW_NARRATIVECited in: Genetics and Hereditary Predisposition, Histopathology and Molecular Biology
[242]
Lozano-Rabella M, Garcia-Garijo A, Palomero J et al.. “Exploring the Immunogenicity of Noncanonical HLA-I Tumor Ligands Identified through Proteogenomics.” Clinical cancer research : an official journal of the American Association for Cancer Research (2023). PMID: 36749875 ↗
L4OTHERCited in: Genetics and Hereditary Predisposition
[243]
Shen A, Arbesman M, Lodha R et al.. “Clinical and Immunologic Features of Germline Pathogenic Variant-Positive Patients with Melanoma.” Clinical cancer research : an official journal of the American Association for Cancer Research (2024). PMID: 38032355 ↗
L2OTHERCited in: Genetics and Hereditary Predisposition
[244]
Chen WS, Haynes WA, Waitz R et al.. “Autoantibody Landscape in Patients with Advanced Prostate Cancer.” Clinical cancer research : an official journal of the American Association for Cancer Research (2020). PMID: 32967941 ↗
L4OTHERCited in: Genetics and Hereditary Predisposition
[245]
Silva IP, Salhi A, Giles KM et al.. “Identification of a Novel Pathogenic Germline KDR Variant in Melanoma.” Clinical cancer research : an official journal of the American Association for Cancer Research (2015). PMID: 26631613 ↗
L4OTHERCited in: Genetics and Hereditary Predisposition
[246]
de Snoo FA, Bishop DT, Bergman W et al.. “Increased risk of cancer other than melanoma in CDKN2A founder mutation (p16-Leiden)-positive melanoma families.” Clinical cancer research : an official journal of the American Association for Cancer Research (2008). PMID: 18981015 ↗
L2OTHERCited in: Genetics and Hereditary Predisposition
[247]
Tan MH, Mester JL, Ngeow J et al.. “Lifetime cancer risks in individuals with germline PTEN mutations.” Clinical cancer research : an official journal of the American Association for Cancer Research (2012). PMID: 22252256 ↗
L2OTHERCited in: Genetics and Hereditary Predisposition
[248]
Sucker A, Zhao F, Real B et al.. “Genetic evolution of T-cell resistance in the course of melanoma progression.” Clinical cancer research : an official journal of the American Association for Cancer Research (2014). PMID: 25294904 ↗
L4OTHERCited in: Genetics and Hereditary Predisposition
[249]
Paradis JS, Acosta M, Saddawi-Konefka R et al.. “Synthetic Lethal Screens Reveal Cotargeting FAK and MEK as a Multimodal Precision Therapy for GNAQ-Driven Uveal Melanoma.” Clinical cancer research : an official journal of the American Association for Cancer Research (2021). PMID: 33568347 ↗
L5OTHERCited in: Genetics and Hereditary Predisposition
[250]
Carbone M, Yang H. “Molecular pathways: targeting mechanisms of asbestos and erionite carcinogenesis in mesothelioma.” Clinical cancer research : an official journal of the American Association for Cancer Research (2011). PMID: 22065079 ↗
L5OTHERCited in: Genetics and Hereditary Predisposition
[251]
Mocellin S, Hoon DS, Pilati P et al.. “Sentinel lymph node molecular ultrastaging in patients with melanoma: a systematic review and meta-analysis of prognosis.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2007). PMID: 17443001 ↗
L1SR_OBSCited in: Histopathology and Molecular Biology, Biopsy and Histologic Diagnosis
[252]
Ulloa-Montoya F, Louahed J, Dizier B et al.. “Predictive gene signature in MAGE-A3 antigen-specific cancer immunotherapy.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2013). PMID: 23715562 ↗
L2RCTCited in: Histopathology and Molecular Biology, Molecular Diagnostics and Biomarkers
[253]
Saiag P, Gutzmer R, Ascierto PA et al.. “Prospective assessment of a gene signature potentially predictive of clinical benefit in metastatic melanoma patients following MAGE-A3 immunotherapeutic (PREDICT).” Annals of oncology : official journal of the European Society for Medical Oncology (2016). PMID: 27502712 ↗
L2TRIAL_NONRANDOMCited in: Histopathology and Molecular Biology
[254]
Dean E, Jodrell D, Connolly K et al.. “Phase I trial of AEG35156 administered as a 7-day and 3-day continuous intravenous infusion in patients with advanced refractory cancer.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2009). PMID: 19237630 ↗
L4TRIAL_NONRANDOMCited in: Histopathology and Molecular Biology
[255]
Spratt DE, Gordon Spratt EA, Wu S et al.. “Efficacy of skin-directed therapy for cutaneous metastases from advanced cancer: a meta-analysis.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2014). PMID: 25154827 ↗
L1SR_OBSCited in: Histopathology and Molecular Biology
[256]
Davis KL, Fox E, Merchant MS et al.. “Nivolumab in children and young adults with relapsed or refractory solid tumours or lymphoma (ADVL1412): a multicentre, open-label, single-arm, phase 1-2 trial.” The Lancet. Oncology (2020). PMID: 32192573 ↗
L2TRIAL_NONRANDOMCited in: Histopathology and Molecular Biology
[257]
Hyman DM, Puzanov I, Subbiah V et al.. “Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations.” The New England journal of medicine (2015). PMID: 26287849 ↗
L2TRIAL_NONRANDOMCited in: Histopathology and Molecular Biology
[258]
Buglioni A, Guo R, Rumilla KM et al.. “An Unexpected Diagnosis Uncovered by Quantitative Molecular Findings: A Case Report.” Journal of the National Comprehensive Cancer Network : JNCCN (2023). PMID: 37549909 ↗
L4CASE_REPORTCited in: Histopathology and Molecular Biology, Clinical Presentation, Special Populations
[259]
Solomon JP, Benayed R, Hechtman JF et al.. “Identifying patients with NTRK fusion cancer.” Annals of oncology : official journal of the European Society for Medical Oncology (2019). PMID: 32223934 ↗
L5REVIEW_NARRATIVECited in: Histopathology and Molecular Biology, Biopsy and Histologic Diagnosis, Molecular Diagnostics and Biomarkers
[260]
Solomon JP, Benayed R, Hechtman JF et al.. “Identifying patients with NTRK fusion cancer.” Annals of oncology : official journal of the European Society for Medical Oncology (2019). PMID: 31738428 ↗
L5REVIEW_NARRATIVECited in: Histopathology and Molecular Biology, Biopsy and Histologic Diagnosis
[261]
Diamond EL, Subbiah V, Lockhart AC et al.. “Vemurafenib for BRAF V600-Mutant Erdheim-Chester Disease and Langerhans Cell Histiocytosis: Analysis of Data From the Histology-Independent, Phase 2, Open-label VE-BASKET Study.” JAMA oncology (2018). PMID: 29188284 ↗
L2TRIAL_NONRANDOMCited in: Histopathology and Molecular Biology, Imaging, Management Overview, Prognosis and Prognostic Factors, Special Populations
[262]
Zou F, Abu-Sbeih H, Ma W et al.. “Association of Chronic Immune-Mediated Diarrhea and Colitis With Favorable Cancer Response.” Journal of the National Comprehensive Cancer Network : JNCCN (2020). PMID: 33316767 ↗
L2OTHERCited in: Histopathology and Molecular Biology, Clinical Presentation
[263]
Spagnolo F, Caltabiano G, Queirolo P. “Uveal melanoma.” Cancer treatment reviews (2012). PMID: 22270078 ↗
L5REVIEW_NARRATIVECited in: Histopathology and Molecular Biology, Management Overview
[264]
Geukes Foppen MH, Rozeman EA, van Wilpe S et al.. “Immune checkpoint inhibition-related colitis: symptoms, endoscopic features, histology and response to management.” ESMO open (2018). PMID: 29387476 ↗
L4REVIEW_NARRATIVECited in: Histopathology and Molecular Biology, Clinical Presentation
[265]
Metaxas Y, Oikonomopoulos G, Pentheroudakis G. “Update on clinical research and state of the art management of patients with advanced sarcomas and GIST.” ESMO open (2016). PMID: 27843616 ↗
L5REVIEW_NARRATIVECited in: Histopathology and Molecular Biology
[266]
Manchana T, Ittiwut C, Mutirangura A et al.. “Targeted therapies for rare gynaecological cancers.” The Lancet. Oncology (2010). PMID: 20362508 ↗
L5REVIEW_NARRATIVECited in: Histopathology and Molecular Biology
[267]
Lefkovits YR, McLean LS, Middleton MR et al.. “BRAF-targeted therapy in non-melanomatous BRAF-mutant tumours: a systematic review of broad but histology-modulated efficacy.” International journal of clinical oncology (2026). PMID: 42277540 ↗
L2SR_OBSCited in: Histopathology and Molecular Biology
[268]
Tetzlaff MT, Messina JL, Stein JE et al.. “Pathological assessment of resection specimens after neoadjuvant therapy for metastatic melanoma.” Annals of oncology : official journal of the European Society for Medical Oncology (2018). PMID: 29945191 ↗
L5OTHERCited in: Histopathology and Molecular Biology, Biopsy and Histologic Diagnosis, Management Overview, Prognosis and Prognostic Factors
[269]
Smyth EC, Hsu M, Panageas KS et al.. “Histology and outcomes of newly detected lung lesions in melanoma patients.” Annals of oncology : official journal of the European Society for Medical Oncology (2011). PMID: 21821550 ↗
L2OTHERCited in: Histopathology and Molecular Biology, Biopsy and Histologic Diagnosis, Imaging
[270]
McTyre E, Ayala-Peacock D, Contessa J et al.. “Multi-institutional competing risks analysis of distant brain failure and salvage patterns after upfront radiosurgery without whole brain radiotherapy for brain metastasis.” Annals of oncology : official journal of the European Society for Medical Oncology (2018). PMID: 29161348 ↗
L2OTHERCited in: Histopathology and Molecular Biology
[271]
Thariat J, Dupin C, de Gabory L. “REFCOR good practice guidelines for radiotherapy in sinonasal carcinomas and mucosal melanomas.” European annals of otorhinolaryngology, head and neck diseases (2026). PMID: 41735111 ↗
L5GUIDELINECited in: Histopathology and Molecular Biology
[272]
Harbour JW, Correa ZM, Schefler AC et al.. “15-Gene Expression Profile and PRAME as Integrated Prognostic Test for Uveal Melanoma: First Report of Collaborative Ocular Oncology Group Study No. 2 (COOG2.1).” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024). PMID: 39052972 ↗
L2OTHERCited in: Histopathology and Molecular Biology, Molecular Diagnostics and Biomarkers, Prognosis and Prognostic Factors
[273]
Salama AKS, Li S, Macrae ER et al.. “Dabrafenib and Trametinib in Patients With Tumors With BRAFV600E Mutations: Results of the NCI-MATCH Trial Subprotocol H.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2020). PMID: 32758030 ↗
L2OTHERCited in: Histopathology and Molecular Biology
[274]
Rangel J, Torabian S, Shaikh L et al.. “Prognostic significance of nuclear receptor coactivator-3 overexpression in primary cutaneous melanoma.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2006). PMID: 17008696 ↗
L2OTHERCited in: Histopathology and Molecular Biology
[275]
Voit C, Van Akkooi AC, Schäfer-Hesterberg G et al.. “Ultrasound morphology criteria predict metastatic disease of the sentinel nodes in patients with melanoma.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2010). PMID: 20065175 ↗
L2OTHERCited in: Histopathology and Molecular Biology
[276]
Bastiaannet E, Wobbes T, Hoekstra OS et al.. “Prospective comparison of [18F]fluorodeoxyglucose positron emission tomography and computed tomography in patients with melanoma with palpable lymph node metastases: diagnostic accuracy and impact on treatment.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2009). PMID: 19720925 ↗
L2OTHERCited in: Histopathology and Molecular Biology
[277]
Zell JA, Cinar P, Mobasher M et al.. “Survival for patients with invasive cutaneous melanoma among ethnic groups: the effects of socioeconomic status and treatment.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2008). PMID: 18165642 ↗
L2OTHERCited in: Histopathology and Molecular Biology
[278]
Voit CA, van Akkooi AC, Schäfer-Hesterberg G et al.. “Rotterdam Criteria for sentinel node (SN) tumor burden and the accuracy of ultrasound (US)-guided fine-needle aspiration cytology (FNAC): can US-guided FNAC replace SN staging in patients with melanoma?” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2009). PMID: 19738131 ↗
L2OTHERCited in: Histopathology and Molecular Biology
[279]
Hinrichs CS. “Molecular Pathways: Breaking the Epithelial Cancer Barrier for Chimeric Antigen Receptor and T-cell Receptor Gene Therapy.” Clinical cancer research : an official journal of the American Association for Cancer Research (2016). PMID: 27037253 ↗
L5REVIEW_NARRATIVECited in: Histopathology and Molecular Biology
[280]
Sullivan RJ, Lorusso PM, Flaherty KT. “The intersection of immune-directed and molecularly targeted therapy in advanced melanoma: where we have been, are, and will be.” Clinical cancer research : an official journal of the American Association for Cancer Research (2013). PMID: 24089441 ↗
L5REVIEW_NARRATIVECited in: Histopathology and Molecular Biology, Staging, History and Evolution of Treatment
[281]
Labadie BW, Bao R, Luke JJ. “Reimagining IDO Pathway Inhibition in Cancer Immunotherapy via Downstream Focus on the Tryptophan-Kynurenine-Aryl Hydrocarbon Axis.” Clinical cancer research : an official journal of the American Association for Cancer Research (2018). PMID: 30377198 ↗
L5REVIEW_NARRATIVECited in: Histopathology and Molecular Biology
[282]
Lenti MV, Ribaldone DG, Borrelli de Andreis F et al.. “A 1-year follow-up study on checkpoint inhibitor-induced colitis: results from a European consortium.” ESMO open (2024). PMID: 38970840 ↗
L2OTHERCited in: Histopathology and Molecular Biology, History and Evolution of Treatment, Special Populations
[283]
Büttner R, Longshore JW, López-Ríos F et al.. “Implementing TMB measurement in clinical practice: considerations on assay requirements.” ESMO open (2019). PMID: 30792906 ↗
L5OTHERCited in: Histopathology and Molecular Biology
[284]
Mandalà M, Rutkowski P, Galli F et al.. “Acral lentiginous melanoma histotype predicts outcome in clinical stage I-II melanoma patients: an International multicenter study.” ESMO open (2022). PMID: 35421840 ↗
L2OTHERCited in: Histopathology and Molecular Biology, Prognosis and Prognostic Factors
[285]
Hibino Y, Ito M, Satake T et al.. “Clinical benefits of precision medicine in treating solid cancers: European Society of Medical Oncology-Magnitude of Clinical Benefit Scale score-based analysis.” ESMO open (2021). PMID: 34118770 ↗
L5OTHERCited in: Histopathology and Molecular Biology
[286]
Karlsson A, Ellonen A, Irjala H et al.. “Impact of deep learning-determined smoking status on mortality of cancer patients: never too late to quit.” ESMO open (2021). PMID: 34091262 ↗
L2OTHERCited in: Histopathology and Molecular Biology, Clinical Presentation
[287]
Rafaelian A, Schneider M, Dubinski D et al.. “Impact of infratentorial location on survival after surgical resection of brain metastases: a multicenter retrospective study.” Neuro-oncology advances (2026). PMID: 42325607 ↗
L2COHORTCited in: Histopathology and Molecular Biology
[288]
Degerholm SC, Salo TA, Mauramo MO. “Mucosal Melanoma of Head and Neck: A Rare and Aggressive Disease-A Register-Based Cohort Study.” Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology (2026). PMID: 41704147 ↗
L2COHORTCited in: Histopathology and Molecular Biology
[289]
Schuiveling M, van Duin IAJ, Ter Maat LS et al.. “Artificial Intelligence-Detected Tumor-Infiltrating Lymphocytes and Outcomes in Anti-PD-1-Based Treated Melanoma.” JAMA oncology (2025). PMID: 41100131 ↗
L2OTHERCited in: Histopathology and Molecular Biology, Management Overview, Prognosis and Prognostic Factors, Special Populations
[290]
Flentie K, Kocher B, Gammon ST et al.. “A bioluminescent transposon reporter-trap identifies tumor-specific microenvironment-induced promoters in Salmonella for conditional bacterial-based tumor therapy.” Cancer discovery (2012). PMID: 22728436 ↗
L5OTHERCited in: Histopathology and Molecular Biology
[291]
Rai K, Akdemir KC, Kwong LN et al.. “Dual Roles of RNF2 in Melanoma Progression.” Cancer discovery (2015). PMID: 26450788 ↗
L5OTHERCited in: Histopathology and Molecular Biology, Prognosis and Prognostic Factors
[292]
Song C, Piva M, Sun L et al.. “Recurrent Tumor Cell-Intrinsic and -Extrinsic Alterations during MAPKi-Induced Melanoma Regression and Early Adaptation.” Cancer discovery (2017). PMID: 28864476 ↗
L4OTHERCited in: Histopathology and Molecular Biology
[293]
Wang K, Patkar S, Lee JS et al.. “Deconvolving Clinically Relevant Cellular Immune Cross-talk from Bulk Gene Expression Using CODEFACS and LIRICS Stratifies Patients with Melanoma to Anti-PD-1 Therapy.” Cancer discovery (2022). PMID: 34983745 ↗
L2OTHERCited in: Histopathology and Molecular Biology
[294]
Miao B, Ji Z, Tan L et al.. “EPHA2 is a mediator of vemurafenib resistance and a novel therapeutic target in melanoma.” Cancer discovery (2014). PMID: 25542448 ↗
L5OTHERCited in: Histopathology and Molecular Biology
[295]
Smith MP, Sanchez-Laorden B, O'Brien K et al.. “The immune microenvironment confers resistance to MAPK pathway inhibitors through macrophage-derived TNFα.” Cancer discovery (2014). PMID: 25256614 ↗
L5OTHERCited in: Histopathology and Molecular Biology
[296]
Teh JLF, Cheng PF, Purwin TJ et al.. “In Vivo E2F Reporting Reveals Efficacious Schedules of MEK1/2-CDK4/6 Targeting and mTOR-S6 Resistance Mechanisms.” Cancer discovery (2018). PMID: 29496664 ↗
L5OTHERCited in: Histopathology and Molecular Biology
[297]
Weeraratna AT, Gorospe M. “UNRelenting Translation UNRestrains Melanoma Migration.” Cancer cell (2016). PMID: 27846383 ↗
L5OTHERCited in: Histopathology and Molecular Biology
[298]
Grasso CS, Tsoi J, Onyshchenko M et al.. “Conserved Interferon-γ Signaling Drives Clinical Response to Immune Checkpoint Blockade Therapy in Melanoma.” Cancer cell (2020). PMID: 32916126 ↗
L2OTHERCited in: Histopathology and Molecular Biology, Special Populations
[299]
Damsky WE, Curley DP, Santhanakrishnan M et al.. “β-catenin signaling controls metastasis in Braf-activated Pten-deficient melanomas.” Cancer cell (2011). PMID: 22172720 ↗
L5OTHERCited in: Histopathology and Molecular Biology
[300]
Arozarena I, Sanchez-Laorden B, Packer L et al.. “Oncogenic BRAF induces melanoma cell invasion by downregulating the cGMP-specific phosphodiesterase PDE5A.” Cancer cell (2011). PMID: 21215707 ↗
L5OTHERCited in: Histopathology and Molecular Biology
[301]
Lionarons DA, Hancock DC, Rana S et al.. “RAC1P29S Induces a Mesenchymal Phenotypic Switch via Serum Response Factor to Promote Melanoma Development and Therapy Resistance.” Cancer cell (2019). PMID: 31257073 ↗
L5OTHERCited in: Histopathology and Molecular Biology, Prognosis and Prognostic Factors
[302]
Shain AH, Joseph NM, Yu R et al.. “Genomic and Transcriptomic Analysis Reveals Incremental Disruption of Key Signaling Pathways during Melanoma Evolution.” Cancer cell (2018). PMID: 29990500 ↗
L4OTHERCited in: Histopathology and Molecular Biology, Molecular Diagnostics and Biomarkers, History and Evolution of Treatment
[303]
. “Specific Anatomic Transcriptomes Drive Oncogenesis in Melanoma.” Cancer discovery (2022). PMID: 35394483 ↗
L5OTHERCited in: Histopathology and Molecular Biology
[304]
. “Single-Cell RNA-Seq Reveals Melanoma Transcriptional Heterogeneity.” Cancer discovery (2016). PMID: 27102072 ↗
L4OTHERCited in: Histopathology and Molecular Biology
[305]
. “Nucleotide Stress Controls Transcriptional Regulation through HEXIM1.” Cancer discovery (2016). PMID: 27102073 ↗
L5OTHERCited in: Histopathology and Molecular Biology
[306]
Dore S, Sacchi M, Pinna A et al.. “Clinical Molecular Pathology and Treatment Developments in Advanced Uveal Melanoma: State of the Art.” Oncology research (2026). PMID: 41613812 ↗
L5REVIEW_NARRATIVECited in: Histopathology and Molecular Biology
[307]
Banlin M, Goh MS, Khong JJ. “Contemporary Management of Malignant Eyelid Tumours: Surgical and Immunotherapeutic Advances.” Clinical & experimental ophthalmology (2026). PMID: 41603445 ↗
L5REVIEW_NARRATIVECited in: Histopathology and Molecular Biology
[308]
Li X, Zhang X, Zhao S et al.. “The Dynamically Evolving Cell States and Ecosystem from Benign Nevi to Melanoma.” Clinical cancer research : an official journal of the American Association for Cancer Research (2025). PMID: 40094420 ↗
L4OTHERCited in: Histopathology and Molecular Biology, History and Evolution of Treatment
[309]
Li Y, Cui Z, Song X et al.. “Single-Cell Transcriptomic Landscape Deciphers Intratumoral Heterogeneity and Subtypes of Acral and Mucosal Melanomas.” Clinical cancer research : an official journal of the American Association for Cancer Research (2025). PMID: 40192737 ↗
L4OTHERCited in: Histopathology and Molecular Biology, Molecular Diagnostics and Biomarkers
[310]
Fa'ak F, Coudray N, Jour G et al.. “Artificial Intelligence Algorithm Predicts Response to Immune Checkpoint Inhibitors.” Clinical cancer research : an official journal of the American Association for Cancer Research (2025). PMID: 40553453 ↗
L4OTHERCited in: Histopathology and Molecular Biology, Molecular Diagnostics and Biomarkers, Management Overview, Prognosis and Prognostic Factors, Special Populations
[311]
Wiggins JM, Zhang Q, Zhang Y et al.. “Tumor miRNA Signatures Associate with Outcomes of Patients with Stage II/III Melanoma.” Clinical cancer research : an official journal of the American Association for Cancer Research (2025). PMID: 41114662 ↗
L4OTHERCited in: Histopathology and Molecular Biology, Molecular Diagnostics and Biomarkers, Staging, Special Populations
[312]
Lagos G, Groisberg R, Elliott A et al.. “Large-Scale Multiomic Analysis Identifies Anatomic Differences and Immunogenic Potential in Subtypes of Leiomyosarcoma.” Clinical cancer research : an official journal of the American Association for Cancer Research (2025). PMID: 40100098 ↗
L4OTHERCited in: Histopathology and Molecular Biology
[313]
Aung TN, Warrell J, Martinez-Morilla S et al.. “Spatially Informed Gene Signatures for Response to Immunotherapy in Melanoma.” Clinical cancer research : an official journal of the American Association for Cancer Research (2024). PMID: 38837895 ↗
L4OTHERCited in: Histopathology and Molecular Biology
[314]
Kakavand H, Rawson RV, Pupo GM et al.. “PD-L1 Expression and Immune Escape in Melanoma Resistance to MAPK Inhibitors.” Clinical cancer research : an official journal of the American Association for Cancer Research (2017). PMID: 28724663 ↗
L4OTHERCited in: Histopathology and Molecular Biology, Biopsy and Histologic Diagnosis
[315]
Patel M, Smyth E, Chapman PB et al.. “Therapeutic implications of the emerging molecular biology of uveal melanoma.” Clinical cancer research : an official journal of the American Association for Cancer Research (2011). PMID: 21444680 ↗
L5OTHERCited in: Histopathology and Molecular Biology
[316]
Stein JE, Lipson EJ, Cottrell TR et al.. “Pan-Tumor Pathologic Scoring of Response to PD-(L)1 Blockade.” Clinical cancer research : an official journal of the American Association for Cancer Research (2019). PMID: 31672770 ↗
L4OTHERCited in: Histopathology and Molecular Biology
[317]
Thakur R, Laye JP, Lauss M et al.. “Transcriptomic Analysis Reveals Prognostic Molecular Signatures of Stage I Melanoma.” Clinical cancer research : an official journal of the American Association for Cancer Research (2019). PMID: 31515461 ↗
L2OTHERCited in: Histopathology and Molecular Biology
[318]
Goldinger SM, Stieger P, Meier B et al.. “Cytotoxic Cutaneous Adverse Drug Reactions during Anti-PD-1 Therapy.” Clinical cancer research : an official journal of the American Association for Cancer Research (2016). PMID: 26957557 ↗
L4OTHERCited in: Histopathology and Molecular Biology, Biopsy and Histologic Diagnosis
[319]
Duruisseau J, Salaud C, Loussouarn D et al.. “Contribution of molecular profiling in primary cervical intramedullary melanoma: case report and literature review.” Journal of neuroradiology = Journal de neuroradiologie (2026). PMID: 41863996 ↗
L4CASE_REPORTCited in: Histopathology and Molecular Biology
[320]
Losol P, O'Driscoll D, Pulido AV et al.. “Transcriptomic Profiling of Cutaneous Melanoma Metastases Treated With Microwave Ablation-Pilot Study.” Clinical and translational science (2026). PMID: 42316430 ↗
L4OTHERCited in: Histopathology and Molecular Biology, Molecular Diagnostics and Biomarkers
[321]
Yu Y, Wang M, Zhao B. “A Macrophage/Monocyte-Related Four-Gene Signature for Prognostic Assessment of Uveal Melanoma: BTBD6, C2CD4B, CCL24, and S100A4.” Human mutation (2026). PMID: 42311235 ↗
L5OTHERCited in: Histopathology and Molecular Biology, Molecular Diagnostics and Biomarkers
[322]
Zakeri M, Wagner S, Zhu X et al.. “Analysis of Treatment Patterns for Mucosal Melanoma Using Real-World Data in the SEER-Medicare-Linked Database.” Cancer medicine (2026). PMID: 42304628 ↗
L4OTHERCited in: Histopathology and Molecular Biology
[323]
Hu Y, Xie Q. “CheckDyn: a multi-cohort computational framework for profiling treatment-induced immune checkpoint dynamics and predicting adaptive resistance to immune checkpoint blockade.” Frontiers in immunology (2026). PMID: 42292485 ↗
L5OTHERCited in: Histopathology and Molecular Biology
[324]
Tchurikov NA, Klushevskaya ES, Lukicheva VN et al.. “Highly Aggressive and Metastatic MDA-MB-231 and Mel Z Cancer Cells Have Common Sets of Down- and Upregulated Genes During Formation of the Vasculogenic Mimicry Phenotype.” International journal of molecular sciences (2026). PMID: 42278478 ↗
L5OTHERCited in: Histopathology and Molecular Biology
[325]
Gong Z, Zhang F, Xiao K et al.. “Integrative Single-Cell and Bulk Transcriptomic Analysis Defines a Molecular Stratification Strategy Based on Intra-Tumoral Heterogeneity in Acral Melanoma.” Pigment cell & melanoma research (2026). PMID: 42266021 ↗
L4OTHERCited in: Histopathology and Molecular Biology
[326]
Zhao L, Li ZC, Tang ZY et al.. “A tryptophan metabolism-related gene signature predicts prognosis and immune features in cutaneous melanoma.” Frontiers in immunology (2026). PMID: 42238596 ↗
L5OTHERCited in: Histopathology and Molecular Biology
[327]
Zhou J, Ge P, Cui J et al.. “Dexmedetomidine may alleviate severe acute pancreatitis-associated lung injury by targeting the AIM2 inflammasome in endothelial cells.” BMC anesthesiology (2026). PMID: 42226110 ↗
L5OTHERCited in: Histopathology and Molecular Biology
[328]
Schuiveling M, van Duin IAJ, Ter Maat LS et al.. “AI-based histopathology analysis predicts checkpoint inhibitor response in advanced melanoma and identifies patterns associated with response.” European journal of cancer (Oxford, England : 1990) (2026). PMID: 42208280 ↗
L2OTHERCited in: Histopathology and Molecular Biology
[329]
Bichakjian CK, Olencki T, Alam M et al.. “Merkel cell carcinoma, version 1.2014.” Journal of the National Comprehensive Cancer Network : JNCCN (2014). PMID: 24616545 ↗
L1GUIDELINECited in: Clinical Presentation, Management Overview, History and Evolution of Treatment
[330]
Piulats JM, Watkins C, Costa-García M et al.. “Overall survival from tebentafusp versus nivolumab plus ipilimumab in first-line metastatic uveal melanoma: a propensity score-weighted analysis.” Annals of oncology : official journal of the European Society for Medical Oncology (2023). PMID: 38048850 ↗
L2RCTCited in: Clinical Presentation, History and Evolution of Treatment
[331]
Cavalieri S, Rivoltini L, Bergamini C et al.. “Immuno-oncology in head and neck squamous cell cancers: News from clinical trials, emerging predictive factors and unmet needs.” Cancer treatment reviews (2018). PMID: 29574334 ↗
L5TRIAL_NONRANDOMCited in: Clinical Presentation
[332]
Resteghini C, Baujat B, Bossi P et al.. “Sinonasal malignancy: ESMO-EURACAN Clinical Practice Guideline for diagnosis, treatment and follow-up.” ESMO open (2025). PMID: 39986703 ↗
L1GUIDELINECited in: Clinical Presentation, Imaging, Management Overview, History and Evolution of Treatment
[333]
Piperno-Neumann S, Angi M, Ascierto PA et al.. “Uveal melanoma: ESMO-EURACAN Clinical Practice Guideline for diagnosis, treatment and follow-up.” ESMO open (2026). PMID: 42020098 ↗
L1GUIDELINECited in: Clinical Presentation, Imaging, Management Overview, History and Evolution of Treatment
[334]
Andtbacka RH, Kaufman HL, Collichio F et al.. “Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2015). PMID: 26014293 ↗
L1RCTCited in: Clinical Presentation, Staging, Management Overview, History and Evolution of Treatment, Prognosis and Prognostic Factors, Special Populations
[335]
Diab A, Ascierto PA, Maio M et al.. “Randomized, Open-Label, Phase III Study of Tilsotolimod in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced Refractory Melanoma (ILLUMINATE-301).” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2025). PMID: 40048691 ↗
L1RCTCited in: Clinical Presentation
[336]
Khazzaka A, Rassy E, Sleiman Z et al.. “Systematic review of fetal and placental metastases among pregnant patients with cancer.” Cancer treatment reviews (2022). PMID: 35182890 ↗
L4SR_OBSCited in: Clinical Presentation, Prognosis and Prognostic Factors, Special Populations
[337]
Smith B, Church-Martin J, Abed H et al.. “False Positive Rate from Prospective Studies of PET-CT in Cutaneous Malignant Melanoma: A Systematic Review and Meta-Analysis.” Cancer treatment reviews (2024). PMID: 39522329 ↗
L2SR_OBSCited in: Clinical Presentation, Imaging
[338]
Coit DG, Olszanski AJ. “Progress in the management of melanoma in 2013.” Journal of the National Comprehensive Cancer Network : JNCCN (2013). PMID: 23704234 ↗
L5REVIEW_NARRATIVECited in: Clinical Presentation, Biopsy and Histologic Diagnosis, Management Overview, Prognosis and Prognostic Factors
[339]
Sabel MS, Wong SL. “Review of evidence-based support for pretreatment imaging in melanoma.” Journal of the National Comprehensive Cancer Network : JNCCN (2009). PMID: 19401061 ↗
L5REVIEW_NARRATIVECited in: Clinical Presentation, Biopsy and Histologic Diagnosis, Imaging
[340]
Long GV, Stroyakovskiy D, Gogas H et al.. “Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma.” The New England journal of medicine (2014). PMID: 25265492 ↗
L1RCTCited in: Clinical Presentation
[341]
Brahmer JR, Drake CG, Wollner I et al.. “Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2010). PMID: 20516446 ↗
L4TRIAL_NONRANDOMCited in: Clinical Presentation, Prognosis and Prognostic Factors, Special Populations
[342]
Dercle L, Zhao B, Gönen M et al.. “Early Readout on Overall Survival of Patients With Melanoma Treated With Immunotherapy Using a Novel Imaging Analysis.” JAMA oncology (2022). PMID: 35050320 ↗
L2RCTCited in: Clinical Presentation, History and Evolution of Treatment
[343]
De Giorgi V, Grazzini M, Benemei S et al.. “Propranolol for Off-label Treatment of Patients With Melanoma: Results From a Cohort Study.” JAMA oncology (2018). PMID: 28973254 ↗
L2COHORTCited in: Clinical Presentation, Staging
[344]
Davies MA, Saiag P, Robert C et al.. “Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial.” The Lancet. Oncology (2017). PMID: 28592387 ↗
L4TRIAL_NONRANDOMCited in: Clinical Presentation, Imaging, Management Overview, Special Populations
[345]
Patel SP, Sheth RA, Davis C et al.. “Combination Immunotherapy With Nivolumab Plus Ipilimumab in Melanoma of Unknown Primary.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2025). PMID: 39913893 ↗
L4CASE_REPORTCited in: Clinical Presentation
[346]
Powell CA. “Pulmonary Infiltrates in a Patient With Advanced Melanoma.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2016). PMID: 28029320 ↗
L4CASE_REPORTCited in: Clinical Presentation, Imaging
[347]
Nallapaneni NN, Mourya R, Bhatt VR et al.. “Ipilimumab-induced hypophysitis and uveitis in a patient with metastatic melanoma and a history of ipilimumab-induced skin rash.” Journal of the National Comprehensive Cancer Network : JNCCN (2014). PMID: 25099440 ↗
L4CASE_REPORTCited in: Clinical Presentation
[348]
Schadendorf D, Algarra SM, Bastholt L et al.. “Immunotherapy of distant metastatic disease.” Annals of oncology : official journal of the European Society for Medical Oncology (2009). PMID: 19617297 ↗
L5REVIEW_NARRATIVECited in: Clinical Presentation, Management Overview
[349]
Mohr P, Eggermont AM, Hauschild A et al.. “Staging of cutaneous melanoma.” Annals of oncology : official journal of the European Society for Medical Oncology (2009). PMID: 19617293 ↗
L5REVIEW_NARRATIVECited in: Clinical Presentation, Imaging, Staging, Prognosis and Prognostic Factors
[350]
Naidoo J, Page DB, Li BT et al.. “Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies.” Annals of oncology : official journal of the European Society for Medical Oncology (2015). PMID: 26371282 ↗
L5REVIEW_NARRATIVECited in: Clinical Presentation, History and Evolution of Treatment
[351]
Anthony Greco F. “Cancer of unknown primary site and TNM staging: a new paradigm for patient management.” Annals of oncology : official journal of the European Society for Medical Oncology (2025). PMID: 40701441 ↗
L5REVIEW_NARRATIVECited in: Clinical Presentation, Imaging, Staging, History and Evolution of Treatment
[352]
Haymaker C, Johnson DH, Murthy R et al.. “Tilsotolimod with Ipilimumab Drives Tumor Responses in Anti-PD-1 Refractory Melanoma.” Cancer discovery (2021). PMID: 33707233 ↗
L2TRIAL_NONRANDOMCited in: Clinical Presentation, Special Populations
[353]
Singh H, Sethi S, Raber M et al.. “Errors in cancer diagnosis: current understanding and future directions.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2007). PMID: 17971601 ↗
L5REVIEW_NARRATIVECited in: Clinical Presentation
[354]
Weber JS, Kähler KC, Hauschild A. “Management of immune-related adverse events and kinetics of response with ipilimumab.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2012). PMID: 22614989 ↗
L5REVIEW_NARRATIVECited in: Clinical Presentation
[355]
Rao PK, Barker C, Coit DG et al.. “NCCN Guidelines Insights: Uveal Melanoma, Version 1.2019.” Journal of the National Comprehensive Cancer Network : JNCCN (2020). PMID: 32023525 ↗
L1OTHERCited in: Clinical Presentation, Imaging
[356]
Zibelman M, Olszanski AJ. “Full Spectrum: Efficacy and Toxicity of Immunotherapy in Metastatic Melanoma.” Journal of the National Comprehensive Cancer Network : JNCCN (2014). PMID: 31094496 ↗
L5OTHERCited in: Clinical Presentation
[357]
Borgers JSW, Tobin RP, Torphy RJ et al.. “Melanoma Metastases to the Adrenal Gland Are Highly Resistant to Immune Checkpoint Inhibitors.” Journal of the National Comprehensive Cancer Network : JNCCN (2021). PMID: 34348236 ↗
L2OTHERCited in: Clinical Presentation
[358]
Spain L, Diem S, Larkin J. “Management of toxicities of immune checkpoint inhibitors.” Cancer treatment reviews (2016). PMID: 26874776 ↗
L5REVIEW_NARRATIVECited in: Clinical Presentation, Management Overview
[359]
Gutzmer R, Vordermark D, Hassel JC et al.. “Melanoma brain metastases - Interdisciplinary management recommendations 2020.” Cancer treatment reviews (2020). PMID: 32736188 ↗
L5REVIEW_NARRATIVECited in: Clinical Presentation, Prognosis and Prognostic Factors
[360]
Wattana MK, Rowland J, Qdaisat A et al.. “Diagnosis and management of bispecific T cell-engaging antibody toxicity: A primer for emergency physicians.” Cancer treatment reviews (2025). PMID: 39913958 ↗
L5REVIEW_NARRATIVECited in: Clinical Presentation
[361]
Crucitta S, Cucchiara F, Mathijssen R et al.. “Treatment-driven tumour heterogeneity and drug resistance: Lessons from solid tumours.” Cancer treatment reviews (2022). PMID: 35151155 ↗
L5REVIEW_NARRATIVECited in: Clinical Presentation, History and Evolution of Treatment
[362]
Arangalage D, Degrauwe N, Michielin O et al.. “Pathophysiology, diagnosis and management of cardiac toxicity induced by immune checkpoint inhibitors and BRAF and MEK inhibitors.” Cancer treatment reviews (2021). PMID: 34438238 ↗
L5REVIEW_NARRATIVECited in: Clinical Presentation
[363]
Hassel JC, Heinzerling L, Aberle J et al.. “Combined immune checkpoint blockade (anti-PD-1/anti-CTLA-4): Evaluation and management of adverse drug reactions.” Cancer treatment reviews (2017). PMID: 28550712 ↗
L5REVIEW_NARRATIVECited in: Clinical Presentation
[364]
Prieto Muñoz I, Pardo Masferrer J, Olivera Vegas J et al.. “Merkel cell carcinoma from 2008 to 2012: reaching a new level of understanding.” Cancer treatment reviews (2013). PMID: 23375558 ↗
L5REVIEW_NARRATIVECited in: Clinical Presentation
[365]
Favara DM, Spain L, Au L et al.. “Five-year review of corticosteroid duration and complications in the management of immune checkpoint inhibitor-related diarrhoea and colitis in advanced melanoma.” ESMO open (2020). PMID: 32641348 ↗
L4REVIEW_NARRATIVECited in: Clinical Presentation
[366]
Tremante E, Ginebri A, Lo Monaco E et al.. “Melanoma molecular classes and prognosis in the postgenomic era.” The Lancet. Oncology (2012). PMID: 22554548 ↗
L5REVIEW_NARRATIVECited in: Clinical Presentation, Molecular Diagnostics and Biomarkers
[367]
Murali R, Thompson JF, Uren RF et al.. “Fine-needle biopsy of metastatic melanoma: clinical use and new applications.” The Lancet. Oncology (2010). PMID: 20106719 ↗
L5REVIEW_NARRATIVECited in: Clinical Presentation, Biopsy and Histologic Diagnosis
[368]
Lyle M, Long GV. “Diagnosis and treatment of KIT-mutant metastatic melanoma.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2013). PMID: 23940219 ↗
L4CASE_REPORTCited in: Clinical Presentation, Imaging, Molecular Diagnostics and Biomarkers
[369]
Laghmani K, Beck BB, Yang SS et al.. “Polyhydramnios, Transient Antenatal Bartter's Syndrome, and MAGED2 Mutations.” The New England journal of medicine (2016). PMID: 27120771 ↗
L4CASE_REPORTCited in: Clinical Presentation
[370]
Sargen MR, Barnhill RL, Elder DE et al.. “Evaluation and Surgical Management of Pediatric Cutaneous Melanoma and Atypical Spitz and Non-Spitz Melanocytic Tumors (Melanocytomas): A Report From Children's Oncology Group.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024). PMID: 39365959 ↗
L1OTHERCited in: Clinical Presentation, Biopsy and Histologic Diagnosis, Management Overview
[371]
Sperduto PW, Mesko S, Li J et al.. “Survival in Patients With Brain Metastases: Summary Report on the Updated Diagnosis-Specific Graded Prognostic Assessment and Definition of the Eligibility Quotient.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2020). PMID: 32931399 ↗
L2OTHERCited in: Clinical Presentation, Prognosis and Prognostic Factors
[372]
McClelland PH, Nah SK, Gustafson AM et al.. “Adoptive Cell Transfer of Tumor-Infiltrating Lymphocytes for Metastatic Acral Lentiginous Melanoma.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2025). PMID: 40513039 ↗
L2OTHERCited in: Clinical Presentation
[373]
Elder DE. “Pathology of melanoma.” Clinical cancer research : an official journal of the American Association for Cancer Research (2006). PMID: 16609050 ↗
L5REVIEW_NARRATIVECited in: Clinical Presentation, Biopsy and Histologic Diagnosis, Management Overview
[374]
Whiteside TL, Demaria S, Rodriguez-Ruiz ME et al.. “Emerging Opportunities and Challenges in Cancer Immunotherapy.” Clinical cancer research : an official journal of the American Association for Cancer Research (2016). PMID: 27084738 ↗
L5REVIEW_NARRATIVECited in: Clinical Presentation
[375]
Dougherty KE, Peery GB, Saravanan A et al.. “Implementing Paradigm Shifting Clinical Trials: Real-World Outcomes of Neoadjuvant Versus Adjuvant Immune Checkpoint Inhibitors in Advanced Melanoma Patients.” Annals of surgical oncology (2026). PMID: 42360644 ↗
L2TRIAL_NONRANDOMCited in: Clinical Presentation, History and Evolution of Treatment
[376]
Borgers JSW, van Schijndel AW, van Thienen JV et al.. “Clinical presentation of cardiac symptoms following treatment with tumor-infiltrating lymphocytes: diagnostic challenges and lessons learned.” ESMO open (2024). PMID: 38364453 ↗
L5OTHERCited in: Clinical Presentation
[377]
Franken MG, Leeneman B, Aarts MJB et al.. “Trends in survival and costs in metastatic melanoma in the era of novel targeted and immunotherapeutic drugs.” ESMO open (2021). PMID: 34856511 ↗
L2OTHERCited in: Clinical Presentation
[378]
Koo MM, Swann R, McPhail S et al.. “Presenting symptoms of cancer and stage at diagnosis: evidence from a cross-sectional, population-based study.” The Lancet. Oncology (2019). PMID: 31704137 ↗
L2OTHERCited in: Clinical Presentation
[379]
Spencer K, Jones CM, Girdler R et al.. “The impact of the COVID-19 pandemic on radiotherapy services in England, UK: a population-based study.” The Lancet. Oncology (2021). PMID: 33493433 ↗
L2OTHERCited in: Clinical Presentation
[380]
Turajlic S, Litchfield K, Xu H et al.. “Insertion-and-deletion-derived tumour-specific neoantigens and the immunogenic phenotype: a pan-cancer analysis.” The Lancet. Oncology (2017). PMID: 28694034 ↗
L4OTHERCited in: Clinical Presentation
[381]
Ward ZJ, Moraes FY, Scott AM et al.. “Estimating the impact of scaling up workforce personnel on global cancer mortality from 2030 to 2050: a simulation-based analysis of 17 cancers and 18 personnel types.” The Lancet. Oncology (2026). PMID: 42061369 ↗
L5OTHERCited in: Clinical Presentation
[382]
McQuade JL, Daniel CR, Hess KR et al.. “Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis.” The Lancet. Oncology (2018). PMID: 29449192 ↗
L2OTHERCited in: Clinical Presentation
[383]
Zaretsky JM, Garcia-Diaz A, Shin DS et al.. “Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma.” The New England journal of medicine (2016). PMID: 27433843 ↗
L4OTHERCited in: Clinical Presentation, Biopsy and Histologic Diagnosis
[384]
Mezquita L, Auclin E, Ferrara R et al.. “Association of the Lung Immune Prognostic Index With Immune Checkpoint Inhibitor Outcomes in Patients With Advanced Non-Small Cell Lung Cancer.” JAMA oncology (2018). PMID: 29327044 ↗
L2OTHERCited in: Clinical Presentation, Molecular Diagnostics and Biomarkers, Management Overview, Prognosis and Prognostic Factors, Special Populations
[385]
Unger JM, Fisch MJ, Jones SMW et al.. “Baseline Fatigue and Severe Toxic Effects in Patients With Cancer Receiving Systemic Therapy.” JAMA oncology (2026). PMID: 41452615 ↗
L2OTHERCited in: Clinical Presentation
[386]
Spain L, Coulton A, Lobon I et al.. “Late-Stage Metastatic Melanoma Emerges through a Diversity of Evolutionary Pathways.” Cancer discovery (2023). PMID: 36977461 ↗
L4OTHERCited in: Clinical Presentation, History and Evolution of Treatment
[387]
Kalaora S, Wolf Y, Feferman T et al.. “Combined Analysis of Antigen Presentation and T-cell Recognition Reveals Restricted Immune Responses in Melanoma.” Cancer discovery (2018). PMID: 30209080 ↗
L4OTHERCited in: Clinical Presentation
[388]
Torrejon DY, Abril-Rodriguez G, Champhekar AS et al.. “Overcoming Genetically Based Resistance Mechanisms to PD-1 Blockade.” Cancer discovery (2020). PMID: 32467343 ↗
L5OTHERCited in: Clinical Presentation
[389]
Sahu A, Wang X, Munson P et al.. “Discovery of Targets for Immune-Metabolic Antitumor Drugs Identifies Estrogen-Related Receptor Alpha.” Cancer discovery (2023). PMID: 36745048 ↗
L4OTHERCited in: Clinical Presentation
[390]
. “How Melanoma Resists PD-1 Blockade.” Cancer discovery (2016). PMID: 27486158 ↗
L5OTHERCited in: Clinical Presentation
[391]
Germano G, Lu S, Rospo G et al.. “CD4 T Cell-Dependent Rejection of Beta-2 Microglobulin Null Mismatch Repair-Deficient Tumors.” Cancer discovery (2021). PMID: 33653693 ↗
L5OTHERCited in: Clinical Presentation
[392]
Zhou X, Singh M, Sanz Santos G et al.. “Pharmacologic Activation of p53 Triggers Viral Mimicry Response Thereby Abolishing Tumor Immune Evasion and Promoting Antitumor Immunity.” Cancer discovery (2021). PMID: 34230007 ↗
L5OTHERCited in: Clinical Presentation
[393]
Roberts EW, Broz ML, Binnewies M et al.. “Critical Role for CD103(+)/CD141(+) Dendritic Cells Bearing CCR7 for Tumor Antigen Trafficking and Priming of T Cell Immunity in Melanoma.” Cancer cell (2016). PMID: 27424807 ↗
L4OTHERCited in: Clinical Presentation
[394]
Schiantarelli J, Benamar M, Park J et al.. “Genomic mediators of acquired resistance to immunotherapy in metastatic melanoma.” Cancer cell (2025). PMID: 39933900 ↗
L4OTHERCited in: Clinical Presentation
[395]
Crosby B, Guerra M, Crosby A et al.. “Biomarkers in Melanoma: Updates in Prognosis and Management.” Cancers (2026). PMID: 42352524 ↗
L5REVIEW_NARRATIVECited in: Clinical Presentation, Imaging, History and Evolution of Treatment
[396]
Caziuc A, Ilieș RA, Golea GI et al.. “Diagnostic Aspects and Management Strategies in Primary and Metastatic Intestinal Melanoma: A Literature Review.” Medical sciences (Basel, Switzerland) (2026). PMID: 42346820 ↗
L5REVIEW_NARRATIVECited in: Clinical Presentation, Biopsy and Histologic Diagnosis
[397]
van den Bulk J, Verdegaal EME, van der Ploeg M et al.. “Neoantigen Targetability in Progressive Advanced Melanoma.” Clinical cancer research : an official journal of the American Association for Cancer Research (2023). PMID: 37540567 ↗
L4OTHERCited in: Clinical Presentation, Staging, Prognosis and Prognostic Factors, Special Populations
[398]
Cortellini A, D'Alessio A, Cleary S et al.. “Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer.” Clinical cancer research : an official journal of the American Association for Cancer Research (2023). PMID: 37125965 ↗
L2OTHERCited in: Clinical Presentation
[399]
Atkins MB, Curiel-Lewandrowski C, Fisher DE et al.. “The State of Melanoma: Emergent Challenges and Opportunities.” Clinical cancer research : an official journal of the American Association for Cancer Research (2021). PMID: 33414132 ↗
L5OTHERCited in: Clinical Presentation
[400]
Babiker H, Borazanci E, Subbiah V et al.. “Tilsotolimod Exploits the TLR9 Pathway to Promote Antigen Presentation and Type 1 IFN Signaling in Solid Tumors: A Multicenter International Phase I/II Trial (ILLUMINATE-101).” Clinical cancer research : an official journal of the American Association for Cancer Research (2022). PMID: 35917516 ↗
L4OTHERCited in: Clinical Presentation
[401]
Smalley KSM. “Too Much Fuel on the Fire? Linking Obesity, Metabolism, and Melanoma Outcomes.” Clinical cancer research : an official journal of the American Association for Cancer Research (2023). PMID: 36315002 ↗
L5OTHERCited in: Clinical Presentation
[402]
Barger LN, Wang D, Saravia AL et al.. “Population Analysis and Immunologic Landscape of Melanoma in People Living with HIV.” Clinical cancer research : an official journal of the American Association for Cancer Research (2026). PMID: 41504629 ↗
L2OTHERCited in: Clinical Presentation
[403]
Menzies AM, Long GV. “Dabrafenib and trametinib, alone and in combination for BRAF-mutant metastatic melanoma.” Clinical cancer research : an official journal of the American Association for Cancer Research (2014). PMID: 24583796 ↗
L5OTHERCited in: Clinical Presentation
[404]
Shaffer T, Natarajan A, Gambhir SS. “PET Imaging of TIGIT Expression on Tumor-Infiltrating Lymphocytes.” Clinical cancer research : an official journal of the American Association for Cancer Research (2021). PMID: 33408249 ↗
L5OTHERCited in: Clinical Presentation, Imaging
[405]
Toussaint AL, Sánchez-Cárdenas C, Fuentes-García R et al.. “PRAME Immunostaining in Acral Melanocytic Proliferations: A Meta-Analysis.” The American Journal of dermatopathology (2026). PMID: 42357995 ↗
L1SR_OBSCited in: Clinical Presentation, Biopsy and Histologic Diagnosis
[406]
O'Neill K. “An Evolutionary Patient Journey in Uveal Melanoma.” Pigment cell & melanoma research (2026). PMID: 42433121 ↗
L5CASE_REPORTCited in: Clinical Presentation
[407]
Wang H, Zhang R, Zhou L et al.. “Case Report: Vogt-Koyanagi-Harada-like uveitis associated with combined dabrafenib/trametinib and cadonilimab therapy for cutaneous melanoma.” Frontiers in medicine (2026). PMID: 42422839 ↗
L4CASE_REPORTCited in: Clinical Presentation
[408]
Garbe C, Keim U, Amaral T et al.. “Years of life lost in patients with a false-negative diagnosis of primary melanoma. A prospective study of the German Central Malignant Melanoma Registry involving 9063 patients over 28 years.” Nature communications (2026). PMID: 42393046 ↗
L2COHORTCited in: Clinical Presentation
[409]
Phan N, Hackett A, Schmitt RE. “Oncoptysis as the primary presentation of metastatic melanoma: A case report.” The American journal of emergency medicine (2026). PMID: 42320419 ↗
L4CASE_REPORTCited in: Clinical Presentation
[410]
Rissotto F, Matteo C, Cicinelli MV et al.. “Multimodal Imaging of Choroidal Lymphoma: Diagnostic Features, Differential Diagnosis, and Clinical Monitoring.” Ocular immunology and inflammation (2026). PMID: 42402846 ↗
L5REVIEW_NARRATIVECited in: Clinical Presentation
[411]
Jeun C, Mayhew MM, Joshua K et al.. “The Evolving Role of Intralesional Therapy in In-Transit Melanoma.” Current oncology (Toronto, Ont.) (2026). PMID: 42346244 ↗
L5REVIEW_NARRATIVECited in: Clinical Presentation
[412]
Ponvilawan B, Bansal D, Modi K et al.. “Molecular Tumor Board-Directed Treatment for Patients with Advanced-Stage Solid Tumors: A Case-Control Real-World Study.” Current oncology (Toronto, Ont.) (2026). PMID: 42346204 ↗
L3CASE_CONTROLCited in: Clinical Presentation, Management Overview
[413]
Swetter SM, Thompson JA, Albertini MR et al.. “NCCN Guidelines® Insights: Melanoma: Cutaneous, Version 2.2021.” Journal of the National Comprehensive Cancer Network : JNCCN (2021). PMID: 33845460 ↗
L1GUIDELINECited in: Biopsy and Histologic Diagnosis, History and Evolution of Treatment
[414]
Coit DG, Andtbacka R, Anker CJ et al.. “Melanoma, version 2.2013: featured updates to the NCCN guidelines.” Journal of the National Comprehensive Cancer Network : JNCCN (2013). PMID: 23584343 ↗
L1GUIDELINECited in: Biopsy and Histologic Diagnosis
[415]
Curtis KK, Fakult NJ, Strunck JL et al.. “Establishing Consensus for Mohs Micrographic Surgical Techniques in the Treatment of Melanoma in Situ for Future Clinical Trials: A Modified Delphi Study.” Journal of the National Comprehensive Cancer Network : JNCCN (2024). PMID: 39079545 ↗
L5TRIAL_NONRANDOMCited in: Biopsy and Histologic Diagnosis, Management Overview
[416]
Stein JE, Soni A, Danilova L et al.. “Major pathologic response on biopsy (MPRbx) in patients with advanced melanoma treated with anti-PD-1: evidence for an early, on-therapy biomarker of response.” Annals of oncology : official journal of the European Society for Medical Oncology (2019). PMID: 30689736 ↗
L2RCTCited in: Biopsy and Histologic Diagnosis
[417]
Wong SL, Faries MB, Kennedy EB et al.. “Sentinel Lymph Node Biopsy and Management of Regional Lymph Nodes in Melanoma: American Society of Clinical Oncology and Society of Surgical Oncology Clinical Practice Guideline Update.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2017). PMID: 29232171 ↗
L1GUIDELINECited in: Biopsy and Histologic Diagnosis, Staging
[418]
Wong SL, Balch CM, Hurley P et al.. “Sentinel lymph node biopsy for melanoma: American Society of Clinical Oncology and Society of Surgical Oncology joint clinical practice guideline.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2012). PMID: 22778321 ↗
L1GUIDELINECited in: Biopsy and Histologic Diagnosis, Imaging
[419]
McMasters KM, Egger ME, Edwards MJ et al.. “Final Results of the Sunbelt Melanoma Trial: A Multi-Institutional Prospective Randomized Phase III Study Evaluating the Role of Adjuvant High-Dose Interferon Alfa-2b and Completion Lymph Node Dissection for Patients Staged by Sentinel Lymph Node Biopsy.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2016). PMID: 26858331 ↗
L1RCTCited in: Biopsy and Histologic Diagnosis
[420]
Hoshimoto S, Shingai T, Morton DL et al.. “Association between circulating tumor cells and prognosis in patients with stage III melanoma with sentinel lymph node metastasis in a phase III international multicenter trial.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2012). PMID: 23008288 ↗
L2RCTCited in: Biopsy and Histologic Diagnosis, Molecular Diagnostics and Biomarkers
[421]
Algazi A, Bhatia S, Agarwala S et al.. “Intratumoral delivery of tavokinogene telseplasmid yields systemic immune responses in metastatic melanoma patients.” Annals of oncology : official journal of the European Society for Medical Oncology (2020). PMID: 32147213 ↗
L2TRIAL_NONRANDOMCited in: Biopsy and Histologic Diagnosis
[422]
Lian B, Li Z, Wu N et al.. “Phase II clinical trial of neoadjuvant anti-PD-1 (toripalimab) combined with axitinib in resectable mucosal melanoma.” Annals of oncology : official journal of the European Society for Medical Oncology (2023). PMID: 37956739 ↗
L2TRIAL_NONRANDOMCited in: Biopsy and Histologic Diagnosis, Staging
[423]
Soria JC, Gan HK, Blagden SP et al.. “A phase I, pharmacokinetic and pharmacodynamic study of GSK2256098, a focal adhesion kinase inhibitor, in patients with advanced solid tumors.” Annals of oncology : official journal of the European Society for Medical Oncology (2016). PMID: 27733373 ↗
L4TRIAL_NONRANDOMCited in: Biopsy and Histologic Diagnosis
[424]
Gogas H, Polyzos A, Stavrinidis I et al.. “Temozolomide in combination with celecoxib in patients with advanced melanoma. A phase II study of the Hellenic Cooperative Oncology Group.” Annals of oncology : official journal of the European Society for Medical Oncology (2006). PMID: 16980601 ↗
L2TRIAL_NONRANDOMCited in: Biopsy and Histologic Diagnosis
[425]
Leiter U, Stadler R, Mauch C et al.. “Complete lymph node dissection versus no dissection in patients with sentinel lymph node biopsy positive melanoma (DeCOG-SLT): a multicentre, randomised, phase 3 trial.” The Lancet. Oncology (2016). PMID: 27161539 ↗
L1RCTCited in: Biopsy and Histologic Diagnosis
[426]
Faries MB, Thompson JF, Cochran AJ et al.. “Completion Dissection or Observation for Sentinel-Node Metastasis in Melanoma.” The New England journal of medicine (2017). PMID: 28591523 ↗
L1RCTCited in: Biopsy and Histologic Diagnosis, Staging, Prognosis and Prognostic Factors, Special Populations
[427]
Morton DL, Thompson JF, Cochran AJ et al.. “Final trial report of sentinel-node biopsy versus nodal observation in melanoma.” The New England journal of medicine (2014). PMID: 24521106 ↗
L1RCTCited in: Biopsy and Histologic Diagnosis, Imaging
[428]
Famoso J, Lemole G, Sundararajan S et al.. “Targeting PD-L1 After Adjuvant Radiation in Subtotally Resected Primary Pineal Melanoma: A Case Report and Literature Review.” Journal of the National Comprehensive Cancer Network : JNCCN (2019). PMID: 31590158 ↗
L4CASE_REPORTCited in: Biopsy and Histologic Diagnosis
[429]
Plitas G, Ariyan CE. “Controversies in the management of regional nodes in melanoma.” Journal of the National Comprehensive Cancer Network : JNCCN (2012). PMID: 22393199 ↗
L5REVIEW_NARRATIVECited in: Biopsy and Histologic Diagnosis
[430]
Valsecchi ME, Silbermins D, de Rosa N et al.. “Lymphatic mapping and sentinel lymph node biopsy in patients with melanoma: a meta-analysis.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2011). PMID: 21383281 ↗
L1SR_OBSCited in: Biopsy and Histologic Diagnosis, Imaging
[431]
Ashworth MT, Daud A. “Management of a patient with advanced BRAF-mutant melanoma.” Journal of the National Comprehensive Cancer Network : JNCCN (2014). PMID: 24616537 ↗
L4CASE_REPORTCited in: Biopsy and Histologic Diagnosis, Imaging, Staging
[432]
Alwaqfi RR, Samuelson MI, Guseva NN et al.. “PTCH1-GLI1 Fusion-Positive Ovarian Tumor: Report of a Unique Case With Response to Tyrosine Kinase Inhibitor Pazopanib.” Journal of the National Comprehensive Cancer Network : JNCCN (2021). PMID: 34551385 ↗
L4CASE_REPORTCited in: Biopsy and Histologic Diagnosis
[433]
De Simoni E, Spagnolo F, Gandini S et al.. “Circulating tumor DNA-based assessment of molecular residual disease in non-metastatic melanoma.” Cancer treatment reviews (2024). PMID: 38908229 ↗
L5REVIEW_NARRATIVECited in: Biopsy and Histologic Diagnosis, Molecular Diagnostics and Biomarkers, History and Evolution of Treatment, Prognosis and Prognostic Factors
[434]
Sloot S, Speijers MJ, Bastiaannet E et al.. “Is there a relation between type of primary melanoma treatment and the development of intralymphatic metastasis? A review of the literature.” Cancer treatment reviews (2016). PMID: 27015564 ↗
L2REVIEW_NARRATIVECited in: Biopsy and Histologic Diagnosis
[435]
Pasquali S, Spillane A. “Contemporary controversies and perspectives in the staging and treatment of patients with lymph node metastasis from melanoma, especially with regards positive sentinel lymph node biopsy.” Cancer treatment reviews (2014). PMID: 25023758 ↗
L5REVIEW_NARRATIVECited in: Biopsy and Histologic Diagnosis, Imaging, Staging
[436]
Gibney GT, Weiner LM, Atkins MB. “Predictive biomarkers for checkpoint inhibitor-based immunotherapy.” The Lancet. Oncology (2016). PMID: 27924752 ↗
L5REVIEW_NARRATIVECited in: Biopsy and Histologic Diagnosis
[437]
Kim R, Emi M, Tanabe K et al.. “Immunobiology of the sentinel lymph node and its potential role for antitumour immunity.” The Lancet. Oncology (2006). PMID: 17138222 ↗
L5REVIEW_NARRATIVECited in: Biopsy and Histologic Diagnosis
[438]
El Sharouni MA, Stodell MD, Ahmed T et al.. “Sentinel node biopsy in patients with melanoma improves the accuracy of staging when added to clinicopathological features of the primary tumor.” Annals of oncology : official journal of the European Society for Medical Oncology (2020). PMID: 33253862 ↗
L2OTHERCited in: Biopsy and Histologic Diagnosis, Imaging
[439]
Massi D, Brusa D, Merelli B et al.. “The status of PD-L1 and tumor-infiltrating immune cells predict resistance and poor prognosis in BRAFi-treated melanoma patients harboring mutant BRAFV600.” Annals of oncology : official journal of the European Society for Medical Oncology (2015). PMID: 26037795 ↗
L2OTHERCited in: Biopsy and Histologic Diagnosis, Molecular Diagnostics and Biomarkers
[440]
Bristow IR, Reynolds ML, Young M. “Malignant Melanoma Misdiagnosis in the Diabetic Foot. What Can We Learn From the Published Literature?” Journal of foot and ankle research (2026). PMID: 42165691 ↗
L4SR_OBSCited in: Biopsy and Histologic Diagnosis
[441]
Balch CM, Gershenwald JE, Soong SJ et al.. “Final version of 2009 AJCC melanoma staging and classification.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2009). PMID: 19917835 ↗
L1OTHERCited in: Biopsy and Histologic Diagnosis, Imaging, Staging, Prognosis and Prognostic Factors
[442]
Gould Rothberg BE, Berger AJ, Molinaro AM et al.. “Melanoma prognostic model using tissue microarrays and genetic algorithms.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2009). PMID: 19884546 ↗
L2OTHERCited in: Biopsy and Histologic Diagnosis, Molecular Diagnostics and Biomarkers
[443]
Han D, Zager JS, Shyr Y et al.. “Clinicopathologic predictors of sentinel lymph node metastasis in thin melanoma.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2013). PMID: 24190111 ↗
L2OTHERCited in: Biopsy and Histologic Diagnosis
[444]
Essner R. “Sentinel lymph node biopsy and melanoma biology.” Clinical cancer research : an official journal of the American Association for Cancer Research (2006). PMID: 16609052 ↗
L5REVIEW_NARRATIVECited in: Biopsy and Histologic Diagnosis, Imaging
[445]
Klempner SJ, Gershenhorn B, Tran P et al.. “BRAFV600E Mutations in High-Grade Colorectal Neuroendocrine Tumors May Predict Responsiveness to BRAF-MEK Combination Therapy.” Cancer discovery (2016). PMID: 27048246 ↗
L4CASE_REPORTCited in: Biopsy and Histologic Diagnosis, Imaging, Special Populations
[446]
Zhang X, Ferris L, Faries MB et al.. “Debating Sentinel Lymph Node Biopsy for Melanoma in the Modern Adjuvant Era.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023). PMID: 37410978 ↗
L5OTHERCited in: Biopsy and Histologic Diagnosis
[447]
Kiratikanon S, Xiong Y, Moran JMT et al.. “Sarcomatoid Squamous Cell Carcinoma and Its Mimics: A Meta-Analysis of Institutional Cases and Published Reports.” Cancers (2026). PMID: 42122208 ↗
L2SR_OBSCited in: Biopsy and Histologic Diagnosis
[448]
Stassen RC, Maas CCHM, van der Veldt AAM et al.. “Development and validation of a novel model to predict recurrence-free survival and melanoma-specific survival after sentinel lymph node biopsy in patients with melanoma: an international, retrospective, multicentre analysis.” The Lancet. Oncology (2024). PMID: 38547894 ↗
L2OTHERCited in: Biopsy and Histologic Diagnosis, Imaging
[449]
Reynolds HM, Dunbar PR, Uren RF et al.. “Three-dimensional visualisation of lymphatic drainage patterns in patients with cutaneous melanoma.” The Lancet. Oncology (2007). PMID: 17643351 ↗
L2OTHERCited in: Biopsy and Histologic Diagnosis
[450]
Lükewille L, Wiegand S, Fazel A et al.. “Diagnostic performance and clinical limitations of sentinel lymph node biopsy in head and neck melanoma: a 20-year retrospective cohort study.” Journal of cancer research and clinical oncology (2026). PMID: 42217063 ↗
L3COHORTCited in: Biopsy and Histologic Diagnosis, Imaging, Special Populations
[451]
McLaughlin J, Han G, Schalper KA et al.. “Quantitative Assessment of the Heterogeneity of PD-L1 Expression in Non-Small-Cell Lung Cancer.” JAMA oncology (2016). PMID: 26562159 ↗
L2OTHERCited in: Biopsy and Histologic Diagnosis, Molecular Diagnostics and Biomarkers
[452]
Chen PL, Roh W, Reuben A et al.. “Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade.” Cancer discovery (2016). PMID: 27301722 ↗
L2OTHERCited in: Biopsy and Histologic Diagnosis
[453]
Girotti MR, Gremel G, Lee R et al.. “Application of Sequencing, Liquid Biopsies, and Patient-Derived Xenografts for Personalized Medicine in Melanoma.” Cancer discovery (2015). PMID: 26715644 ↗
L4OTHERCited in: Biopsy and Histologic Diagnosis, Molecular Diagnostics and Biomarkers, Staging
[454]
Goto H, Bito T, Kawai R et al.. “Analysis of therapeutic strategy changes for patients with melanoma using a national dataset in Japan.” International journal of clinical oncology (2026). PMID: 42209932 ↗
L2REVIEW_NARRATIVECited in: Biopsy and Histologic Diagnosis, Special Populations
[455]
Ventin M, Cattaneo G, Arya S et al.. “Chimeric Antigen Receptor T Cell with an Inducible Caspase-9 Suicide Gene Eradicates Uveal Melanoma Liver Metastases via B7-H3 Targeting.” Clinical cancer research : an official journal of the American Association for Cancer Research (2024). PMID: 38767611 ↗
L5OTHERCited in: Biopsy and Histologic Diagnosis
[456]
Scala S, Giuliano P, Ascierto PA et al.. “Human melanoma metastases express functional CXCR4.” Clinical cancer research : an official journal of the American Association for Cancer Research (2006). PMID: 16638848 ↗
L4OTHERCited in: Biopsy and Histologic Diagnosis
[457]
Wang T, Xiao M, Ge Y et al.. “BRAF Inhibition Stimulates Melanoma-Associated Macrophages to Drive Tumor Growth.” Clinical cancer research : an official journal of the American Association for Cancer Research (2015). PMID: 25617424 ↗
L5OTHERCited in: Biopsy and Histologic Diagnosis
[458]
Minor DR, Kashani-Sabet M, Garrido M et al.. “Sunitinib therapy for melanoma patients with KIT mutations.” Clinical cancer research : an official journal of the American Association for Cancer Research (2012). PMID: 22261812 ↗
L4OTHERCited in: Biopsy and Histologic Diagnosis
[459]
Yaddanapudi K, Stamp BF, Subrahmanyam PB et al.. “Single-Cell Immune Mapping of Melanoma Sentinel Lymph Nodes Reveals an Actionable Immunotolerant Microenvironment.” Clinical cancer research : an official journal of the American Association for Cancer Research (2022). PMID: 35046061 ↗
L4OTHERCited in: Biopsy and Histologic Diagnosis
[460]
Kyi C, Roudko V, Sabado R et al.. “Therapeutic Immune Modulation against Solid Cancers with Intratumoral Poly-ICLC: A Pilot Trial.” Clinical cancer research : an official journal of the American Association for Cancer Research (2018). PMID: 29950349 ↗
L4OTHERCited in: Biopsy and Histologic Diagnosis, Imaging
[461]
Amaravadi RK, Hamilton KE, Ma X et al.. “Multiple Gastrointestinal Polyps in Patients Treated with BRAF Inhibitors.” Clinical cancer research : an official journal of the American Association for Cancer Research (2015). PMID: 26202952 ↗
L4OTHERCited in: Biopsy and Histologic Diagnosis, Imaging
[462]
Weishaupt C, Munoz KN, Buzney E et al.. “T-cell distribution and adhesion receptor expression in metastatic melanoma.” Clinical cancer research : an official journal of the American Association for Cancer Research (2007). PMID: 17473183 ↗
L4OTHERCited in: Biopsy and Histologic Diagnosis
[463]
Fu Y, Li P, Li K et al.. “Unmasking the "targetless" illusion: branched clonal evolution of TERT and KIT in acral melanoma revealed by sequential multi-site biopsies- a case report.” Frontiers in immunology (2026). PMID: 42245639 ↗
L4CASE_REPORTCited in: Biopsy and Histologic Diagnosis
[464]
Stratton M, Davies J, Joshi H. “Rethinking lymphadenectomy in the immunotherapy era of colorectal cancer: A hypothesis-generating perspective.” Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland (2026). PMID: 42396616 ↗
L5REVIEW_NARRATIVECited in: Biopsy and Histologic Diagnosis
[465]
Zhang Y, Borna S, Saw-Martinez R. “Sentinel lymph node detection in melanoma: indocyanine green fluorescence compared with conventional mapping techniques.” Melanoma research (2026). PMID: 42108206 ↗
L5REVIEW_NARRATIVECited in: Biopsy and Histologic Diagnosis
[466]
Ravulapalli K, Coughlan D, Abbott R et al.. “Optimising personalised melanoma care: A national e-Delphi consensus survey exploring expert perspectives on the use of a novel prognostic biomarker for early-stage cutaneous malignant melanoma.” Journal of plastic, reconstructive & aesthetic surgery : JPRAS (2026). PMID: 42379085 ↗
L5OTHERCited in: Biopsy and Histologic Diagnosis, Imaging
[467]
Pérez-Baños A, Gleisner MA, Tittarelli A et al.. “Early neutrophil infiltration promotes TRIMELVax-induced antitumor immunity by linking local inflammation to tumor control.” Oncoimmunology (2026). PMID: 42345602 ↗
L5OTHERCited in: Biopsy and Histologic Diagnosis
[468]
Swetter SM, Johnson D, Albertini MR et al.. “NCCN Guidelines® Insights: Melanoma: Cutaneous, Version 2.2024.” Journal of the National Comprehensive Cancer Network : JNCCN (2024). PMID: 39019054 ↗
L1GUIDELINECited in: Imaging, Staging, Management Overview, History and Evolution of Treatment, Prognosis and Prognostic Factors
[469]
Eggermont AMM, Blank CU, Mandalà M et al.. “Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial.” The Lancet. Oncology (2021). PMID: 33857412 ↗
L1RCTCited in: Imaging, Staging, Management Overview, History and Evolution of Treatment, Prognosis and Prognostic Factors, Special Populations
[470]
Dummer R, Guo J, Luke JJ et al.. “Vibostolimab coformulated with pembrolizumab versus pembrolizumab alone as adjuvant therapy for high-risk stage IIB-IV melanoma (KEYVIBE-010): a randomised, double-blind, phase 3 study.” The Lancet. Oncology (2026). PMID: 41698381 ↗
L1RCTCited in: Imaging, Staging
[471]
Ladjevardi CO, Naeser Y, Dyrke U et al.. “Physical examinations and whole-body imaging versus physical examinations alone during follow-up after radical surgery of stage IIB-C and III cutaneous malignant melanoma (TRIM): an interim analysis of a multicentre, randomised, phase 3 trial in Sweden.” The Lancet. Oncology (2025). PMID: 41167217 ↗
L1RCTCited in: Imaging, Staging
[472]
Weber JS, Kudchadkar RR, Yu B et al.. “Safety, efficacy, and biomarkers of nivolumab with vaccine in ipilimumab-refractory or -naive melanoma.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2013). PMID: 24145345 ↗
L4TRIAL_NONRANDOMCited in: Imaging, Molecular Diagnostics and Biomarkers, Staging
[473]
McArthur GA, Puzanov I, Amaravadi R et al.. “Marked, homogeneous, and early [18F]fluorodeoxyglucose-positron emission tomography responses to vemurafenib in BRAF-mutant advanced melanoma.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2012). PMID: 22454415 ↗
L4TRIAL_NONRANDOMCited in: Imaging
[474]
Park BH, Hwang T, Liu TC et al.. “Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial.” The Lancet. Oncology (2008). PMID: 18495536 ↗
L4TRIAL_NONRANDOMCited in: Imaging
[475]
Blachly JS, Lozanski G, Lucas DM et al.. “Cotreatment of hairy cell leukemia and melanoma with the BRAF inhibitor dabrafenib.” Journal of the National Comprehensive Cancer Network : JNCCN (2015). PMID: 25583765 ↗
L4CASE_REPORTCited in: Imaging
[476]
Pires da Silva I, Ahmed T, Reijers ILM et al.. “Ipilimumab alone or ipilimumab plus anti-PD-1 therapy in patients with metastatic melanoma resistant to anti-PD-(L)1 monotherapy: a multicentre, retrospective, cohort study.” The Lancet. Oncology (2021). PMID: 33989557 ↗
L2COHORTCited in: Imaging, Management Overview, Prognosis and Prognostic Factors
[477]
Carvajal RD, Spencer SA, Lydiatt W. “Mucosal melanoma: a clinically and biologically unique disease entity.” Journal of the National Comprehensive Cancer Network : JNCCN (2012). PMID: 22393195 ↗
L5REVIEW_NARRATIVECited in: Imaging, Staging, Prognosis and Prognostic Factors
[478]
Moya-Plana A, Khalaf M, Casiraghi O et al.. “Sinonasal mucosal melanoma: REFCOR guidelines for diagnosis, treatment and follow-up.” European annals of otorhinolaryngology, head and neck diseases (2026). PMID: 42106208 ↗
L1GUIDELINECited in: Imaging
[479]
Falchook GS, Long GV, Kurzrock R et al.. “Dose selection, pharmacokinetics, and pharmacodynamics of BRAF inhibitor dabrafenib (GSK2118436).” Clinical cancer research : an official journal of the American Association for Cancer Research (2014). PMID: 24958809 ↗
L4TRIAL_NONRANDOMCited in: Imaging
[480]
Merchant MS, Wright M, Baird K et al.. “Phase I Clinical Trial of Ipilimumab in Pediatric Patients with Advanced Solid Tumors.” Clinical cancer research : an official journal of the American Association for Cancer Research (2015). PMID: 26534966 ↗
L4TRIAL_NONRANDOMCited in: Imaging
[481]
Nishino M, Ramaiya NH, Awad MM et al.. “PD-1 Inhibitor-Related Pneumonitis in Advanced Cancer Patients: Radiographic Patterns and Clinical Course.” Clinical cancer research : an official journal of the American Association for Cancer Research (2016). PMID: 27535979 ↗
L4TRIAL_NONRANDOMCited in: Imaging
[482]
Lee ES, Park JH, Lee DY et al.. “Functional surgery for invasive nail apparatus melanoma: A cohort study and systematic review.” European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology (2026). PMID: 42208343 ↗
L2SR_OBSCited in: Imaging, Staging, Prognosis and Prognostic Factors, Special Populations
[483]
Stylianakis D, Solinas C, Petrelli F et al.. “The prognostic impact of pregnancy-associated melanoma on overall and melanoma-specific survival: A systematic review and meta-analysis.” Critical reviews in oncology/hematology (2026). PMID: 42128245 ↗
L2SR_OBSCited in: Imaging, Prognosis and Prognostic Factors
[484]
Trebeschi S, Drago SG, Birkbak NJ et al.. “Predicting response to cancer immunotherapy using noninvasive radiomic biomarkers.” Annals of oncology : official journal of the European Society for Medical Oncology (2019). PMID: 30895304 ↗
L2OTHERCited in: Imaging, Management Overview, Prognosis and Prognostic Factors
[485]
Dimitriou F, Long GV, Menzies AM. “Novel adjuvant options for cutaneous melanoma.” Annals of oncology : official journal of the European Society for Medical Oncology (2021). PMID: 33771664 ↗
L5REVIEW_NARRATIVECited in: Imaging, Management Overview
[486]
Testori A, Rutkowski P, Marsden J et al.. “Surgery and radiotherapy in the treatment of cutaneous melanoma.” Annals of oncology : official journal of the European Society for Medical Oncology (2009). PMID: 19617294 ↗
L5REVIEW_NARRATIVECited in: Imaging
[487]
Kok IC, Hooiveld JS, van de Donk PP et al.. “89Zr-pembrolizumab imaging as a non-invasive approach to assess clinical response to PD-1 blockade in cancer.” Annals of oncology : official journal of the European Society for Medical Oncology (2021). PMID: 34736925 ↗
L2OTHERCited in: Imaging
[488]
Dimitriou F, Lo SN, Tan AC et al.. “FDG-PET to predict long-term outcome from anti-PD-1 therapy in metastatic melanoma.” Annals of oncology : official journal of the European Society for Medical Oncology (2021). PMID: 34687894 ↗
L2OTHERCited in: Imaging
[489]
Schadendorf D, Vaubel J, Livingstone E et al.. “Advances and perspectives in immunotherapy of melanoma.” Annals of oncology : official journal of the European Society for Medical Oncology (2012). PMID: 22987943 ↗
L5OTHERCited in: Imaging, Staging
[490]
Tan AC, Emmett L, Lo S et al.. “FDG-PET response and outcome from anti-PD-1 therapy in metastatic melanoma.” Annals of oncology : official journal of the European Society for Medical Oncology (2018). PMID: 30137228 ↗
L2OTHERCited in: Imaging
[491]
Lewin J, Sayers L, Kee D et al.. “Surveillance imaging with FDG-PET/CT in the post-operative follow-up of stage 3 melanoma.” Annals of oncology : official journal of the European Society for Medical Oncology (2018). PMID: 29659679 ↗
L2OTHERCited in: Imaging
[492]
Rossi CR, Mozzillo N, Maurichi A et al.. “The number of excised lymph nodes is associated with survival of melanoma patients with lymph node metastasis.” Annals of oncology : official journal of the European Society for Medical Oncology (2014). PMID: 24356635 ↗
L2OTHERCited in: Imaging
[493]
Guo BH, Zhang X, Zhang HZ et al.. “Low expression of Mel-18 predicts poor prognosis in patients with breast cancer.” Annals of oncology : official journal of the European Society for Medical Oncology (2010). PMID: 20444850 ↗
L2OTHERCited in: Imaging
[494]
Wojarska M, Kokot K, Bernecka P et al.. “Clinical Utility of Circulating Tumour DNA (ctDNA) Analysis for Assessing Completeness of Primary Lesion Resection and Disease Stage in Patients with Melanoma: A Systematic Review.” Medicina (Kaunas, Lithuania) (2026). PMID: 41901544 ↗
L2SR_OBSCited in: Imaging, Staging
[495]
Varey AHR, Li I, El Sharouni MA et al.. “Predicting Recurrence-Free and Overall Survival for Patients With Stage II Melanoma: The MIA Calculator.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024). PMID: 38315961 ↗
L2OTHERCited in: Imaging, Staging
[496]
Santillan AA, Messina JL, Marzban SS et al.. “Pathology review of thin melanoma and melanoma in situ in a multidisciplinary melanoma clinic: impact on treatment decisions.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2009). PMID: 20008627 ↗
L4REVIEW_NARRATIVECited in: Imaging, Staging
[497]
Aloia TA, Gershenwald JE, Andtbacka RH et al.. “Utility of computed tomography and magnetic resonance imaging staging before completion lymphadenectomy in patients with sentinel lymph node-positive melanoma.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2006). PMID: 16782925 ↗
L2OTHERCited in: Imaging
[498]
El Sharouni MA, Ahmed T, Varey AHR et al.. “Development and Validation of Nomograms to Predict Local, Regional, and Distant Recurrence in Patients With Thin (T1) Melanomas.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2021). PMID: 33600211 ↗
L2OTHERCited in: Imaging
[499]
Hagopian G, Jiang X, Grant C et al.. “Survival impact of post-operative immunotherapy in resected stage III cutaneous melanomas in the checkpoint era.” ESMO open (2024). PMID: 38271786 ↗
L2OTHERCited in: Imaging, Staging, Prognosis and Prognostic Factors
[500]
Franke V, van Akkooi ACJ. “The extent of surgery for stage III melanoma: how much is appropriate?” The Lancet. Oncology (2019). PMID: 30842060 ↗
L5REVIEW_NARRATIVECited in: Imaging, Staging
[501]
Piura B. “Management of primary melanoma of the female urogenital tract.” The Lancet. Oncology (2008). PMID: 19071254 ↗
L5REVIEW_NARRATIVECited in: Imaging, Staging
[502]
Baeza-Hernández G, Moro R, Requena C et al.. “Lentigo Maligna Treated With Microscopically Controlled Surgery: A 194-Patient Retrospective Study.” International journal of dermatology (2026). PMID: 42135968 ↗
L4COHORTCited in: Imaging
[503]
Patnaik A, Rosen LS, Tolaney SM et al.. “Efficacy and Safety of Abemaciclib, an Inhibitor of CDK4 and CDK6, for Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Other Solid Tumors.” Cancer discovery (2016). PMID: 27217383 ↗
L4OTHERCited in: Imaging, Staging, Management Overview, Prognosis and Prognostic Factors
[504]
Romano G, Chen PL, Song P et al.. “A Preexisting Rare PIK3CAE545K Subpopulation Confers Clinical Resistance to MEK plus CDK4/6 Inhibition in NRAS Melanoma and Is Dependent on S6K1 Signaling.” Cancer discovery (2018). PMID: 29496665 ↗
L4OTHERCited in: Imaging
[505]
Ross MI. “Early-stage melanoma: staging criteria and prognostic modeling.” Clinical cancer research : an official journal of the American Association for Cancer Research (2006). PMID: 16609051 ↗
L5REVIEW_NARRATIVECited in: Imaging, Staging, History and Evolution of Treatment, Prognosis and Prognostic Factors
[506]
Lin Z, Tang C, Liu T et al.. “Comparison of [18F]PFPN and [18F]FDG PET in Mucosal Melanoma: Diagnostic Performance, Staging Impact, and Correlation with Molecular Markers.” Clinical cancer research : an official journal of the American Association for Cancer Research (2026). PMID: 41779012 ↗
L2OTHERCited in: Imaging, Staging
[507]
Segura MF, Belitskaya-Lévy I, Rose AE et al.. “Melanoma MicroRNA signature predicts post-recurrence survival.” Clinical cancer research : an official journal of the American Association for Cancer Research (2010). PMID: 20179230 ↗
L2OTHERCited in: Imaging, Staging
[508]
Beer AJ, Haubner R, Sarbia M et al.. “Positron emission tomography using [18F]Galacto-RGD identifies the level of integrin alpha(v)beta3 expression in man.” Clinical cancer research : an official journal of the American Association for Cancer Research (2006). PMID: 16818691 ↗
L4OTHERCited in: Imaging
[509]
Vashisht Gopal YN, Gammon S, Prasad R et al.. “A Novel Mitochondrial Inhibitor Blocks MAPK Pathway and Overcomes MAPK Inhibitor Resistance in Melanoma.” Clinical cancer research : an official journal of the American Association for Cancer Research (2019). PMID: 31439581 ↗
L5OTHERCited in: Imaging
[510]
Dankner M, Lajoie M, Moldoveanu D et al.. “Dual MAPK Inhibition Is an Effective Therapeutic Strategy for a Subset of Class II BRAF Mutant Melanomas.” Clinical cancer research : an official journal of the American Association for Cancer Research (2018). PMID: 29903896 ↗
L5OTHERCited in: Imaging
[511]
Atwan N, Beckman T, Mudhar HS et al.. “Secondary extraocular extension of choroidal melanoma following primary photodynamic therapy.” Eye (London, England) (2026). PMID: 41975213 ↗
L4CASE_REPORTCited in: Imaging
[512]
Basaran AE, Fahsold L, Vychopen M et al.. “Serum lactate dehydrogenase is associated with the presence and extent of preoperative peritumoral edema in melanoma brain metastases.” Journal of neuro-oncology (2026). PMID: 42406153 ↗
L4OTHERCited in: Imaging, Molecular Diagnostics and Biomarkers, Management Overview
[513]
Sharma R, Kulkarni RP, Essner R et al.. “Comparing the i31-SLNB and the MIA Nomogram for Sentinel Lymph Node Biopsy Positivity Prediction in Cutaneous Melanoma: A Prospective Cohort Analysis.” Dermatology and therapy (2026). PMID: 42337205 ↗
L2OTHERCited in: Imaging
[514]
Chang CY, Li CY, Wang TH et al.. “Recurrence Patterns and Prognostic Factors in Sentinel Lymph Node-Negative Melanoma in a Taiwanese Cohort With Predominant Acral Melanoma.” The Journal of dermatology (2026). PMID: 42310943 ↗
L4OTHERCited in: Imaging
[515]
Burton EM, Milton DR, Tetzlaff MT et al.. “Long-Term Survival and Biomarker Analysis Evaluating Neoadjuvant Plus Adjuvant Relatlimab (anti-LAG3) and Nivolumab (anti-PD1) in Patients With Resectable Melanoma.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2025). PMID: 40638872 ↗
L4TRIAL_NONRANDOMCited in: Molecular Diagnostics and Biomarkers
[516]
Hodi FS, Chiarion-Sileni V, Gonzalez R et al.. “Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial.” The Lancet. Oncology (2018). PMID: 30361170 ↗
L1RCTCited in: Molecular Diagnostics and Biomarkers, Staging, Management Overview, History and Evolution of Treatment, Prognosis and Prognostic Factors
[517]
Dummer R, Ascierto PA, Gogas HJ et al.. “Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial.” The Lancet. Oncology (2018). PMID: 29573941 ↗
L1RCTCited in: Molecular Diagnostics and Biomarkers, Management Overview, History and Evolution of Treatment, Prognosis and Prognostic Factors, Special Populations
[518]
Syeda MM, Long GV, Garrett J et al.. “Clinical validation of droplet digital PCR assays in detecting BRAFV600-mutant circulating tumour DNA as a prognostic biomarker in patients with resected stage III melanoma receiving adjuvant therapy (COMBI-AD): a biomarker analysis from a double-blind, randomised phase 3 trial.” The Lancet. Oncology (2025). PMID: 40250457 ↗
L2RCTCited in: Molecular Diagnostics and Biomarkers, Staging, History and Evolution of Treatment
[519]
Schadendorf D, Hauschild A, Santinami M et al.. “Patient-reported outcomes in patients with resected, high-risk melanoma with BRAFV600E or BRAFV600K mutations treated with adjuvant dabrafenib plus trametinib (COMBI-AD): a randomised, placebo-controlled, phase 3 trial.” The Lancet. Oncology (2019). PMID: 30928620 ↗
L1RCTCited in: Molecular Diagnostics and Biomarkers
[520]
Ascierto PA, McArthur GA, Dréno B et al.. “Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial.” The Lancet. Oncology (2016). PMID: 27480103 ↗
L1RCTCited in: Molecular Diagnostics and Biomarkers
[521]
Robert C, Lewis KD, Gutzmer R et al.. “Biomarkers of treatment benefit with atezolizumab plus vemurafenib plus cobimetinib in BRAFV600 mutation-positive melanoma.” Annals of oncology : official journal of the European Society for Medical Oncology (2022). PMID: 35131452 ↗
L1RCTCited in: Molecular Diagnostics and Biomarkers
[522]
Goldberg SB, Schalper KA, Gettinger SN et al.. “Pembrolizumab for management of patients with NSCLC and brain metastases: long-term results and biomarker analysis from a non-randomised, open-label, phase 2 trial.” The Lancet. Oncology (2020). PMID: 32251621 ↗
L4TRIAL_NONRANDOMCited in: Molecular Diagnostics and Biomarkers, Management Overview, Special Populations
[523]
Planchard D, Besse B, Groen HJM et al.. “Dabrafenib plus trametinib in patients with previously treated BRAF(V600E)-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial.” The Lancet. Oncology (2016). PMID: 27283860 ↗
L4TRIAL_NONRANDOMCited in: Molecular Diagnostics and Biomarkers, Staging, Prognosis and Prognostic Factors, Special Populations
[524]
Brose MS, Cabanillas ME, Cohen EE et al.. “Vemurafenib in patients with BRAF(V600E)-positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine: a non-randomised, multicentre, open-label, phase 2 trial.” The Lancet. Oncology (2016). PMID: 27460442 ↗
L4TRIAL_NONRANDOMCited in: Molecular Diagnostics and Biomarkers
[525]
Glitza IC, Seo YD, Spencer CN et al.. “Randomized Placebo-Controlled, Biomarker-Stratified Phase Ib Microbiome Modulation in Melanoma: Impact of Antibiotic Preconditioning on Microbiome and Immunity.” Cancer discovery (2024). PMID: 38588588 ↗
L1RCTCited in: Molecular Diagnostics and Biomarkers, History and Evolution of Treatment, Special Populations
[526]
Christenson ES, Ho WJ, Shu D et al.. “Nivolumab and Relatlimab for the Treatment of Patients with Unresectable or Metastatic Mismatch Repair-Proficient Colorectal Cancer.” Clinical cancer research : an official journal of the American Association for Cancer Research (2025). PMID: 40388545 ↗
L4TRIAL_NONRANDOMCited in: Molecular Diagnostics and Biomarkers, Special Populations
[527]
Strom T, Torres-Roca JF, Parekh A et al.. “Regional Radiation Therapy Impacts Outcome for Node-Positive Cutaneous Melanoma.” Journal of the National Comprehensive Cancer Network : JNCCN (2017). PMID: 28404758 ↗
L4OTHERCited in: Molecular Diagnostics and Biomarkers, Special Populations
[528]
Hu X, Xu Y, Wang Z et al.. “Adjuvant recombinant human endostatin combined with toripalimab (anti-PD-1) in locally advanced melanoma: an exploratory phase 2 clinical trial incorporating single-cell RNA/TCR/BCR sequencing.” Molecular cancer (2026). PMID: 42046135 ↗
L4TRIAL_NONRANDOMCited in: Molecular Diagnostics and Biomarkers, Staging
[529]
Gogas H, Eggermont AM, Hauschild A et al.. “Biomarkers in melanoma.” Annals of oncology : official journal of the European Society for Medical Oncology (2009). PMID: 19617299 ↗
L5REVIEW_NARRATIVECited in: Molecular Diagnostics and Biomarkers, Prognosis and Prognostic Factors
[530]
McGrail DJ, Pilié PG, Rashid NU et al.. “High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types.” Annals of oncology : official journal of the European Society for Medical Oncology (2021). PMID: 33736924 ↗
L2OTHERCited in: Molecular Diagnostics and Biomarkers, Management Overview, Prognosis and Prognostic Factors
[531]
Khoja L, Lorigan P, Dive C et al.. “Circulating tumour cells as tumour biomarkers in melanoma: detection methods and clinical relevance.” Annals of oncology : official journal of the European Society for Medical Oncology (2014). PMID: 24907634 ↗
L5REVIEW_NARRATIVECited in: Molecular Diagnostics and Biomarkers
[532]
Tan L, Sandhu S, Lee RJ et al.. “Prediction and monitoring of relapse in stage III melanoma using circulating tumor DNA.” Annals of oncology : official journal of the European Society for Medical Oncology (2019). PMID: 30838379 ↗
L2OTHERCited in: Molecular Diagnostics and Biomarkers, Staging
[533]
Mubarak O, Middleton GW. “The impact of the immunological context on outcomes of solid cancer patients treated with genotype-matched targeted therapies: a comprehensive review.” Annals of oncology : official journal of the European Society for Medical Oncology (2025). PMID: 40118150 ↗
L2REVIEW_NARRATIVECited in: Molecular Diagnostics and Biomarkers
[534]
McCarthy MM, Pick E, Kluger Y et al.. “HSP90 as a marker of progression in melanoma.” Annals of oncology : official journal of the European Society for Medical Oncology (2007). PMID: 18037622 ↗
L3OTHERCited in: Molecular Diagnostics and Biomarkers
[535]
Bartels F, Strönisch T, Farmer K et al.. “Neuronal autoantibodies associated with cognitive impairment in melanoma patients.” Annals of oncology : official journal of the European Society for Medical Oncology (2019). PMID: 30840061 ↗
L2OTHERCited in: Molecular Diagnostics and Biomarkers, Special Populations
[536]
Liu L, Toung JM, Jassowicz AF et al.. “Targeted methylation sequencing of plasma cell-free DNA for cancer detection and classification.” Annals of oncology : official journal of the European Society for Medical Oncology (2018). PMID: 29635542 ↗
L4OTHERCited in: Molecular Diagnostics and Biomarkers
[537]
Ferrucci PF, Ascierto PA, Pigozzo J et al.. “Baseline neutrophils and derived neutrophil-to-lymphocyte ratio: prognostic relevance in metastatic melanoma patients receiving ipilimumab.” Annals of oncology : official journal of the European Society for Medical Oncology (2016). PMID: 26802161 ↗
L2OTHERCited in: Molecular Diagnostics and Biomarkers
[538]
Ugurel S, Schadendorf D, Horny K et al.. “Elevated baseline serum PD-1 or PD-L1 predicts poor outcome of PD-1 inhibition therapy in metastatic melanoma.” Annals of oncology : official journal of the European Society for Medical Oncology (2020). PMID: 31912789 ↗
L2OTHERCited in: Molecular Diagnostics and Biomarkers
[539]
Zou J, Qian W, Guo J. “CircRNAs in Cutaneous Squamous Cell Carcinoma: Emerging Biomarkers and Potential Therapeutic Targets.” Cell biochemistry and function (2026). PMID: 42007522 ↗
L5SR_OBSCited in: Molecular Diagnostics and Biomarkers
[540]
Postow MA, Callahan MK, Wolchok JD. “Immune Checkpoint Blockade in Cancer Therapy.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2015). PMID: 25605845 ↗
L5REVIEW_NARRATIVECited in: Molecular Diagnostics and Biomarkers, Management Overview, Prognosis and Prognostic Factors
[541]
Zabierowski SE, Herlyn M. “Melanoma stem cells: the dark seed of melanoma.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2008). PMID: 18539969 ↗
L5REVIEW_NARRATIVECited in: Molecular Diagnostics and Biomarkers
[542]
Fang S, Wang Y, Sui D et al.. “C-reactive protein as a marker of melanoma progression.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2015). PMID: 25779565 ↗
L2OTHERCited in: Molecular Diagnostics and Biomarkers
[543]
Curtin JA, Busam K, Pinkel D et al.. “Somatic activation of KIT in distinct subtypes of melanoma.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2006). PMID: 16908931 ↗
L4OTHERCited in: Molecular Diagnostics and Biomarkers
[544]
Jensen TO, Schmidt H, Møller HJ et al.. “Macrophage markers in serum and tumor have prognostic impact in American Joint Committee on Cancer stage I/II melanoma.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2009). PMID: 19528371 ↗
L2OTHERCited in: Molecular Diagnostics and Biomarkers
[545]
Bachmann IM, Halvorsen OJ, Collett K et al.. “EZH2 expression is associated with high proliferation rate and aggressive tumor subgroups in cutaneous melanoma and cancers of the endometrium, prostate, and breast.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2005). PMID: 16330673 ↗
L4OTHERCited in: Molecular Diagnostics and Biomarkers
[546]
He Y, Gao C, Zhang S et al.. “Integration Analysis of Bayesian and Machine Learning for Heterogeneity, Biomarkers, and Optimal Combination Regimens of Pucotenlimab in Solid Tumors.” Cancer medicine (2026). PMID: 42043855 ↗
L1SR_OBSCited in: Molecular Diagnostics and Biomarkers
[547]
Tyagi L, Mishra S, Simran et al.. “Cancer biomarker that are currently used in cancer therapy and under evaluation in clinical trials.” Advances in cancer research (2026). PMID: 42167845 ↗
L5TRIAL_NONRANDOMCited in: Molecular Diagnostics and Biomarkers
[548]
Tarhini A, Kudchadkar RR. “Predictive and on-treatment monitoring biomarkers in advanced melanoma: Moving toward personalized medicine.” Cancer treatment reviews (2018). PMID: 30273812 ↗
L5REVIEW_NARRATIVECited in: Molecular Diagnostics and Biomarkers
[549]
Henricks LM, Schellens JH, Huitema AD et al.. “The use of combinations of monoclonal antibodies in clinical oncology.” Cancer treatment reviews (2015). PMID: 26547132 ↗
L5REVIEW_NARRATIVECited in: Molecular Diagnostics and Biomarkers, Prognosis and Prognostic Factors
[550]
Scaglione IM, Bazzichetto C, Borghesani M et al.. “Interleukin-8: a tumor-agnostic biomarker integrating cancer biology and host response across solid tumors.” Cancer treatment reviews (2026). PMID: 41997080 ↗
L5REVIEW_NARRATIVECited in: Molecular Diagnostics and Biomarkers
[551]
Nezos A, Msaouel P, Pissimissis N et al.. “Methods of detection of circulating melanoma cells: a comparative overview.” Cancer treatment reviews (2010). PMID: 21106295 ↗
L5REVIEW_NARRATIVECited in: Molecular Diagnostics and Biomarkers
[552]
Burdett N, Desai J. “New biomarkers for checkpoint inhibitor therapy.” ESMO open (2020). PMID: 32933940 ↗
L5REVIEW_NARRATIVECited in: Molecular Diagnostics and Biomarkers, Management Overview
[553]
Genta S, Araujo DV, Hueniken K et al.. “Bespoke ctDNA for longitudinal detection of molecular residual disease in high-risk melanoma patients.” ESMO open (2024). PMID: 39549683 ↗
L2OTHERCited in: Molecular Diagnostics and Biomarkers, History and Evolution of Treatment, Prognosis and Prognostic Factors
[554]
Zheng Y, Chen Y, Lin W et al.. “Association between tumor genomic mutations and the risk of PD-1 inhibitor-induced hypophysitis: a retrospective cohort study.” Frontiers in endocrinology (2026). PMID: 42339089 ↗
L3COHORTCited in: Molecular Diagnostics and Biomarkers, Management Overview, Special Populations
[555]
Haratani K, Hayashi H, Chiba Y et al.. “Association of Immune-Related Adverse Events With Nivolumab Efficacy in Non-Small-Cell Lung Cancer.” JAMA oncology (2018). PMID: 28975219 ↗
L3OTHERCited in: Molecular Diagnostics and Biomarkers, Management Overview, History and Evolution of Treatment, Prognosis and Prognostic Factors, Special Populations
[556]
Lawler SE, Speranza MC, Cho CF et al.. “Oncolytic Viruses in Cancer Treatment: A Review.” JAMA oncology (2017). PMID: 27441411 ↗
L5REVIEW_NARRATIVECited in: Molecular Diagnostics and Biomarkers, Management Overview, History and Evolution of Treatment
[557]
Johnson DB, Sosman JA. “Therapeutic Advances and Treatment Options in Metastatic Melanoma.” JAMA oncology (2015). PMID: 26181188 ↗
L5REVIEW_NARRATIVECited in: Molecular Diagnostics and Biomarkers, Management Overview, Prognosis and Prognostic Factors
[558]
Lee JH, Long GV, Menzies AM et al.. “Association Between Circulating Tumor DNA and Pseudoprogression in Patients With Metastatic Melanoma Treated With Anti-Programmed Cell Death 1 Antibodies.” JAMA oncology (2018). PMID: 29423503 ↗
L2OTHERCited in: Molecular Diagnostics and Biomarkers
[559]
Valero C, Lee M, Hoen D et al.. “Response Rates to Anti-PD-1 Immunotherapy in Microsatellite-Stable Solid Tumors With 10 or More Mutations per Megabase.” JAMA oncology (2021). PMID: 33599686 ↗
L3OTHERCited in: Molecular Diagnostics and Biomarkers
[560]
Hong X, Roh W, Sullivan RJ et al.. “The Lipogenic Regulator SREBP2 Induces Transferrin in Circulating Melanoma Cells and Suppresses Ferroptosis.” Cancer discovery (2020). PMID: 33203734 ↗
L4OTHERCited in: Molecular Diagnostics and Biomarkers
[561]
Zhu L, Wang X, Cheng G et al.. “A Circulating GPNMB-Based Multimodal Model Integrates Tumor-Immune Crosstalk to Predict Immunotherapy Response in Esophageal Cancer.” Cancer discovery (2026). PMID: 41747244 ↗
L3OTHERCited in: Molecular Diagnostics and Biomarkers, Management Overview
[562]
Hoeijmakers LL, Reijers ILM, Blank CU. “Biomarker-Driven Personalization of Neoadjuvant Immunotherapy in Melanoma.” Cancer discovery (2023). PMID: 37668337 ↗
L5REVIEW_NARRATIVECited in: Molecular Diagnostics and Biomarkers, Management Overview
[563]
Fischer GM, Jalali A, Kircher DA et al.. “Molecular Profiling Reveals Unique Immune and Metabolic Features of Melanoma Brain Metastases.” Cancer discovery (2019). PMID: 30787016 ↗
L4OTHERCited in: Molecular Diagnostics and Biomarkers
[564]
Eskiocak B, McMillan EA, Mendiratta S et al.. “Biomarker Accessible and Chemically Addressable Mechanistic Subtypes of BRAF Melanoma.” Cancer discovery (2017). PMID: 28455392 ↗
L4OTHERCited in: Molecular Diagnostics and Biomarkers
[565]
. “Blood Assay Predicts Response to Pembrolizumab.” Cancer discovery (2016). PMID: 27698203 ↗
L5OTHERCited in: Molecular Diagnostics and Biomarkers
[566]
Liu H, Gao J, Feng M et al.. “Integrative molecular and spatial analysis reveals evolutionary dynamics and tumor-immune interplay of in situ and invasive acral melanoma.” Cancer cell (2024). PMID: 38759655 ↗
L4OTHERCited in: Molecular Diagnostics and Biomarkers, History and Evolution of Treatment, Prognosis and Prognostic Factors, Special Populations
[567]
Robertson AG, Shih J, Yau C et al.. “Integrative Analysis Identifies Four Molecular and Clinical Subsets in Uveal Melanoma.” Cancer cell (2017). PMID: 28810145 ↗
L4OTHERCited in: Molecular Diagnostics and Biomarkers, Prognosis and Prognostic Factors
[568]
Campbell KM, Amouzgar M, Pfeiffer SM et al.. “Prior anti-CTLA-4 therapy impacts molecular characteristics associated with anti-PD-1 response in advanced melanoma.” Cancer cell (2023). PMID: 37037616 ↗
L3OTHERCited in: Molecular Diagnostics and Biomarkers
[569]
Newell F, Pires da Silva I, Johansson PA et al.. “Multiomic profiling of checkpoint inhibitor-treated melanoma: Identifying predictors of response and resistance, and markers of biological discordance.” Cancer cell (2021). PMID: 34951955 ↗
L3OTHERCited in: Molecular Diagnostics and Biomarkers
[570]
Straessler KM, Jones KB, Hu H et al.. “Modeling clear cell sarcomagenesis in the mouse: cell of origin differentiation state impacts tumor characteristics.” Cancer cell (2013). PMID: 23410975 ↗
L5OTHERCited in: Molecular Diagnostics and Biomarkers
[571]
Alonso-Curbelo D, Riveiro-Falkenbach E, Pérez-Guijarro E et al.. “RAB7 controls melanoma progression by exploiting a lineage-specific wiring of the endolysosomal pathway.” Cancer cell (2014). PMID: 24981740 ↗
L5OTHERCited in: Molecular Diagnostics and Biomarkers, Staging, Prognosis and Prognostic Factors
[572]
Quintana E, Shackleton M, Foster HR et al.. “Phenotypic heterogeneity among tumorigenic melanoma cells from patients that is reversible and not hierarchically organized.” Cancer cell (2010). PMID: 21075313 ↗
L4OTHERCited in: Molecular Diagnostics and Biomarkers
[573]
Settleman J. “A therapeutic opportunity in melanoma: ErbB4 makes a mark on skin.” Cancer cell (2009). PMID: 19800573 ↗
L5OTHERCited in: Molecular Diagnostics and Biomarkers
[574]
. “Dynamic regulation of endolysosomal programs drives melanoma progression.” Cancer discovery (2014). PMID: 25185197 ↗
L5OTHERCited in: Molecular Diagnostics and Biomarkers
[575]
Galbo PM, Zang X, Zheng D. “Molecular Features of Cancer-associated Fibroblast Subtypes and their Implication on Cancer Pathogenesis, Prognosis, and Immunotherapy Resistance.” Clinical cancer research : an official journal of the American Association for Cancer Research (2021). PMID: 33622705 ↗
L5OTHERCited in: Molecular Diagnostics and Biomarkers, Prognosis and Prognostic Factors
[576]
Sam I, Ben Hamouda N, Alkatrib M et al.. “The CD70-CD27 Axis in Cancer Immunotherapy: Predictive Biomarker and Therapeutic Target.” Clinical cancer research : an official journal of the American Association for Cancer Research (2025). PMID: 40388162 ↗
L5REVIEW_NARRATIVECited in: Molecular Diagnostics and Biomarkers, Management Overview
[577]
Zila N, Eichhoff OM, Steiner I et al.. “Proteomic Profiling of Advanced Melanoma Patients to Predict Therapeutic Response to Anti-PD-1 Therapy.” Clinical cancer research : an official journal of the American Association for Cancer Research (2024). PMID: 37861398 ↗
L3OTHERCited in: Molecular Diagnostics and Biomarkers
[578]
Gide TN, Mao Y, Scolyer RA et al.. “Tissue-Based Profiling Techniques to Achieve Precision Medicine in Cancer: Opportunities and Challenges in Melanoma.” Clinical cancer research : an official journal of the American Association for Cancer Research (2024). PMID: 39373690 ↗
L5REVIEW_NARRATIVECited in: Molecular Diagnostics and Biomarkers, History and Evolution of Treatment
[579]
Gide TN, Wilmott JS, Scolyer RA et al.. “Primary and Acquired Resistance to Immune Checkpoint Inhibitors in Metastatic Melanoma.” Clinical cancer research : an official journal of the American Association for Cancer Research (2017). PMID: 29127120 ↗
L5REVIEW_NARRATIVECited in: Molecular Diagnostics and Biomarkers, Staging, Prognosis and Prognostic Factors
[580]
Michel M, Heidary M, Mechri A et al.. “Noninvasive Multicancer Detection Using DNA Hypomethylation of LINE-1 Retrotransposons.” Clinical cancer research : an official journal of the American Association for Cancer Research (2025). PMID: 39620930 ↗
L3OTHERCited in: Molecular Diagnostics and Biomarkers
[581]
Vanpouille-Box C, Formenti SC, Demaria S. “Toward Precision Radiotherapy for Use with Immune Checkpoint Blockers.” Clinical cancer research : an official journal of the American Association for Cancer Research (2017). PMID: 28751442 ↗
L5REVIEW_NARRATIVECited in: Molecular Diagnostics and Biomarkers
[582]
Lucci A, Hall CS, Patel SP et al.. “Circulating Tumor Cells and Early Relapse in Node-positive Melanoma.” Clinical cancer research : an official journal of the American Association for Cancer Research (2020). PMID: 32015020 ↗
L2OTHERCited in: Molecular Diagnostics and Biomarkers, Staging
[583]
Cousin S, Italiano A. “Molecular Pathways: Immune Checkpoint Antibodies and their Toxicities.” Clinical cancer research : an official journal of the American Association for Cancer Research (2016). PMID: 27435397 ↗
L5REVIEW_NARRATIVECited in: Molecular Diagnostics and Biomarkers, Prognosis and Prognostic Factors
[584]
Zeverijn LJ, Geurts BS, Battaglia TW et al.. “The Innate Immune Landscape of dMMR/MSI Cancers Predicts the Outcome of Nivolumab Treatment: Results from the Drug Rediscovery Protocol.” Clinical cancer research : an official journal of the American Association for Cancer Research (2024). PMID: 39024037 ↗
L2OTHERCited in: Molecular Diagnostics and Biomarkers
[585]
Lipson EJ, Dolfi S, Tang H et al.. “Unraveling Relatlimab-Specific Biology Using Biomarker Analyses in Patients with Advanced Melanoma in RELATIVITY-047.” Clinical cancer research : an official journal of the American Association for Cancer Research (2025). PMID: 40607902 ↗
L2OTHERCited in: Molecular Diagnostics and Biomarkers
[586]
Weiß SV, Heider J, Niebel D et al.. “Immunohistochemical Analysis of pH-Sensitive TRPV5 in Common Skin Tumors.” International journal of molecular sciences (2026). PMID: 42353007 ↗
L4OTHERCited in: Molecular Diagnostics and Biomarkers
[587]
Banaszek J, Bąk D, Barańska K et al.. “Predicting Response to Immune Checkpoint Inhibitors in Melanoma: Emerging Approaches in Digital Pathology, Spatial Profiling and Machine Learning.” International journal of molecular sciences (2026). PMID: 42352966 ↗
L5REVIEW_NARRATIVECited in: Molecular Diagnostics and Biomarkers
[588]
Nam CH, Kim YJ, Youk J et al.. “Metastasis-related genomic aberrations and evolutionary trajectory in uveal melanoma.” Experimental & molecular medicine (2026). PMID: 42310376 ↗
L4OTHERCited in: Molecular Diagnostics and Biomarkers
[589]
de Arruda JAA, Villarroel-Dorrego M, Peña-Vega CP et al.. “Oral Melanoma: A South American Collaborative Series of 21 Cases.” Head and neck pathology (2026). PMID: 42307794 ↗
L4OTHERCited in: Molecular Diagnostics and Biomarkers
[590]
Peraza-Labrador A, Bishop J, Schmidt LS et al.. “Parotid Oncocytomas Express the Glycoprotein Non-metastatic Melanoma Protein B (GPNMB): A Potential Link with Birt-Hogg-Dubé Syndrome.” Head and neck pathology (2026). PMID: 42295526 ↗
L4OTHERCited in: Molecular Diagnostics and Biomarkers
[591]
Akpalamut D. “NF1 mutation may be associated with lung-tropic metastasis in cutaneous melanoma: a genomic analysis of 520 patients.” Clinical & experimental metastasis (2026). PMID: 42251234 ↗
L3OTHERCited in: Molecular Diagnostics and Biomarkers
[592]
Coit DG, Thompson JA, Algazi A et al.. “NCCN Guidelines Insights: Melanoma, Version 3.2016.” Journal of the National Comprehensive Cancer Network : JNCCN (2016). PMID: 27496110 ↗
L1GUIDELINECited in: Staging, History and Evolution of Treatment, Prognosis and Prognostic Factors
[593]
Johnson DB, Bao R, Ancell KK et al.. “Response to Anti-PD-1 in Uveal Melanoma Without High-Volume Liver Metastasis.” Journal of the National Comprehensive Cancer Network : JNCCN (2019). PMID: 30787124 ↗
L4TRIAL_NONRANDOMCited in: Staging, Prognosis and Prognostic Factors
[594]
Long GV, Carlino MS, McNeil C et al.. “Pembrolizumab versus ipilimumab for advanced melanoma: 10-year follow-up of the phase III KEYNOTE-006 study.” Annals of oncology : official journal of the European Society for Medical Oncology (2024). PMID: 39306585 ↗
L1RCTCited in: Staging, Management Overview, History and Evolution of Treatment, Prognosis and Prognostic Factors, Special Populations
[595]
Kähler KC, Hassel JC, Ziemer M et al.. “Neoadjuvant intralesional targeted immunocytokines (daromun) in stage III melanoma.” Annals of oncology : official journal of the European Society for Medical Oncology (2025). PMID: 40633690 ↗
L1RCTCited in: Staging, Management Overview, History and Evolution of Treatment, Prognosis and Prognostic Factors, Special Populations
[596]
Wolchok JD, Chiarion-Sileni V, Gonzalez R et al.. “Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2021). PMID: 34818112 ↗
L1RCTCited in: Staging, Management Overview, History and Evolution of Treatment, Prognosis and Prognostic Factors
[597]
Luke JJ, Ascierto PA, Khattak MA et al.. “Pembrolizumab Versus Placebo as Adjuvant Therapy in Resected Stage IIB or IIC Melanoma: Final Analysis of Distant Metastasis-Free Survival in the Phase III KEYNOTE-716 Study.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024). PMID: 38452313 ↗
L1RCTCited in: Staging, Management Overview, History and Evolution of Treatment, Prognosis and Prognostic Factors, Special Populations
[598]
Weber JS, Schadendorf D, Del Vecchio M et al.. “Adjuvant Therapy of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Patients With Resected Stage IIIB-D or Stage IV Melanoma (CheckMate 915).” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2022). PMID: 36162037 ↗
L1RCTCited in: Staging, History and Evolution of Treatment, Prognosis and Prognostic Factors
[599]
Weber J, Del Vecchio M, Mandalá M et al.. “Outcomes With Postrecurrence Systemic Therapy Following Adjuvant Checkpoint Inhibitor Treatment for Resected Melanoma in CheckMate 238.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024). PMID: 39102624 ↗
L2RCTCited in: Staging, Prognosis and Prognostic Factors
[600]
Menzies AM, Lo SN, Saw RPM et al.. “Five-year analysis of neoadjuvant dabrafenib and trametinib for stage III melanoma.” Annals of oncology : official journal of the European Society for Medical Oncology (2024). PMID: 38754780 ↗
L4TRIAL_NONRANDOMCited in: Staging, Special Populations
[601]
Siena S, Crinò L, Danova M et al.. “Dose-dense temozolomide regimen for the treatment of brain metastases from melanoma, breast cancer, or lung cancer not amenable to surgery or radiosurgery: a multicenter phase II study.” Annals of oncology : official journal of the European Society for Medical Oncology (2009). PMID: 19767314 ↗
L4TRIAL_NONRANDOMCited in: Staging
[602]
Bhatia S, Thompson JA. “Systemic therapy for metastatic melanoma in 2012: dawn of a new era.” Journal of the National Comprehensive Cancer Network : JNCCN (2012). PMID: 22393198 ↗
L5REVIEW_NARRATIVECited in: Staging, Prognosis and Prognostic Factors
[603]
Weber JS, D'Angelo SP, Minor D et al.. “Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial.” The Lancet. Oncology (2015). PMID: 25795410 ↗
L1RCTCited in: Staging, Management Overview, History and Evolution of Treatment, Prognosis and Prognostic Factors, Special Populations
[604]
Robert C, Ribas A, Schachter J et al.. “Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study.” The Lancet. Oncology (2019). PMID: 31345627 ↗
L1RCTCited in: Staging, Management Overview, History and Evolution of Treatment, Prognosis and Prognostic Factors, Special Populations
[605]
Dummer R, Schadendorf D, Ascierto PA et al.. “Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial.” The Lancet. Oncology (2017). PMID: 28284557 ↗
L1RCTCited in: Staging, Management Overview, History and Evolution of Treatment, Prognosis and Prognostic Factors, Special Populations
[606]
Bührer E, Kicinski M, Mandala M et al.. “Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): long-term, health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial.” The Lancet. Oncology (2024). PMID: 39146951 ↗
L1RCTCited in: Staging
[607]
Blank CU, Lucas MW, Scolyer RA et al.. “Neoadjuvant Nivolumab and Ipilimumab in Resectable Stage III Melanoma.” The New England journal of medicine (2024). PMID: 38828984 ↗
L1RCTCited in: Staging, Management Overview, History and Evolution of Treatment, Prognosis and Prognostic Factors, Special Populations
[608]
Wolchok JD, Chiarion-Sileni V, Rutkowski P et al.. “Final, 10-Year Outcomes with Nivolumab plus Ipilimumab in Advanced Melanoma.” The New England journal of medicine (2024). PMID: 39282897 ↗
L1RCTCited in: Staging, Management Overview, History and Evolution of Treatment, Prognosis and Prognostic Factors, Special Populations
[609]
Long GV, Hauschild A, Santinami M et al.. “Final Results for Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma.” The New England journal of medicine (2024). PMID: 38899716 ↗
L1RCTCited in: Staging, Management Overview, History and Evolution of Treatment, Prognosis and Prognostic Factors
[610]
Weber J, Mandala M, Del Vecchio M et al.. “Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma.” The New England journal of medicine (2017). PMID: 28891423 ↗
L1RCTCited in: Staging, Prognosis and Prognostic Factors, Special Populations
[611]
Long GV, Hauschild A, Santinami M et al.. “Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma.” The New England journal of medicine (2017). PMID: 28891408 ↗
L1RCTCited in: Staging, Prognosis and Prognostic Factors
[612]
Wolchok JD, Chiarion-Sileni V, Gonzalez R et al.. “Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma.” The New England journal of medicine (2017). PMID: 28889792 ↗
L1RCTCited in: Staging, Prognosis and Prognostic Factors
[613]
Eggermont AMM, Blank CU, Mandala M et al.. “Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma.” The New England journal of medicine (2018). PMID: 29658430 ↗
L1RCTCited in: Staging, Prognosis and Prognostic Factors
[614]
Ascierto PA, Del Vecchio M, Merelli B et al.. “Nivolumab for Resected Stage III or IV Melanoma at 9 Years.” The New England journal of medicine (2025). PMID: 41124198 ↗
L1RCTCited in: Staging, Prognosis and Prognostic Factors
[615]
Gogas H, Ioannovich J, Dafni U et al.. “Prognostic significance of autoimmunity during treatment of melanoma with interferon.” The New England journal of medicine (2006). PMID: 16481638 ↗
L2RCTCited in: Staging
[616]
Diab A, Tykodi SS, Daniels GA et al.. “Bempegaldesleukin Plus Nivolumab in First-Line Metastatic Melanoma.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2021). PMID: 34255535 ↗
L4TRIAL_NONRANDOMCited in: Staging
[617]
Wolchok JD, Kluger H, Callahan MK et al.. “Nivolumab plus ipilimumab in advanced melanoma.” The New England journal of medicine (2013). PMID: 23724867 ↗
L4TRIAL_NONRANDOMCited in: Staging
[618]
Mejias C, Morgan RL, Arora SS et al.. “ACR Appropriateness Criteria® Staging and Follow-Up of Melanoma.” Journal of the American College of Radiology : JACR (2026). PMID: 41823939 ↗
L1GUIDELINECited in: Staging
[619]
Tella SH, Kommalapati A, Ganti AK et al.. “Association Between Hospital Volume, Therapy Types, and Overall Survival in Stage III and IV Cutaneous Malignant Melanoma.” Journal of the National Comprehensive Cancer Network : JNCCN (2019). PMID: 31693989 ↗
L2OTHERCited in: Staging
[620]
Reed D, Kudchadkar R, Zager JS et al.. “Controversies in the evaluation and management of atypical melanocytic proliferations in children, adolescents, and young adults.” Journal of the National Comprehensive Cancer Network : JNCCN (2013). PMID: 23744867 ↗
L5OTHERCited in: Staging
[621]
Patnaik A, Kang SP, Rasco D et al.. “Phase I Study of Pembrolizumab (MK-3475; Anti-PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors.” Clinical cancer research : an official journal of the American Association for Cancer Research (2015). PMID: 25977344 ↗
L4TRIAL_NONRANDOMCited in: Staging, Management Overview, Prognosis and Prognostic Factors, Special Populations
[622]
Curigliano G, Gelderblom H, Mach N et al.. “Phase I/Ib Clinical Trial of Sabatolimab, an Anti-TIM-3 Antibody, Alone and in Combination with Spartalizumab, an Anti-PD-1 Antibody, in Advanced Solid Tumors.” Clinical cancer research : an official journal of the American Association for Cancer Research (2021). PMID: 33883177 ↗
L4TRIAL_NONRANDOMCited in: Staging, Prognosis and Prognostic Factors, Special Populations
[623]
Di Giacomo AM, Covre A, Finotello F et al.. “Guadecitabine Plus Ipilimumab in Unresectable Melanoma: The NIBIT-M4 Clinical Trial.” Clinical cancer research : an official journal of the American Association for Cancer Research (2019). PMID: 31530631 ↗
L4TRIAL_NONRANDOMCited in: Staging
[624]
Michielin O, Hoeller C. “Gaining momentum: New options and opportunities for the treatment of advanced melanoma.” Cancer treatment reviews (2015). PMID: 26096079 ↗
L5REVIEW_NARRATIVECited in: Staging, Prognosis and Prognostic Factors
[625]
Pietrantonio F, Randon G, Romagnoli D et al.. “Biomarker-guided implementation of the old drug temozolomide as a novel treatment option for patients with metastatic colorectal cancer.” Cancer treatment reviews (2019). PMID: 31821983 ↗
L5REVIEW_NARRATIVECited in: Staging
[626]
Martinez SR, Young SE. “A rational surgical approach to the treatment of distant melanoma metastases.” Cancer treatment reviews (2008). PMID: 18556133 ↗
L5REVIEW_NARRATIVECited in: Staging
[627]
Grover P, Lo SN, Li I et al.. “Efficacy of adjuvant therapy in patients with stage IIIA cutaneous melanoma.” Annals of oncology : official journal of the European Society for Medical Oncology (2025). PMID: 40204154 ↗
L2OTHERCited in: Staging, Management Overview, Prognosis and Prognostic Factors, Special Populations
[628]
Lee JH, Saw RP, Thompson JF et al.. “Pre-operative ctDNA predicts survival in high-risk stage III cutaneous melanoma patients.” Annals of oncology : official journal of the European Society for Medical Oncology (2019). PMID: 30860590 ↗
L2OTHERCited in: Staging, Special Populations
[629]
Rawson RV, Maher NG, Menzies AM et al.. “Pathological response calculation assessment remains accurate with reduced tumor bed examination after neoadjuvant immunotherapy in clinically detectable stage III melanoma.” Annals of oncology : official journal of the European Society for Medical Oncology (2025). PMID: 41183783 ↗
L4OTHERCited in: Staging
[630]
Dummer R, Rozati S, Eggmann N et al.. “From chemotherapy to targeted treatment.” Annals of oncology : official journal of the European Society for Medical Oncology (2012). PMID: 22987942 ↗
L5OTHERCited in: Staging
[631]
Maio M, Danielli R, Chiarion-Sileni V et al.. “Efficacy and safety of ipilimumab in patients with pre-treated, uveal melanoma.” Annals of oncology : official journal of the European Society for Medical Oncology (2013). PMID: 24067719 ↗
L4OTHERCited in: Staging
[632]
Leachman SA, Luke JJ, Ascierto PA et al.. “Adjuvant Pembrolizumab for Stage IIB or IIC Melanoma: A Secondary Analysis of a Randomized Clinical Trial.” JAMA network open (2026). PMID: 41701495 ↗
L1RCTCited in: Staging
[633]
Lodde GC, Hassel JC, von Wasielewski I et al.. “Long-Term Follow-Up of Real-World Adjuvant Anti-PD-1 Checkpoint Inhibition and Targeted Therapy in Patients With Stage III Melanoma.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2025). PMID: 40460331 ↗
L2OTHERCited in: Staging
[634]
Ott PA, Hodi FS, Robert C. “CTLA-4 and PD-1/PD-L1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patients.” Clinical cancer research : an official journal of the American Association for Cancer Research (2013). PMID: 24089443 ↗
L5REVIEW_NARRATIVECited in: Staging
[635]
Hieken TJ, Flotte TJ, Zahrieh D et al.. “Accuracy of Index Lymph Node Pathology in Predicting Overall Response to Neoadjuvant Immunotherapy for Clinical Stage III Melanoma: Results From the Prospective NeoACTIVATE Arm C (NCT03554083) Substudy.” Annals of surgical oncology (2026). PMID: 42218345 ↗
L4TRIAL_NONRANDOMCited in: Staging, Prognosis and Prognostic Factors, Special Populations
[636]
Chatziioannou E, Higuita LMS, Kreft S et al.. “Nomogram for predicting survival after first-line anti-PD-1-based immunotherapy in unresectable stage IV melanoma: a multicenter international study.” ESMO open (2024). PMID: 39096893 ↗
L2OTHERCited in: Staging, Prognosis and Prognostic Factors
[637]
Nelson A, Alghaib S, Björkström K et al.. “Time of day of neoadjuvant immune checkpoint inhibitor administration is associated with survival but not pathological response in resectable stage III-IV melanoma: A retrospective cohort study.” European journal of cancer (Oxford, England : 1990) (2026). PMID: 42218102 ↗
L2COHORTCited in: Staging, Prognosis and Prognostic Factors, Special Populations
[638]
Srour H, Chamorey E, Hovhannisyan A et al.. “Melanoma Brain Metastasis, Prognostic Factors, and Survival Outcomes After First Metastatic Line Therapy: A Monocentric Retrospective Study.” Cancer medicine (2026). PMID: 42136087 ↗
L2COHORTCited in: Staging, Prognosis and Prognostic Factors
[639]
Ejder P, Jespersen H, Hernberg M et al.. “Grand SLAM study protocol: a prospective randomised multicentre study of shortened versus standard duration adjuvant immune checkpoint inhibition for stage IIB-C, III and IV cutaneous melanoma.” BMC cancer (2026). PMID: 41896823 ↗
L5TRIAL_NONRANDOMCited in: Staging
[640]
Sinnamon AJ, Neuwirth MG, Gimotty PA et al.. “Association of First-in-Class Immune Checkpoint Inhibition and Targeted Therapy With Survival in Patients With Stage IV Melanoma.” JAMA oncology (2018). PMID: 29145547 ↗
L2OTHERCited in: Staging
[641]
Smithy JW, Shoushtari AN. “Adjuvant PD-1 Blockade in Resected Melanoma: Is Preventing Recurrence Enough?” Cancer discovery (2022). PMID: 35257151 ↗
L5OTHERCited in: Staging, Prognosis and Prognostic Factors
[642]
. “Adjuvant Therapy for Melanoma Prolongs RFS.” Cancer discovery (2018). PMID: 29657137 ↗
L5OTHERCited in: Staging
[643]
Dammeijer F, van Gulijk M, Mulder EE et al.. “The PD-1/PD-L1-Checkpoint Restrains T cell Immunity in Tumor-Draining Lymph Nodes.” Cancer cell (2020). PMID: 33007259 ↗
L5OTHERCited in: Staging, Management Overview, Prognosis and Prognostic Factors
[644]
Scott KL, Nogueira C, Heffernan TP et al.. “Proinvasion metastasis drivers in early-stage melanoma are oncogenes.” Cancer cell (2011). PMID: 21741599 ↗
L5OTHERCited in: Staging, Prognosis and Prognostic Factors
[645]
Orenes-Piñero E, Ros-Martínez S, Alonso-Romero JL et al.. “Immunoscore and beyond: evolution and clinical integration of immune contexture-based biomarkers across solid tumours.” Frontiers in immunology (2026). PMID: 42183189 ↗
L5REVIEW_NARRATIVECited in: Staging
[646]
Zhang Y, Zhao D, Wu D. “Advanced Mucosal Melanoma Therapies: Current Status and Future Directions.” Current treatment options in oncology (2026). PMID: 41944928 ↗
L5REVIEW_NARRATIVECited in: Staging
[647]
Uche IK, Lyons JM. “Surgical Management of Stage IV Melanoma: Clinical, Molecular, and Therapeutic Considerations.” International journal of molecular sciences (2026). PMID: 41828551 ↗
L5REVIEW_NARRATIVECited in: Staging
[648]
Stinson JA, Barbosa MMP, Sheen A et al.. “Tumor-Localized Interleukin-2 and Interleukin-12 Combine with Radiation Therapy to Safely Potentiate Regression of Advanced Malignant Melanoma in Pet Dogs.” Clinical cancer research : an official journal of the American Association for Cancer Research (2024). PMID: 38980919 ↗
L5OTHERCited in: Staging, Prognosis and Prognostic Factors
[649]
Najjar YG, McCurry D, Lin H et al.. “Neoadjuvant Pembrolizumab and High-Dose IFNα-2b in Resectable Regionally Advanced Melanoma.” Clinical cancer research : an official journal of the American Association for Cancer Research (2021). PMID: 33753453 ↗
L4OTHERCited in: Staging
[650]
Abu-Rustum NR, Yashar CM, Arend R et al.. “Vulvar Cancer, Version 3.2024, NCCN Clinical Practice Guidelines in Oncology.” Journal of the National Comprehensive Cancer Network : JNCCN (2024). PMID: 38503056 ↗
L1GUIDELINECited in: Management Overview, History and Evolution of Treatment
[651]
Coit DG, Thompson JA, Andtbacka R et al.. “Melanoma, version 4.2014.” Journal of the National Comprehensive Cancer Network : JNCCN (2014). PMID: 24812131 ↗
L1GUIDELINECited in: Management Overview, History and Evolution of Treatment
[652]
Hamid O, Robert C, Daud A et al.. “Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001.” Annals of oncology : official journal of the European Society for Medical Oncology (2019). PMID: 30715153 ↗
L4RCTCited in: Management Overview, History and Evolution of Treatment, Prognosis and Prognostic Factors
[653]
Versluis JM, Menzies AM, Sikorska K et al.. “Survival update of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma in the OpACIN and OpACIN-neo trials.” Annals of oncology : official journal of the European Society for Medical Oncology (2023). PMID: 36681299 ↗
L1RCTCited in: Management Overview, History and Evolution of Treatment
[654]
Seth R, Agarwala SS, Messersmith H et al.. “Systemic Therapy for Melanoma: ASCO Guideline Update.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023). PMID: 37579248 ↗
L1GUIDELINECited in: Management Overview, History and Evolution of Treatment
[655]
Atkins MB, Lee SJ, Chmielowski B et al.. “Combination Dabrafenib and Trametinib Versus Combination Nivolumab and Ipilimumab for Patients With Advanced BRAF-Mutant Melanoma: The DREAMseq Trial-ECOG-ACRIN EA6134.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2022). PMID: 36166727 ↗
L1RCTCited in: Management Overview, History and Evolution of Treatment
[656]
Ascierto PA, Mandalà M, Ferrucci PF et al.. “Sequencing of Ipilimumab Plus Nivolumab and Encorafenib Plus Binimetinib for Untreated BRAF-Mutated Metastatic Melanoma (SECOMBIT): A Randomized, Three-Arm, Open-Label Phase II Trial.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2022). PMID: 36049147 ↗
L1RCTCited in: Management Overview, History and Evolution of Treatment
[657]
Martín-Lluesma S, Svane IM, Dafni U et al.. “Efficacy of TIL therapy in advanced cutaneous melanoma in the current immuno-oncology era: updated systematic review and meta-analysis.” Annals of oncology : official journal of the European Society for Medical Oncology (2024). PMID: 39053767 ↗
L1SR_OBSCited in: Management Overview, Prognosis and Prognostic Factors
[658]
Olofsson Bagge R, Nelson A, Shafazand A et al.. “A phase Ib randomized multicenter trial of isolated hepatic perfusion in combination with ipilimumab and nivolumab for uveal melanoma metastases (SCANDIUM II trial).” ESMO open (2024). PMID: 38959698 ↗
L1RCTCited in: Management Overview, History and Evolution of Treatment, Special Populations
[659]
Henderson MA, Burmeister BH, Ainslie J et al.. “Adjuvant lymph-node field radiotherapy versus observation only in patients with melanoma at high risk of further lymph-node field relapse after lymphadenectomy (ANZMTG 01.02/TROG 02.01): 6-year follow-up of a phase 3, randomised controlled trial.” The Lancet. Oncology (2015). PMID: 26206146 ↗
L1RCTCited in: Management Overview, History and Evolution of Treatment, Prognosis and Prognostic Factors, Special Populations
[660]
Larkin J, Chiarion-Sileni V, Gonzalez R et al.. “Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.” The New England journal of medicine (2015). PMID: 26027431 ↗
L1RCTCited in: Management Overview, History and Evolution of Treatment, Prognosis and Prognostic Factors, Special Populations
[661]
Tawbi HA, Schadendorf D, Lipson EJ et al.. “Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma.” The New England journal of medicine (2022). PMID: 34986285 ↗
L1RCTCited in: Management Overview, History and Evolution of Treatment, Prognosis and Prognostic Factors, Special Populations
[662]
Patel SP, Othus M, Chen Y et al.. “Neoadjuvant-Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma.” The New England journal of medicine (2023). PMID: 36856617 ↗
L1RCTCited in: Management Overview, History and Evolution of Treatment
[663]
Hodi FS, O'Day SJ, McDermott DF et al.. “Improved survival with ipilimumab in patients with metastatic melanoma.” The New England journal of medicine (2010). PMID: 20525992 ↗
L1RCTCited in: Management Overview, History and Evolution of Treatment, Prognosis and Prognostic Factors
[664]
Robert C, Schachter J, Long GV et al.. “Pembrolizumab versus Ipilimumab in Advanced Melanoma.” The New England journal of medicine (2015). PMID: 25891173 ↗
L1RCTCited in: Management Overview, History and Evolution of Treatment, Special Populations
[665]
Topalian SL, Hodi FS, Brahmer JR et al.. “Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.” The New England journal of medicine (2012). PMID: 22658127 ↗
L4RCTCited in: Management Overview, History and Evolution of Treatment
[666]
Hassel JC, Piperno-Neumann S, Rutkowski P et al.. “Three-Year Overall Survival with Tebentafusp in Metastatic Uveal Melanoma.” The New England journal of medicine (2023). PMID: 37870955 ↗
L1RCTCited in: Management Overview, History and Evolution of Treatment
[667]
Rohaan MW, Borch TH, van den Berg JH et al.. “Tumor-Infiltrating Lymphocyte Therapy or Ipilimumab in Advanced Melanoma.” The New England journal of medicine (2022). PMID: 36477031 ↗
L1RCTCited in: Management Overview
[668]
Larkin J, Chiarion-Sileni V, Gonzalez R et al.. “Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma.” The New England journal of medicine (2019). PMID: 31562797 ↗
L1RCTCited in: Management Overview, History and Evolution of Treatment, Special Populations
[669]
Spaas M, Sundahl N, Kruse V et al.. “Checkpoint Inhibitors in Combination With Stereotactic Body Radiotherapy in Patients With Advanced Solid Tumors: The CHEERS Phase 2 Randomized Clinical Trial.” JAMA oncology (2023). PMID: 37410476 ↗
L1RCTCited in: Management Overview, History and Evolution of Treatment, Prognosis and Prognostic Factors, Special Populations
[670]
Agliardi S, Veronese C, Panzeri F et al.. “Immunocytokines in cancer treatment: A systematic review.” Cancer treatment reviews (2025). PMID: 40554920 ↗
L5SR_OBSCited in: Management Overview
[671]
Olson DJ, Eroglu Z, Brockstein B et al.. “Pembrolizumab Plus Ipilimumab Following Anti-PD-1/L1 Failure in Melanoma.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2021). PMID: 33945288 ↗
L4TRIAL_NONRANDOMCited in: Management Overview, Special Populations
[672]
Wong MK, Milhem MM, Sacco JJ et al.. “RP1 Combined With Nivolumab in Advanced Anti-PD-1-Failed Melanoma (IGNYTE).” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2025). PMID: 40627813 ↗
L4TRIAL_NONRANDOMCited in: Management Overview, Special Populations
[673]
Saleem N, Wang J, Rejuso A et al.. “Outcomes of Solid Organ Transplant Recipients With Advanced Cancers Receiving Immune Checkpoint Inhibitors: A Systematic Review and Individual Participant Data Meta-Analysis.” JAMA oncology (2025). PMID: 40545616 ↗
L5SR_OBSCited in: Management Overview, Prognosis and Prognostic Factors
[674]
Gouda MA, Voss MH, Tawbi H et al.. “A phase I/II study of the safety and efficacy of telaglenastat (CB-839) in combination with nivolumab in patients with metastatic melanoma, renal cell carcinoma, and non-small-cell lung cancer.” ESMO open (2025). PMID: 40359708 ↗
L4TRIAL_NONRANDOMCited in: Management Overview, Prognosis and Prognostic Factors, Special Populations
[675]
Janku F, Bauer S, Shoumariyeh K et al.. “Efficacy and safety of ripretinib in patients with KIT-altered metastatic melanoma.” ESMO open (2022). PMID: 35753087 ↗
L4TRIAL_NONRANDOMCited in: Management Overview
[676]
Qian DC, Kleber T, Brammer B et al.. “Effect of immunotherapy time-of-day infusion on overall survival among patients with advanced melanoma in the USA (MEMOIR): a propensity score-matched analysis of a single-centre, longitudinal study.” The Lancet. Oncology (2021). PMID: 34780711 ↗
L3TRIAL_NONRANDOMCited in: Management Overview, Prognosis and Prognostic Factors, Special Populations
[677]
Geoerger B, Kang HJ, Yalon-Oren M et al.. “Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051): interim analysis of an open-label, single-arm, phase 1-2 trial.” The Lancet. Oncology (2019). PMID: 31812554 ↗
L4TRIAL_NONRANDOMCited in: Management Overview, Prognosis and Prognostic Factors
[678]
Tawbi HA, Forsyth PA, Hodi FS et al.. “Long-term outcomes of patients with active melanoma brain metastases treated with combination nivolumab plus ipilimumab (CheckMate 204): final results of an open-label, multicentre, phase 2 study.” The Lancet. Oncology (2021). PMID: 34774225 ↗
L4TRIAL_NONRANDOMCited in: Management Overview, Prognosis and Prognostic Factors, Special Populations
[679]
Hong DS, Fakih MG, Strickler JH et al.. “KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors.” The New England journal of medicine (2020). PMID: 32955176 ↗
L4TRIAL_NONRANDOMCited in: Management Overview
[680]
Gainor JF, Patel MR, Weber JS et al.. “T-cell Responses to Individualized Neoantigen Therapy mRNA-4157 (V940) Alone or in Combination with Pembrolizumab in the Phase 1 KEYNOTE-603 Study.” Cancer discovery (2024). PMID: 39115419 ↗
L4TRIAL_NONRANDOMCited in: Management Overview, Special Populations
[681]
Corcoran RB, André T, Atreya CE et al.. “Combined BRAF, EGFR, and MEK Inhibition in Patients with BRAFV600E-Mutant Colorectal Cancer.” Cancer discovery (2018). PMID: 29431699 ↗
L4TRIAL_NONRANDOMCited in: Management Overview
[682]
Drilon A, Siena S, Ou SI et al.. “Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1).” Cancer discovery (2017). PMID: 28183697 ↗
L4TRIAL_NONRANDOMCited in: Management Overview, Special Populations
[683]
Davar D, Morrison RM, Dzutsev AK et al.. “Neoadjuvant vidutolimod and nivolumab in high-risk resectable melanoma: A prospective phase II trial.” Cancer cell (2024). PMID: 39486411 ↗
L4TRIAL_NONRANDOMCited in: Management Overview, Special Populations
[684]
Fleischmann R, Swierkot J, Durez P et al.. “Long-term safety and efficacy of upadacitinib compared with adalimumab in patients with rheumatoid arthritis: 7-year data from the SELECT-COMPARE study.” RMD open (2026). PMID: 42342288 ↗
L1RCTCited in: Management Overview, History and Evolution of Treatment, Prognosis and Prognostic Factors, Special Populations
[685]
Colevas AD, Cmelak AJ, Pfister DG et al.. “NCCN Guidelines® Insights: Head and Neck Cancers, Version 2.2025.” Journal of the National Comprehensive Cancer Network : JNCCN (2025). PMID: 39938471 ↗
L1OTHERCited in: Management Overview
[686]
Caudell JJ, Gillison ML, Maghami E et al.. “NCCN Guidelines® Insights: Head and Neck Cancers, Version 1.2022.” Journal of the National Comprehensive Cancer Network : JNCCN (2022). PMID: 35276673 ↗
L1OTHERCited in: Management Overview
[687]
Ribas A. “Update on immunotherapy for melanoma.” Journal of the National Comprehensive Cancer Network : JNCCN (2006). PMID: 16884670 ↗
L5REVIEW_NARRATIVECited in: Management Overview
[688]
Fien SM, Oseroff AR. “Photodynamic therapy for non-melanoma skin cancer.” Journal of the National Comprehensive Cancer Network : JNCCN (2007). PMID: 17509255 ↗
L5REVIEW_NARRATIVECited in: Management Overview
[689]
Olszanski AJ. “Principles of immunotherapy.” Journal of the National Comprehensive Cancer Network : JNCCN (2015). PMID: 25995426 ↗
L5OTHERCited in: Management Overview
[690]
Rosenberg SA, Yang JC, Sherry RM et al.. “Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy.” Clinical cancer research : an official journal of the American Association for Cancer Research (2011). PMID: 21498393 ↗
L4TRIAL_NONRANDOMCited in: Management Overview, Prognosis and Prognostic Factors, Special Populations
[691]
Middleton MR, McAlpine C, Woodcock VK et al.. “Tebentafusp, A TCR/Anti-CD3 Bispecific Fusion Protein Targeting gp100, Potently Activated Antitumor Immune Responses in Patients with Metastatic Melanoma.” Clinical cancer research : an official journal of the American Association for Cancer Research (2020). PMID: 32816891 ↗
L4TRIAL_NONRANDOMCited in: Management Overview, Prognosis and Prognostic Factors, Special Populations
[692]
Zhang L, Morgan RA, Beane JD et al.. “Tumor-infiltrating lymphocytes genetically engineered with an inducible gene encoding interleukin-12 for the immunotherapy of metastatic melanoma.” Clinical cancer research : an official journal of the American Association for Cancer Research (2015). PMID: 25695689 ↗
L4TRIAL_NONRANDOMCited in: Management Overview, Prognosis and Prognostic Factors, Special Populations
[693]
Weiss SA, Djureinovic D, Jessel S et al.. “A Phase I Study of APX005M and Cabiralizumab with or without Nivolumab in Patients with Melanoma, Kidney Cancer, or Non-Small Cell Lung Cancer Resistant to Anti-PD-1/PD-L1.” Clinical cancer research : an official journal of the American Association for Cancer Research (2021). PMID: 34140403 ↗
L4TRIAL_NONRANDOMCited in: Management Overview, Special Populations
[694]
Forno-Bell N, Arciniegas Ruiz S, Walker H et al.. “Natural Compounds for the Treatment of Cutaneous Squamous Cell Carcinoma: A Systematic Review.” International journal of molecular sciences (2026). PMID: 42353244 ↗
L4SR_OBSCited in: Management Overview
[695]
Guo B, Zhang G, Sang S et al.. “Current status and trends of immune-related adverse events in lung cancer treated with immune checkpoint inhibitors: a bibliometric analysis of the past decade (2016-2025).” Frontiers in immunology (2026). PMID: 42311664 ↗
L5SR_OBSCited in: Management Overview, History and Evolution of Treatment
[696]
Champiat S, Lambotte O, Barreau E et al.. “Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper.” Annals of oncology : official journal of the European Society for Medical Oncology (2015). PMID: 26715621 ↗
L5REVIEW_NARRATIVECited in: Management Overview
[697]
Johnson DB, Balko JM, Compton ML et al.. “Fulminant Myocarditis with Combination Immune Checkpoint Blockade.” The New England journal of medicine (2016). PMID: 27806233 ↗
L4CASE_REPORTCited in: Management Overview
[698]
Sarnaik AA, Hamid O, Khushalani NI et al.. “Lifileucel, a Tumor-Infiltrating Lymphocyte Therapy, in Metastatic Melanoma.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2021). PMID: 33979178 ↗
L4OTHERCited in: Management Overview, Special Populations
[699]
Medina T, Chesney JA, Kluger HM et al.. “Long-Term Efficacy and Safety of Lifileucel Tumor-Infiltrating Lymphocyte Cell Therapy in Patients With Advanced Melanoma: A 5-Year Analysis of the C-144-01 Study.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2025). PMID: 40454684 ↗
L4OTHERCited in: Management Overview, Special Populations
[700]
Rohrberg KS, Melero I, F Sanmamed M et al.. “First-in-human study of lomvastomig, a PD-1-TIM-3 bispecific antibody, in patients with advanced and/or metastatic solid tumors.” Journal for immunotherapy of cancer (2026). PMID: 42320980 ↗
L4TRIAL_NONRANDOMCited in: Management Overview, Special Populations
[701]
Randic T, Kozar I, Margue C et al.. “NRAS mutant melanoma: Towards better therapies.” Cancer treatment reviews (2021). PMID: 34098219 ↗
L5REVIEW_NARRATIVECited in: Management Overview
[702]
Fujiwara Y, Kato S, Nesline MK et al.. “Indoleamine 2,3-dioxygenase (IDO) inhibitors and cancer immunotherapy.” Cancer treatment reviews (2022). PMID: 36058143 ↗
L5REVIEW_NARRATIVECited in: Management Overview
[703]
Wespiser M, Neidhardt E, Negrier S. “Uveal melanoma: In the era of new treatments.” Cancer treatment reviews (2023). PMID: 37473516 ↗
L5REVIEW_NARRATIVECited in: Management Overview, Prognosis and Prognostic Factors
[704]
O'Donnell JS, Long GV, Scolyer RA et al.. “Resistance to PD1/PDL1 checkpoint inhibition.” Cancer treatment reviews (2016). PMID: 27951441 ↗
L5REVIEW_NARRATIVECited in: Management Overview
[705]
Hamilton E, Infante JR. “Targeting CDK4/6 in patients with cancer.” Cancer treatment reviews (2016). PMID: 27017286 ↗
L5REVIEW_NARRATIVECited in: Management Overview
[706]
Cheng P, Levesque MP, Dummer R et al.. “Targeting complex, adaptive responses in melanoma therapy.” Cancer treatment reviews (2020). PMID: 32179238 ↗
L5REVIEW_NARRATIVECited in: Management Overview
[707]
Queirolo P, Picasso V, Spagnolo F. “Combined BRAF and MEK inhibition for the treatment of BRAF-mutated metastatic melanoma.” Cancer treatment reviews (2015). PMID: 25944484 ↗
L5REVIEW_NARRATIVECited in: Management Overview
[708]
Chatziioannou E, Lallas K, Sinnberg T et al.. “Insights into RAS-driven melanoma and its therapeutic implications.” Cancer treatment reviews (2026). PMID: 41576808 ↗
L5REVIEW_NARRATIVECited in: Management Overview
[709]
Eroglu Z, Topcu TO, Yu HM et al.. “How I treat brain metastases of melanoma.” ESMO open (2022). PMID: 36274439 ↗
L5REVIEW_NARRATIVECited in: Management Overview
[710]
Braden J, Conway JW, Wilmott JS et al.. “Do BRAF-targeted therapies have a role in the era of immunotherapy?” ESMO open (2025). PMID: 40543211 ↗
L5REVIEW_NARRATIVECited in: Management Overview
[711]
Saldanha EF, Ribeiro MF, Hirsch I et al.. “How we treat patients with metastatic uveal melanoma.” ESMO open (2025). PMID: 40112696 ↗
L5REVIEW_NARRATIVECited in: Management Overview
[712]
Sussman TA, Ott PA. “Adjuvant immunotherapy for melanoma patients: progress and opportunities.” ESMO open (2024). PMID: 38626633 ↗
L5REVIEW_NARRATIVECited in: Management Overview
[713]
Hassel JC, Livingstone E, Allam JP et al.. “Fertility preservation and management of pregnancy in melanoma patients requiring systemic therapy.” ESMO open (2021). PMID: 34438241 ↗
L5REVIEW_NARRATIVECited in: Management Overview, Special Populations
[714]
Gouda MA, Subbiah V. “Precision oncology for BRAF-mutant cancers with BRAF and MEK inhibitors: from melanoma to tissue-agnostic therapy.” ESMO open (2023). PMID: 36842301 ↗
L5REVIEW_NARRATIVECited in: Management Overview
[715]
da Silva IP, Zimmer L, Blay JY et al.. “Retreatment, rechallenge, and escalation with subsequent immune checkpoint inhibitor therapies across cancers after initial failure.” ESMO open (2025). PMID: 41202502 ↗
L5REVIEW_NARRATIVECited in: Management Overview, Prognosis and Prognostic Factors
[716]
Pinato DJ, Howlett S, Ottaviani D et al.. “Association of Prior Antibiotic Treatment With Survival and Response to Immune Checkpoint Inhibitor Therapy in Patients With Cancer.” JAMA oncology (2019). PMID: 31513236 ↗
L2OTHERCited in: Management Overview, Prognosis and Prognostic Factors, Special Populations
[717]
Saal J, Eckstein M, Ritter M et al.. “Dissection of Progressive Disease Patterns for a Modified Classification for Immunotherapy.” JAMA oncology (2025). PMID: 39724246 ↗
L3OTHERCited in: Management Overview, Prognosis and Prognostic Factors, Special Populations
[718]
Dummer R, Ascierto PA, Nathan P et al.. “Rationale for Immune Checkpoint Inhibitors Plus Targeted Therapy in Metastatic Melanoma: A Review.” JAMA oncology (2020). PMID: 32970096 ↗
L5REVIEW_NARRATIVECited in: Management Overview
[719]
Zhang M, Di Martino JS, Bowman RL et al.. “Adipocyte-Derived Lipids Mediate Melanoma Progression via FATP Proteins.” Cancer discovery (2018). PMID: 29903879 ↗
L5OTHERCited in: Management Overview
[720]
Shin DS, Zaretsky JM, Escuin-Ordinas H et al.. “Primary Resistance to PD-1 Blockade Mediated by JAK1/2 Mutations.” Cancer discovery (2016). PMID: 27903500 ↗
L4OTHERCited in: Management Overview
[721]
Peng W, Chen JQ, Liu C et al.. “Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy.” Cancer discovery (2015). PMID: 26645196 ↗
L4OTHERCited in: Management Overview
[722]
Pozniak J, Roda N, Landeloos E et al.. “Cytotoxic NK Cells Impede Response to Checkpoint Immunotherapy in Melanoma with an Immune-Excluded Phenotype.” Cancer discovery (2025). PMID: 40530504 ↗
L4OTHERCited in: Management Overview
[723]
Tagore M, Hergenreder E, Perlee SC et al.. “GABA Regulates Electrical Activity and Tumor Initiation in Melanoma.” Cancer discovery (2023). PMID: 37553760 ↗
L5OTHERCited in: Management Overview
[724]
Berraondo P, Cuesta R, Sanmamed MF et al.. “Immunogenicity and Efficacy of Personalized Adjuvant mRNA Cancer Vaccines.” Cancer discovery (2024). PMID: 39485256 ↗
L5OTHERCited in: Management Overview
[725]
. “mRNA Vaccine Slows Melanoma Recurrence.” Cancer discovery (2023). PMID: 37062020 ↗
L5OTHERCited in: Management Overview
[726]
. “Combination therapy approved for melanoma.” Cancer discovery (2014). PMID: 24596183 ↗
L5OTHERCited in: Management Overview, Prognosis and Prognostic Factors
[727]
Routy B, Jackson T, Mählmann L et al.. “Melanoma and microbiota: Current understanding and future directions.” Cancer cell (2023). PMID: 38157864 ↗
L5REVIEW_NARRATIVECited in: Management Overview
[728]
Patton EE, Mueller KL, Adams DJ et al.. “Melanoma models for the next generation of therapies.” Cancer cell (2021). PMID: 33545064 ↗
L5REVIEW_NARRATIVECited in: Management Overview
[729]
Benguigui M, Cooper TJ, Kalkar P et al.. “Interferon-stimulated neutrophils as a predictor of immunotherapy response.” Cancer cell (2024). PMID: 38181798 ↗
L5OTHERCited in: Management Overview
[730]
Gide TN, Quek C, Menzies AM et al.. “Distinct Immune Cell Populations Define Response to Anti-PD-1 Monotherapy and Anti-PD-1/Anti-CTLA-4 Combined Therapy.” Cancer cell (2019). PMID: 30753825 ↗
L3OTHERCited in: Management Overview, Prognosis and Prognostic Factors, Special Populations
[731]
Tsoi J, Robert L, Paraiso K et al.. “Multi-stage Differentiation Defines Melanoma Subtypes with Differential Vulnerability to Drug-Induced Iron-Dependent Oxidative Stress.” Cancer cell (2018). PMID: 29657129 ↗
L5OTHERCited in: Management Overview
[732]
Wang K, Coutifaris P, Brocks D et al.. “Combination anti-PD-1 and anti-CTLA-4 therapy generates waves of clonal responses that include progenitor-exhausted CD8+ T cells.” Cancer cell (2024). PMID: 39214097 ↗
L2OTHERCited in: Management Overview
[733]
Geels SN, Moshensky A, Sousa RS et al.. “Interruption of the intratumor CD8+ T cell:Treg crosstalk improves the efficacy of PD-1 immunotherapy.” Cancer cell (2024). PMID: 38861924 ↗
L5OTHERCited in: Management Overview
[734]
Rodriguez-Baena FJ, Marquez-Galera A, Ballesteros-Martinez P et al.. “Microglial reprogramming enhances antitumor immunity and immunotherapy response in melanoma brain metastases.” Cancer cell (2025). PMID: 39919736 ↗
L5OTHERCited in: Management Overview
[735]
Liu H, Kuang X, Zhang Y et al.. “ADORA1 Inhibition Promotes Tumor Immune Evasion by Regulating the ATF3-PD-L1 Axis.” Cancer cell (2020). PMID: 32183950 ↗
L5OTHERCited in: Management Overview, Special Populations
[736]
Hailemichael Y, Johnson DH, Abdel-Wahab N et al.. “Interleukin-6 blockade abrogates immunotherapy toxicity and promotes tumor immunity.” Cancer cell (2022). PMID: 35537412 ↗
L3OTHERCited in: Management Overview
[737]
Arce Vargas F, Furness AJS, Litchfield K et al.. “Fc Effector Function Contributes to the Activity of Human Anti-CTLA-4 Antibodies.” Cancer cell (2018). PMID: 29576375 ↗
L3OTHERCited in: Management Overview, Prognosis and Prognostic Factors
[738]
Cole AC, Knochelmann HM, Wyatt MM et al.. “Adoptively transferred Th17 cells cooperate with host B cells to achieve durable tumor immunity.” Cancer cell (2025). PMID: 40712565 ↗
L5OTHERCited in: Management Overview
[739]
Lubrano S, Cervantes-Villagrana RD, Faraji F et al.. “FAK inhibition combined with the RAF-MEK clamp avutometinib overcomes resistance to targeted and immune therapies in BRAF V600E melanoma.” Cancer cell (2025). PMID: 40020669 ↗
L5OTHERCited in: Management Overview
[740]
Puthiyakunnel Saji A, Rackley T, Horwood J et al.. “Prognostic impact of anal cancer morphology on survival and local recurrence: A 20-year regional cohort study.” Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland (2026). PMID: 42402758 ↗
L3COHORTCited in: Management Overview, Prognosis and Prognostic Factors
[741]
Betof Warner A, Corrie PG, Hamid O. “Tumor-Infiltrating Lymphocyte Therapy in Melanoma: Facts to the Future.” Clinical cancer research : an official journal of the American Association for Cancer Research (2023). PMID: 36485001 ↗
L5REVIEW_NARRATIVECited in: Management Overview, History and Evolution of Treatment, Prognosis and Prognostic Factors
[742]
Li J, Smalley I, Chen Z et al.. “Single-cell Characterization of the Cellular Landscape of Acral Melanoma Identifies Novel Targets for Immunotherapy.” Clinical cancer research : an official journal of the American Association for Cancer Research (2022). PMID: 35247927 ↗
L4OTHERCited in: Management Overview
[743]
Larkin J, Del Vecchio M, Mandalá M et al.. “Adjuvant Nivolumab versus Ipilimumab in Resected Stage III/IV Melanoma: 5-Year Efficacy and Biomarker Results from CheckMate 238.” Clinical cancer research : an official journal of the American Association for Cancer Research (2023). PMID: 37058595 ↗
L1OTHERCited in: Management Overview
[744]
Levi ST, Boland GM. “ONCOS-102: A Step Forward or Sideways?” Clinical cancer research : an official journal of the American Association for Cancer Research (2023). PMID: 36269283 ↗
L5OTHERCited in: Management Overview
[745]
Weiss SA, Wolchok JD, Sznol M. “Immunotherapy of Melanoma: Facts and Hopes.” Clinical cancer research : an official journal of the American Association for Cancer Research (2019). PMID: 30923036 ↗
L5REVIEW_NARRATIVECited in: Management Overview, Prognosis and Prognostic Factors
[746]
Lu W, Sha X, Lei H et al.. “The CpG island methylator phenotype defines an immune-cold and therapy-resistant subtype of cutaneous melanoma.” Frontiers in immunology (2026). PMID: 42421952 ↗
L3OTHERCited in: Management Overview
[747]
Berciano-Guerrero MÁ, Pérez-Ruiz E, Soria A et al.. “Real-world effectiveness of chemotherapy regimens after immunotherapy in patients with advanced melanoma in Spain: Results from the GEM1801 study.” Cancer (2026). PMID: 42411543 ↗
L3OTHERCited in: Management Overview
[748]
Ghosh Halder T, Kelley E, Soria-Bustos J et al.. “Preclinical proof of concept for a personalized SNAP™-TIL (Specific Neo-Antigen Peptides-TIL) therapy platform.” Oncoimmunology (2026). PMID: 42402813 ↗
L5OTHERCited in: Management Overview
[749]
Gahbauer S, Poiret T. “EGFRxCD16 bispecific antibodies orchestrate superior NK cell-mediated lysis of ovarian cancer and NSCLC cell lines in combination with oncolytic viruses.” Cancer immunology, immunotherapy : CII (2026). PMID: 42397418 ↗
L5OTHERCited in: Management Overview
[750]
A Turner J, D'Antonio M, Montane HN et al.. “Targeting liver metastases in uveal melanoma: ATX-LPA mediated immunosuppression and novel therapeutic approaches.” Frontiers in immunology (2026). PMID: 42396445 ↗
L3OTHERCited in: Management Overview
[751]
Dieckmann SM, Tripp CH, Strandt H et al.. “Metabolic inhibition of glutamate-cysteine ligase increases dendritic cell-mediated antitumor immunity in melanoma.” Journal for immunotherapy of cancer (2026). PMID: 42379703 ↗
L5OTHERCited in: Management Overview
[752]
Teeuwen L, Steiner L, Reinhardt C et al.. “Eliminating PD-L1 on Dendritic Cell Extracellular Vesicles for Immunotherapy Potentiates Immune-Mediated Tumour Rejection in Mice.” Journal of extracellular vesicles (2026). PMID: 42377985 ↗
L5OTHERCited in: Management Overview
[753]
Ma TC, Guo WH, Liu DM et al.. “DNA Damage Response Alterations and Immune Checkpoint Blockade Outcomes Across Multiple Cancers.” JCO precision oncology (2026). PMID: 42372205 ↗
L3OTHERCited in: Management Overview
[754]
Trojaniello C, Marretta AL, Facchini BA et al.. “Anti-PD-1 Combinations: Triplets and Beyond.” Current oncology reports (2026). PMID: 42366313 ↗
L5REVIEW_NARRATIVECited in: Management Overview
[755]
Coit DG, Thompson JA, Algazi A et al.. “Melanoma, Version 2.2016, NCCN Clinical Practice Guidelines in Oncology.” Journal of the National Comprehensive Cancer Network : JNCCN (2016). PMID: 27059193 ↗
L1GUIDELINECited in: History and Evolution of Treatment
[756]
. “Melanoma. Clinical practice guidelines in oncology.” Journal of the National Comprehensive Cancer Network : JNCCN (2004). PMID: 19777694 ↗
L1GUIDELINECited in: History and Evolution of Treatment
[757]
Coit DG, Thompson JA, Albertini MR et al.. “Cutaneous Melanoma, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology.” Journal of the National Comprehensive Cancer Network : JNCCN (2019). PMID: 30959471 ↗
L1GUIDELINECited in: History and Evolution of Treatment
[758]
Petrillo LA, Hsu K, Pintro K et al.. “Pilot Randomized Trial of an Educational Intervention About Immunotherapy for Patients With Advanced Cancer and Their Caregivers.” Journal of the National Comprehensive Cancer Network : JNCCN (2025). PMID: 39938469 ↗
L1RCTCited in: History and Evolution of Treatment, Special Populations
[759]
Arance A, Berciano-Guerrero MA, Guo J et al.. “Randomized, double-blind, phase III LEAP-003 study of first-line lenvatinib plus pembrolizumab versus placebo plus pembrolizumab for unresectable or metastatic melanoma.” Annals of oncology : official journal of the European Society for Medical Oncology (2025). PMID: 40885529 ↗
L1RCTCited in: History and Evolution of Treatment, Prognosis and Prognostic Factors, Special Populations
[760]
Ten Ham RMT, Rohaan MW, Egeler M et al.. “Health-related quality of life of patients with metastatic melanoma treated with tumor-infiltrating lymphocytes compared with ipilimumab in a randomized phase III trial.” Annals of oncology : official journal of the European Society for Medical Oncology (2025). PMID: 40541863 ↗
L1RCTCited in: History and Evolution of Treatment, Special Populations
[761]
Hassel JC, Arance A, Carlino MS et al.. “IO102-IO103 immune-modulatory cancer vaccine and pembrolizumab in melanoma.” Annals of oncology : official journal of the European Society for Medical Oncology (2026). PMID: 42025759 ↗
L1RCTCited in: History and Evolution of Treatment, Special Populations
[762]
Green AC, Williams GM, Logan V et al.. “Reduced melanoma after regular sunscreen use: randomized trial follow-up.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2010). PMID: 21135266 ↗
L1RCTCited in: History and Evolution of Treatment, Special Populations
[763]
Chesney JA, Ribas A, Long GV et al.. “Randomized, Double-Blind, Placebo-Controlled, Global Phase III Trial of Talimogene Laherparepvec Combined With Pembrolizumab for Advanced Melanoma.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2022). PMID: 35998300 ↗
L1RCTCited in: History and Evolution of Treatment
[764]
Tawbi HA, Hodi FS, Lipson EJ et al.. “Three-Year Overall Survival With Nivolumab Plus Relatlimab in Advanced Melanoma From RELATIVITY-047.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024). PMID: 39671533 ↗
L1RCTCited in: History and Evolution of Treatment, Prognosis and Prognostic Factors, Special Populations
[765]
Livingstone E, Gogas HJ, Kandolf L et al.. “Early switch from run-in with targeted to immunotherapy in advanced BRAFV600-positive melanoma: final results of the randomised phase II ImmunoCobiVem trial.” ESMO open (2025). PMID: 40345056 ↗
L1RCTCited in: History and Evolution of Treatment, Special Populations
[766]
Robert C, Kicinski M, Dutriaux C et al.. “Combination of encorafenib and binimetinib followed by ipilimumab and nivolumab versus ipilimumab and nivolumab in patients with advanced melanoma with BRAFV600E or BRAFV600K mutations (EBIN): an international, open-label, randomised, controlled, phase 2 study.” The Lancet. Oncology (2025). PMID: 40449497 ↗
L1RCTCited in: History and Evolution of Treatment
[767]
Long GV, Atkinson V, Lo SN et al.. “Ipilimumab plus nivolumab versus nivolumab alone in patients with melanoma brain metastases (ABC): 7-year follow-up of a multicentre, open-label, randomised, phase 2 study.” The Lancet. Oncology (2025). PMID: 39978375 ↗
L1RCTCited in: History and Evolution of Treatment
[768]
Sheng X, Huang G, Fang M et al.. “Toripalimab vs Dacarbazine as First-Line Therapy for Advanced Melanoma of Acral Subtype: The Phase 3 MELATORCH Randomized Clinical Trial.” JAMA oncology (2026). PMID: 41481311 ↗
L1RCTCited in: History and Evolution of Treatment, Special Populations
[769]
Mao L, Lian B, Li C et al.. “Camrelizumab Plus Apatinib and Temozolomide as First-Line Treatment in Patients With Advanced Acral Melanoma: The CAP 03 Phase 2 Nonrandomized Clinical Trial.” JAMA oncology (2023). PMID: 37261804 ↗
L4RCTCited in: History and Evolution of Treatment
[770]
Unger JM, Darke A, Othus M et al.. “Effectiveness of Adjuvant Pembrolizumab vs High-Dose Interferon or Ipilimumab for Quality-of-Life Outcomes in Patients With Resected Melanoma: A Secondary Analysis of the SWOG S1404 Randomized Clinical Trial.” JAMA oncology (2023). PMID: 36416836 ↗
L1RCTCited in: History and Evolution of Treatment
[771]
Ascierto PA, Long GV, Robert C et al.. “Survival Outcomes in Patients With Previously Untreated BRAF Wild-Type Advanced Melanoma Treated With Nivolumab Therapy: Three-Year Follow-up of a Randomized Phase 3 Trial.” JAMA oncology (2019). PMID: 30422243 ↗
L1RCTCited in: History and Evolution of Treatment, Prognosis and Prognostic Factors
[772]
Puzanov I, Ribas A, Robert C et al.. “Association of BRAF V600E/K Mutation Status and Prior BRAF/MEK Inhibition With Pembrolizumab Outcomes in Advanced Melanoma: Pooled Analysis of 3 Clinical Trials.” JAMA oncology (2020). PMID: 32672795 ↗
L1RCTCited in: History and Evolution of Treatment
[773]
Grossmann KF, Othus M, Patel SP et al.. “Adjuvant Pembrolizumab versus IFNα2b or Ipilimumab in Resected High-Risk Melanoma.” Cancer discovery (2022). PMID: 34764195 ↗
L1RCTCited in: History and Evolution of Treatment
[774]
. “A Three-Drug Combo for Multiple Myeloma.” Cancer discovery (2016). PMID: 27630127 ↗
L5RCTCited in: History and Evolution of Treatment, Prognosis and Prognostic Factors
[775]
Wang G, Yoon D, Nandi A et al.. “Antigen-specific profiling identifies T-bet+ melanoma-specific CD8+ T cells associated with response to neoadjuvant PD-1 blockade.” Cancer cell (2025). PMID: 41478278 ↗
L4RCTCited in: History and Evolution of Treatment
[776]
Goggins M, Kern SE, Offerhaus JA et al.. “Progress in cancer genetics: lessons from pancreatic cancer.” Annals of oncology : official journal of the European Society for Medical Oncology (1999). PMID: 10436774 ↗
L5REVIEW_NARRATIVECited in: History and Evolution of Treatment
[777]
O'Connor JM, Fessele KL, Steiner J et al.. “Speed of Adoption of Immune Checkpoint Inhibitors of Programmed Cell Death 1 Protein and Comparison of Patient Ages in Clinical Practice vs Pivotal Clinical Trials.” JAMA oncology (2018). PMID: 29800974 ↗
L4TRIAL_NONRANDOMCited in: History and Evolution of Treatment
[778]
Dummer R, Deng S, Xie T et al.. “Exploratory Analysis of Biomarkers and Treatment Outcomes from the COLUMBUS Study in BRAF V600E/K-Mutant Advanced or Metastatic Melanoma.” Clinical cancer research : an official journal of the American Association for Cancer Research (2026). PMID: 41537702 ↗
L2RCTCited in: History and Evolution of Treatment
[779]
Luke JJ, Olson DJ, Allred JB et al.. “Randomized Phase II Trial and Tumor Mutational Spectrum Analysis from Cabozantinib versus Chemotherapy in Metastatic Uveal Melanoma (Alliance A091201).” Clinical cancer research : an official journal of the American Association for Cancer Research (2019). PMID: 31558480 ↗
L1RCTCited in: History and Evolution of Treatment
[780]
Smithy JW, Kalvin HL, Ehrich FD et al.. “Early On-Treatment Assessment of T Cells, Cytokines, and Tumor DNA with Adaptively Dosed Nivolumab + Ipilimumab: Final Results from the Phase 2 ADAPT-IT Study.” Clinical cancer research : an official journal of the American Association for Cancer Research (2024). PMID: 38767650 ↗
L4TRIAL_NONRANDOMCited in: History and Evolution of Treatment
[781]
Nebhan CA, Cortellini A, Ma W et al.. “Clinical Outcomes and Toxic Effects of Single-Agent Immune Checkpoint Inhibitors Among Patients Aged 80 Years or Older With Cancer: A Multicenter International Cohort Study.” JAMA oncology (2021). PMID: 34734989 ↗
L2COHORTCited in: History and Evolution of Treatment, Special Populations
[782]
Massi D, Mihic-Probst D, Schadendorf D et al.. “Dedifferentiated melanomas: Morpho-phenotypic profile, genetic reprogramming and clinical implications.” Cancer treatment reviews (2020). PMID: 32619863 ↗
L5REVIEW_NARRATIVECited in: History and Evolution of Treatment
[783]
Baggetto LG, Gambrelle J, Dayan G et al.. “Major cytogenetic aberrations and typical multidrug resistance phenotype of uveal melanoma: current views and new therapeutic prospects.” Cancer treatment reviews (2005). PMID: 15994016 ↗
L5REVIEW_NARRATIVECited in: History and Evolution of Treatment
[784]
Kfoury M, Najean M, Lappara A et al.. “Analysis of the association between prospectively collected immune-related adverse events and survival in patients with solid tumor treated with immune-checkpoint blockers, taking into account immortal-time bias.” Cancer treatment reviews (2022). PMID: 35998515 ↗
L2REVIEW_NARRATIVECited in: History and Evolution of Treatment
[785]
Parkinson DR, Talpaz M, Lee KH et al.. “Interleukin-2 alone and in combination with other cytokines in melanoma: the investigational approach at the University of Texas M.D. Anderson Cancer Center.” Cancer treatment reviews (1989). PMID: 2670214 ↗
L5REVIEW_NARRATIVECited in: History and Evolution of Treatment
[786]
Leonetti A, Facchinetti F, Rossi G et al.. “BRAF in non-small cell lung cancer (NSCLC): Pickaxing another brick in the wall.” Cancer treatment reviews (2018). PMID: 29729495 ↗
L5REVIEW_NARRATIVECited in: History and Evolution of Treatment
[787]
Martin-Liberal J, Márquez-Rodas I, Cerezuela-Fuentes P et al.. “Challenges and perspectives in the management of BRAF-mutated metastatic melanoma: Systemic treatment sequencing and brain metastases.” Cancer treatment reviews (2025). PMID: 39879863 ↗
L5REVIEW_NARRATIVECited in: History and Evolution of Treatment
[788]
Hancock BW, Harris S, Wheatley K et al.. “Adjuvant interferon-alpha in malignant melanoma: current status.” Cancer treatment reviews (2000). PMID: 10772966 ↗
L5REVIEW_NARRATIVECited in: History and Evolution of Treatment
[789]
Zheng H, Lai C, Liu F et al.. “Research landscape, thematic evolution, and translational insights of immune checkpoint inhibitor-induced colitis: a bibliometric analysis (2006-2025).” Frontiers in immunology (2026). PMID: 42233032 ↗
L5SR_OBSCited in: History and Evolution of Treatment
[790]
Piperno-Neumann S, Rutkowski P, Hassel JC et al.. “Five-year survival with tebentafusp in metastatic uveal melanoma.” Annals of oncology : official journal of the European Society for Medical Oncology (2026). PMID: 42162665 ↗
L1OTHERCited in: History and Evolution of Treatment
[791]
Kohman LJ. “Cancer and leukemia group B surgery committee.” Clinical cancer research : an official journal of the American Association for Cancer Research (2006). PMID: 16740796 ↗
L5REVIEW_NARRATIVECited in: History and Evolution of Treatment
[792]
Llovet JM, Hernandez-Gea V. “Hepatocellular carcinoma: reasons for phase III failure and novel perspectives on trial design.” Clinical cancer research : an official journal of the American Association for Cancer Research (2014). PMID: 24589894 ↗
L5REVIEW_NARRATIVECited in: History and Evolution of Treatment
[793]
Panka DJ, Atkins MB, Mier JW. “Targeting the mitogen-activated protein kinase pathway in the treatment of malignant melanoma.” Clinical cancer research : an official journal of the American Association for Cancer Research (2006). PMID: 16609061 ↗
L5REVIEW_NARRATIVECited in: History and Evolution of Treatment
[794]
Mulder EEAP, Smit L, Grünhagen DJ et al.. “Cost-effectiveness of adjuvant systemic therapies for patients with high-risk melanoma in Europe: a model-based economic evaluation.” ESMO open (2021). PMID: 34781194 ↗
L2OTHERCited in: History and Evolution of Treatment
[795]
Chen S, Zhang Z, Zhu X et al.. “The Association of Osteoarthritis With De Novo Inflammatory Arthritis in Patients Receiving Immune Checkpoint Inhibitors: A Retrospective Study.” Arthritis care & research (2026). PMID: 42223227 ↗
L3COHORTCited in: History and Evolution of Treatment
[796]
Nirmal AJ, Maliga Z, Vallius T et al.. “The Spatial Landscape of Progression and Immunoediting in Primary Melanoma at Single-Cell Resolution.” Cancer discovery (2022). PMID: 35404441 ↗
L4OTHERCited in: History and Evolution of Treatment
[797]
. “Companies Scaling Back IDO1 Inhibitor Trials.” Cancer discovery (2018). PMID: 29848606 ↗
L5OTHERCited in: History and Evolution of Treatment
[798]
. “PD-1 Inhibitors Prolong Survival in Leptomeningeal Disease.” Cancer discovery (2023). PMID: 37114878 ↗
L5OTHERCited in: History and Evolution of Treatment
[799]
Shi H, Hugo W, Kong X et al.. “Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy.” Cancer discovery (2013). PMID: 24265155 ↗
L4OTHERCited in: History and Evolution of Treatment, Special Populations
[800]
Hong A, Moriceau G, Sun L et al.. “Exploiting Drug Addiction Mechanisms to Select against MAPKi-Resistant Melanoma.” Cancer discovery (2017). PMID: 28923912 ↗
L5OTHERCited in: History and Evolution of Treatment
[801]
. “Vaccine Increases PFS for Metastatic Tumors.” Cancer discovery (2019). PMID: 31395735 ↗
L5OTHERCited in: History and Evolution of Treatment
[802]
Gaziel-Sovran A, Segura MF, Di Micco R et al.. “miR-30b/30d regulation of GalNAc transferases enhances invasion and immunosuppression during metastasis.” Cancer cell (2011). PMID: 21741600 ↗
L5OTHERCited in: History and Evolution of Treatment
[803]
Janjigian YY, Wolchok JD, Ariyan CE. “Eradicating micrometastases with immune checkpoint blockade: Strike while the iron is hot.” Cancer cell (2021). PMID: 34129818 ↗
L5OTHERCited in: History and Evolution of Treatment
[804]
Hovnanian A, Mondon G, Titeux M. “History and future of RNA medicines.” The Journal of investigative dermatology (2026). PMID: 42417685 ↗
L5REVIEW_NARRATIVECited in: History and Evolution of Treatment
[805]
Long X, Wu T, Hou Y et al.. “Neoadjuvant immunotherapy in melanoma: From pathologic response to response-adapted management.” Critical reviews in oncology/hematology (2026). PMID: 42392242 ↗
L5REVIEW_NARRATIVECited in: History and Evolution of Treatment
[806]
Robert C, Long GV, Brady B et al.. “Nivolumab in previously untreated melanoma without BRAF mutation.” The New England journal of medicine (2014). PMID: 25399552 ↗
L1RCTCited in: Prognosis and Prognostic Factors, Special Populations
[807]
Robert C, Grob JJ, Stroyakovskiy D et al.. “Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma.” The New England journal of medicine (2019). PMID: 31166680 ↗
L1RCTCited in: Prognosis and Prognostic Factors, Special Populations
[808]
Chapman PB, Hauschild A, Robert C et al.. “Improved survival with vemurafenib in melanoma with BRAF V600E mutation.” The New England journal of medicine (2011). PMID: 21639808 ↗
L1RCTCited in: Prognosis and Prognostic Factors
[809]
Weberpals J, Jansen L, Carr PR et al.. “Beta blockers and cancer prognosis - The role of immortal time bias: A systematic review and meta-analysis.” Cancer treatment reviews (2016). PMID: 27179912 ↗
L2SR_OBSCited in: Prognosis and Prognostic Factors
[810]
Pasquali S, Chiarion-Sileni V, Rossi CR et al.. “Immune checkpoint inhibitors and targeted therapies for metastatic melanoma: A network meta-analysis.” Cancer treatment reviews (2017). PMID: 28189914 ↗
L1SR_OBSCited in: Prognosis and Prognostic Factors
[811]
Wheatley K, Wilson JS, Gaunt P et al.. “Surgical excision margins in primary cutaneous melanoma: A meta-analysis and Bayesian probability evaluation.” Cancer treatment reviews (2015). PMID: 26563920 ↗
L1SR_OBSCited in: Prognosis and Prognostic Factors
[812]
Kim CM, Lee JB, Shin SJ et al.. “The efficacy of immune checkpoint inhibitors in elderly patients: a meta-analysis and meta-regression.” ESMO open (2022). PMID: 36156450 ↗
L1SR_OBSCited in: Prognosis and Prognostic Factors, Special Populations
[813]
Devji T, Levine O, Neupane B et al.. “Systemic Therapy for Previously Untreated Advanced BRAF-Mutated Melanoma: A Systematic Review and Network Meta-Analysis of Randomized Clinical Trials.” JAMA oncology (2017). PMID: 27787543 ↗
L1SR_OBSCited in: Prognosis and Prognostic Factors
[814]
Tetzlaff M, Taube JM, Long GV et al.. “Concordance of pathologic response assessment between local and central review in melanoma: a post hoc analysis of KEYMAKER-U02 substudy 02C.” ESMO open (2026). PMID: 42190314 ↗
L4TRIAL_NONRANDOMCited in: Prognosis and Prognostic Factors
[815]
Dirven I, Bertels C, Moreels Y et al.. “Efficacy and safety of regorafenib in patients with advanced pretreated melanoma: results of the RegoMel phase II clinical trial.” ESMO open (2026). PMID: 41962308 ↗
L4TRIAL_NONRANDOMCited in: Prognosis and Prognostic Factors
[816]
Maurichi A, Barretta F, Patuzzo R et al.. “Local Recurrence and Survival in Patients With Melanoma >2 mm in Thickness at Difficult Sites Treated With 1-cm Versus 2-cm Margins.” Journal of the National Comprehensive Cancer Network : JNCCN (2024). PMID: 39536446 ↗
L2OTHERCited in: Prognosis and Prognostic Factors, Special Populations
[817]
Zhou Z, Zhu C, Yang Q et al.. “Umbrella Systematic Review of the Efficacy and Safety of PD-1 Inhibitors Combined with CTLA-4 Inhibitors in the Treatment of Melanoma.” International journal of molecular sciences (2026). PMID: 42123452 ↗
L1SR_OBSCited in: Prognosis and Prognostic Factors
[818]
Glitza Oliva IC, Schvartsman G, Tawbi H. “Advances in the systemic treatment of melanoma brain metastases.” Annals of oncology : official journal of the European Society for Medical Oncology (2018). PMID: 29790899 ↗
L5REVIEW_NARRATIVECited in: Prognosis and Prognostic Factors
[819]
Sanz-Garcia E, Argiles G, Elez E et al.. “BRAF mutant colorectal cancer: prognosis, treatment, and new perspectives.” Annals of oncology : official journal of the European Society for Medical Oncology (2017). PMID: 29045527 ↗
L5REVIEW_NARRATIVECited in: Prognosis and Prognostic Factors
[820]
Andersen R, Jespersen MS, Presti M et al.. “Progression risk among responders to PD-1/PD-L1 blockade is primarily stratified by response depth: A nationwide cohort study of 2127 patients with melanoma, RCC, and NSCLC.” European journal of cancer (Oxford, England : 1990) (2026). PMID: 42284973 ↗
L2COHORTCited in: Prognosis and Prognostic Factors, Special Populations
[821]
Long GV, Lipson EJ, Hodi FS et al.. “First-Line Nivolumab Plus Relatlimab Versus Nivolumab Plus Ipilimumab in Advanced Melanoma: An Indirect Treatment Comparison Using RELATIVITY-047 and CheckMate 067 Trial Data.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024). PMID: 39137386 ↗
L2OTHERCited in: Prognosis and Prognostic Factors
[822]
Chon E, Morsey M, Katz T et al.. “Efficacy and safety evaluation of gilvetmab in dogs with melanoma and mast cell tumor.” Journal of veterinary internal medicine (2026). PMID: 42247661 ↗
L5TRIAL_NONRANDOMCited in: Prognosis and Prognostic Factors
[823]
McDermott D, Lebbé C, Hodi FS et al.. “Durable benefit and the potential for long-term survival with immunotherapy in advanced melanoma.” Cancer treatment reviews (2014). PMID: 25060490 ↗
L5REVIEW_NARRATIVECited in: Prognosis and Prognostic Factors
[824]
Franceschini D, Franzese C, Navarria P et al.. “Radiotherapy and immunotherapy: Can this combination change the prognosis of patients with melanoma brain metastases?” Cancer treatment reviews (2016). PMID: 27566962 ↗
L5REVIEW_NARRATIVECited in: Prognosis and Prognostic Factors
[825]
Byeon S, Cho HJ, Jang KT et al.. “Molecular profiling of Asian patients with advanced melanoma receiving check-point inhibitor treatment.” ESMO open (2020). PMID: 33399091 ↗
L2OTHERCited in: Prognosis and Prognostic Factors
[826]
Blay JY, Cropet C, Mansard S et al.. “Long term activity of vemurafenib in cancers with BRAF mutations: the ACSE basket study for advanced cancers other than BRAFV600-mutated melanoma.” ESMO open (2023). PMID: 37922690 ↗
L4OTHERCited in: Prognosis and Prognostic Factors
[827]
Aamdal E, Skovlund E, Jacobsen KD et al.. “Health-related quality of life in patients with advanced melanoma treated with ipilimumab: prognostic implications and changes during treatment.” ESMO open (2022). PMID: 36116420 ↗
L2OTHERCited in: Prognosis and Prognostic Factors
[828]
. “Durable Responses Achieved with AM0010.” Cancer discovery (2016). PMID: 27803020 ↗
L4OTHERCited in: Prognosis and Prognostic Factors
[829]
Wargo JA, Cooper ZA, Flaherty KT. “Universes collide: combining immunotherapy with targeted therapy for cancer.” Cancer discovery (2014). PMID: 25395294 ↗
L5REVIEW_NARRATIVECited in: Prognosis and Prognostic Factors
[830]
. “Warming "Cold" Melanoma with TLR9 Agonists.” Cancer discovery (2018). PMID: 29669722 ↗
L5OTHERCited in: Prognosis and Prognostic Factors
[831]
. “IFNγ Mutations Prompt CTLA-4 Inhibitor Resistance.” Cancer discovery (2016). PMID: 27864228 ↗
L4OTHERCited in: Prognosis and Prognostic Factors
[832]
. “Expanding the Reach of Anti-PD-1 Therapy.” Cancer discovery (2015). PMID: 26034052 ↗
L5OTHERCited in: Prognosis and Prognostic Factors
[833]
Teng MW, Khanna R, Smyth MJ. “Checkpoint Immunotherapy: Picking a Winner.” Cancer discovery (2016). PMID: 27485001 ↗
L5OTHERCited in: Prognosis and Prognostic Factors
[834]
Lim JS, Turner NC, Yap TA. “CDK4/6 Inhibitors: Promising Opportunities beyond Breast Cancer.” Cancer discovery (2016). PMID: 27371575 ↗
L5OTHERCited in: Prognosis and Prognostic Factors
[835]
Subbiah V, Puzanov I, Blay JY et al.. “Pan-Cancer Efficacy of Vemurafenib in BRAF V600-Mutant Non-Melanoma Cancers.” Cancer discovery (2020). PMID: 32029534 ↗
L4OTHERCited in: Prognosis and Prognostic Factors, Special Populations
[836]
. “PD-1, CTLA-4 Point to Drug Response.” Cancer discovery (2016). PMID: 27655434 ↗
L5OTHERCited in: Prognosis and Prognostic Factors
[837]
Zhang Y, Kurupati R, Liu L et al.. “Enhancing CD8+ T Cell Fatty Acid Catabolism within a Metabolically Challenging Tumor Microenvironment Increases the Efficacy of Melanoma Immunotherapy.” Cancer cell (2017). PMID: 28898698 ↗
L5OTHERCited in: Prognosis and Prognostic Factors
[838]
Orgaz JL, Crosas-Molist E, Sadok A et al.. “Myosin II Reactivation and Cytoskeletal Remodeling as a Hallmark and a Vulnerability in Melanoma Therapy Resistance.” Cancer cell (2020). PMID: 31935375 ↗
L5OTHERCited in: Prognosis and Prognostic Factors
[839]
Hanniford D, Ulloa-Morales A, Karz A et al.. “Epigenetic Silencing of CDR1as Drives IGF2BP3-Mediated Melanoma Invasion and Metastasis.” Cancer cell (2020). PMID: 31935372 ↗
L5OTHERCited in: Prognosis and Prognostic Factors
[840]
Lee JH, Carlino MS, Rizos H. “Dosing of BRAK and MEK Inhibitors in Melanoma: No Point in Taking a Break.” Cancer cell (2020). PMID: 33321086 ↗
L5OTHERCited in: Prognosis and Prognostic Factors
[841]
Caramel J, Papadogeorgakis E, Hill L et al.. “A switch in the expression of embryonic EMT-inducers drives the development of malignant melanoma.” Cancer cell (2013). PMID: 24075834 ↗
L5OTHERCited in: Prognosis and Prognostic Factors
[842]
Feng X, Arang N, Rigiracciolo DC et al.. “A Platform of Synthetic Lethal Gene Interaction Networks Reveals that the GNAQ Uveal Melanoma Oncogene Controls the Hippo Pathway through FAK.” Cancer cell (2019). PMID: 30773340 ↗
L5OTHERCited in: Prognosis and Prognostic Factors
[843]
Johnson DB, Smalley KS, Sosman JA. “Molecular pathways: targeting NRAS in melanoma and acute myelogenous leukemia.” Clinical cancer research : an official journal of the American Association for Cancer Research (2014). PMID: 24895460 ↗
L5REVIEW_NARRATIVECited in: Prognosis and Prognostic Factors
[844]
Queirolo P, Spagnolo F. “Atypical responses in patients with advanced melanoma, lung cancer, renal-cell carcinoma and other solid tumors treated with anti-PD-1 drugs: A systematic review.” Cancer treatment reviews (2017). PMID: 28756306 ↗
L4SR_OBSCited in: Special Populations
[845]
Garutti M, Lambertini M, Puglisi F. “Checkpoint inhibitors, fertility, pregnancy, and sexual life: a systematic review.” ESMO open (2021). PMID: 34597942 ↗
L4SR_OBSCited in: Special Populations
[846]
Khoja L, Atenafu EG, Suciu S et al.. “Meta-analysis in metastatic uveal melanoma to determine progression free and overall survival benchmarks: an international rare cancers initiative (IRCI) ocular melanoma study.” Annals of oncology : official journal of the European Society for Medical Oncology (2019). PMID: 31150059 ↗
L4SR_OBSCited in: Special Populations
[847]
Robert C, Karaszewska B, Schachter J et al.. “Improved overall survival in melanoma with combined dabrafenib and trametinib.” The New England journal of medicine (2014). PMID: 25399551 ↗
L1RCTCited in: Special Populations
[848]
Verheijden RJ, de Groot JS, Fabriek BO et al.. “Corticosteroids for Immune-Related Adverse Events and Checkpoint Inhibitor Efficacy: Analysis of Six Clinical Trials.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024). PMID: 39110922 ↗
L2TRIAL_NONRANDOMCited in: Special Populations
[849]
Chumsri S, Sokol ES, Soyano-Muller AE et al.. “Durable Complete Response With Immune Checkpoint Inhibitor in Breast Cancer With High Tumor Mutational Burden and APOBEC Signature.” Journal of the National Comprehensive Cancer Network : JNCCN (2020). PMID: 32380464 ↗
L4CASE_REPORTCited in: Special Populations
[850]
Nguyen MC, Shah MH, Liebner DA et al.. “The Adrenal Gland as a Sanctuary Site of Metastases After Pembrolizumab Treatment: A Case Series.” Journal of the National Comprehensive Cancer Network : JNCCN (2018). PMID: 30442730 ↗
L4CASE_REPORTCited in: Special Populations
[851]
Carlino MS, Gao B, Michael M et al.. “Nivolumab and Ipilimumab in Advanced Mismatch Repair-Deficient/Microsatellite Instability-High Noncolorectal Cancers: A Nonrandomized Clinical Trial.” JAMA oncology (2026). PMID: 41231502 ↗
L4TRIAL_NONRANDOMCited in: Special Populations
[852]
Ribas A, Medina T, Kummar S et al.. “SD-101 in Combination with Pembrolizumab in Advanced Melanoma: Results of a Phase Ib, Multicenter Study.” Cancer discovery (2018). PMID: 30154193 ↗
L4TRIAL_NONRANDOMCited in: Special Populations
[853]
Wagle N, Van Allen EM, Treacy DJ et al.. “MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibition.” Cancer discovery (2013). PMID: 24265154 ↗
L4TRIAL_NONRANDOMCited in: Special Populations
[854]
Osorio JC, Knorr DA, Weitzenfeld P et al.. “Fc-optimized CD40 agonistic antibody elicits tertiary lymphoid structure formation and systemic antitumor immunity in metastatic cancer.” Cancer cell (2025). PMID: 40816292 ↗
L4TRIAL_NONRANDOMCited in: Special Populations
[855]
Zhang Y, Cerullo M, Esposito A et al.. “Association Between Cancer Center Accreditation and Compliance With Price Disclosure of Common Oncologic Surgical Procedures.” Journal of the National Comprehensive Cancer Network : JNCCN (2022). PMID: 36351331 ↗
L2OTHERCited in: Special Populations
[856]
Gumaste PV, Fleming NH, Silva I et al.. “Analysis of recurrence patterns in acral versus nonacral melanoma: should histologic subtype influence treatment guidelines?” Journal of the National Comprehensive Cancer Network : JNCCN (2014). PMID: 25505211 ↗
L3OTHERCited in: Special Populations
[857]
Davar D, Eroglu Z, Pérez CL et al.. “Combined Targeting of PD-1 and TIM-3 in Patients with Locally Advanced or Metastatic Melanoma: AMBER Cohorts 1c, 1e, and 2A.” Clinical cancer research : an official journal of the American Association for Cancer Research (2025). PMID: 40552935 ↗
L4TRIAL_NONRANDOMCited in: Special Populations
[858]
Geukes Foppen MH, Brandsma D, Blank CU et al.. “Targeted treatment and immunotherapy in leptomeningeal metastases from melanoma.” Annals of oncology : official journal of the European Society for Medical Oncology (2016). PMID: 26961150 ↗
L4OTHERCited in: Special Populations
[859]
Abdel-Wahab O, Klimek VM, Gaskell AA et al.. “Efficacy of intermittent combined RAF and MEK inhibition in a patient with concurrent BRAF- and NRAS-mutant malignancies.” Cancer discovery (2014). PMID: 24589925 ↗
L4CASE_REPORTCited in: Special Populations
[860]
Le Rhun E, Wolpert F, Fialek M et al.. “Response assessment and outcome of combining immunotherapy and radiosurgery for brain metastasis from malignant melanoma.” ESMO open (2020). PMID: 32747372 ↗
L2OTHERCited in: Special Populations
[861]
Montal ED, White RM. “The Aged Microenvironment of Melanoma Feeds Escape from Targeted Therapy.” Cancer discovery (2020). PMID: 32873617 ↗
L5OTHERCited in: Special Populations
[862]
Leanza L, Romio M, Becker KA et al.. “Direct Pharmacological Targeting of a Mitochondrial Ion Channel Selectively Kills Tumor Cells In Vivo.” Cancer cell (2017). PMID: 28399409 ↗
L5OTHERCited in: Special Populations